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Abstract 
At present, 56 types of human adenovirus (HAdVs) have been identified and found to be 
associated with a variety of clinical features in the respiratory tract, eye, gastrointestinal 
tract, and other organs. In additions, HAdVs are able to establish persistent and latent 
infections in humans. Most of the work which has been carried out recently is related to 
adenovirus vectors and little has been done in other areas such as the nature and 
mechanisms of adenovirus persistence and latency in human tissues. Another area needing 
more investigation is the stability of the adenovirus genome which is useful for the 
development of adenovirus vectors and vaccines and for better understanding of adenovirus 
evolution especially with conflicting views about this issue. 
Recombination between two types of adenovirus can happen when the hexon epitope from 
one type and the fibre epitope from another type are found (intermediate strains). These 
recombinants can be detected by the conflicting results for serum neutralization (SN) and 
haemagglutination inhibition (HI) tests or by sequencing and phylogenetic analysis of the 
hexon and fibre regions of the adenovirus genome. The first part of this study is related to 
the stability and evolution of different adenovirus species. A total of 31 clinical isolates 
from AIDS patients previously typed in the hexon L2 region and the fibre knob region were 
analysed. These isolates were found to be from species D adenovirus (HAdV-D) and 28 of 
them had contradictory typing results in these two regions so they are clearly intermediate 
strains. Two isolates appear to be completely new and one isolate (Aids32) was typed as 
HAdV-D23 variant in both hexon L2 and fibre knob regions. Sequencing and phylogenetic 
analysis of the hexon L1, fibre shaft and penton regions of these adenoviruses revealed that 
no intragene recombination events occurred between the hexon L1 and L2 regions or 
between the fibre knob and fibre shaft regions. Sequencing and phylogenetic analysis of the 
penton showed that some of the intermediate strains had sequences from a third type of 
adenovirus in these regions. The penton analysis showed also that intragene recombination 
between penton HVR and RGD loop regions was common. New types of adenovirus were 
detected and sequential infection with different adenovirus variants was observed in some 
patients which indicates that the genome of HAdV-D from AIDS patients are not stable.  
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Full genome sequencing and analysis was carried out for three isolates, two of them 
appeared to be new types of HAdV-D and the result of multi-recombination events and the 
third isolate appeared to be a variant of HAdV-D23. 
The stability of species B adenovirus (HAdV-B) was also analysed. A total of 96 isolates 
collected from the Manchester area typed previously by serum neutralization (SN) were 
analysed in five genome regions. Most of these isolates were HAdV-B3 and HAdV-B7 
collected during a 15 months outbreak. The rest of the isolates were HAdV-B types 3 and 7 
collected in different years following the outbreak in addition to other adenovirus types 
isolated from different years. The phylogenetic analysis results of all the isolates in the 
structural regions: hexon L2, penton and fibre knob were found to be consistent and no 
mismatches (hexon from one type and fiber from another type) were observed. Most of the 
isolates in the DNA polymerase and E1A regions had the same clustering patterns as the 
structural regions. However, one HAdV-B7 and one HAdV-B11 isolate changed their 
clustering patterns in the DNA polymerase region. In addition, HAdV-B16 isolates changed 
their clustering patterns in both DNA polymerase and E1A regions. The changes of the 
clustering patterns of some isolates is more likely related to natural variations rather than 
recombination which indicate that species B adenovirus genome is stable in general.    
The last part of this study is investigating adenovirus persistence and latency in human 
tissues. Tonsils and adenoids (106 right and left tonsils and 10 adenoids) were obtained 
from 57 patients who underwent routine tonsillectomies and/or adenoidectomies. Eighty 
four (72.41%) tonsils and adenoids samples were positive for HAdV by real-time PCR. The 
viral load was not the same in the right and left tonsils in most of the cases and ranged from 
280 to more than 2.6 x 10
6
 copies/10
7
 cells. Seventy eight of 84 positive samples could be 
typed by sequencing of the hexon L1 region. Species C types were detected in 82% of the 
samples followed by species B (7.7%), HAdV-E4 (7.7%) and HAdV-F41 (2.56%). No 
DNA methylation was detected in the major late promoter (MLP) and E1A promoter 
regions of six tonsils and adenoids samples and two clinical isolates. 
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1. Introduction 
1.1 General introduction:  
Adenoviruses were first discovered by Rowe et al. (1953) during their preparation of cell 
lines from adenoidal tissues. Hilleman and Werner (1954) isolated the same virus during 
their investigation of respiratory disease in military recruits. The name adenovirus was 
given to this infectious agent in 1956 because it was first isolated from adenoids (Enders et 
al. 1956). The oncogenicity of human adenovirus type 12 in new born hamsters was 
discovered by Trentin et al. (1962) but no evidence of the association between adenovirus 
and human cancer has been found (Shenk 2001). 
Today, 56 types of human adenovirus have been identified and found to be associated with 
a variety of clinical features in the respiratory tract, eye, gastrointestinal tract and other 
organs (Walls et al. 2003). These infections are usually mild in immunocompetent patients 
but could be severe in immunocompromised patients (Hierholzer 1995). Adenovirus is also 
able to establish persistent and latent infections in humans (Garnett et al. 2009) and has 
been used as a vector for gene and cancer therapy in many clinical trials (Young et al. 
2006). 
1.2 Classification and typing: 
 Adenovirus is a member of the family Adenoviridae  which is divided formally into two 
genera Mastadenovirus and Aviadenovirus (Shenk 2001). Molecular studies indicated that 
there are another two genera  Atadenovirus and Siadenovirus and some have suggested a 
fifth genus to include fish adenovirus (Benko et al. 2002; Davison et al. 2003). The human 
adenoviruses (HAdVs) belong to the genus Mastadenovirus (Fig. 1.1) (Davison et al. 
2003). 
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Figure 1.1: Phylogenetic analysis of the adenovirus hexon genes. Abbreviations of virus names: 
BAdV, bovine adenovirus; C, canine; D, duck; E, equine; F, fowl; Fr, frog; H, human; M, murine; 
O, ovine; P, porcine; Po, possum; Sn, snake; T, turkey; and TS, tree shrew. Reproduced from 
(Davison et al. 2003) with permission from the publisher. 
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Fifty six types of HAdVs have been identified and classified into seven species (A-G) 
(Jones et al. 2007). Fifty one of these types were defined based on their immunobiological 
characteristics and called serotypes. Other properties have been used to confirm this 
classification such as oncogenicity, G+C content, restriction endonuclease profiles and 
DNA sequencing (Ruuskanen et al. 2002; Shenk 2001). The latest five types (HAdV-G52, 
HAdV-D53, HAdV-D54, HAdV-B55 and HAdV-D56) have been defined by genomics and 
molecular analysis (De Jong et al. 1999; Ishiko and Aoki 2009; Jones et al. 2007; Walsh et 
al. 2009; Walsh et al. 2010a).  
Type specific determinants of HAdVs are located on the capsid proteins hexon, fibre and 
penton (Horwitz 2001a; Norrby 1969).  Historically, neutralizing properties of the hexon 
epitope and haemagglutinating properties of the fibre epitope were used for HAdVs typing 
by serum neutralization (SN) and haemagglutination inhibition (HI) (Rosen 1960; Russell 
et al. 1967). Haemagglutination test is used also for species identification (Van 
Regenmortel 2000). 
SN tests are time consuming (Kidd et al. 1996; Shimada et al. 2004), need standard antisera 
(Shimada et al. 2004) and interpretation of the results can be difficult (Fife et al. 1985). On 
the other hand, HI tests are more rapid than SN tests (Rosen 1960) but cross reactions 
between two types may happen (Madisch et al. 2005).  
Immunoelectron microscopy (Luton 1973), immunofluorescence (IF) (Wood et al. 1997), 
restriction enzyme analysis (Cooper et al. 1993; Cooper et al. 2000) and enzyme-linked 
immunosorbent assay (ELISA) (Singh-Naz et al. 1988) have also been used for typing. 
Later, other methods such as polymerase chain reaction (PCR) combined with restriction 
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enzyme analysis (Allard et al. 2001), and PCR-restriction fragment length polymorphism 
(Saitoh-Inagawa et al. 1996) have been used.  
Nowadays, PCR, sequencing and phylogenetic analysis of HAdVs genome regions have 
been used for identification and molecular typing (Madisch  et al. 2005; Sarantis et al. 
2004). More recently, full genome sequencing has been used for identification of new types 
of adenovirus (Ishiko and  Aoki  2009; Walsh et al. 2009; Walsh et al. 2010a). 
Recombination between two types can happen when the hexon epitope from one type and 
the fibre epitope from another type are found (intermediate strains) (Madisch et al. 2005; 
Shenk 2001). These recombinants can be detected by the conflicting results for SN and HI 
tests (Hierholzer 1992) or by sequencing and phylogenetic analysis of the hexon and fibre 
regions of the adenovirus genome (Madisch et al. 2005). 
Typing is important in epidemiological studies and for the identification of new types 
(Allard et al. 2001; Madisch et al. 2006). It is also important in immunocompromised 
patients when certain types are responsible for disseminated infections (Madisch et al. 
2006). In addition, specific types are associated with certain clinical features (Zhang & 
Bergelson 2005) (Table 1.1). 
Species Type Common site of infection 
A 12, 18, 31 Intestinal 
B B1: 3, 7, 16, 21, 50 Respiratory 
B2: 11, 14, 34, 35, 55 Respiratory,  urinary 
C 1, 2, 5, 6 Respiratory  
D 8, 9, 10, 13, 15, 17, 19, 20, 22-30, 32, 33, 36-39,  
42-49, 51, 53, 54, 56 
Ocular, intestinal 
E 4 Respiratory 
F 40, 41 Intestinal 
G 52 Intestinal 
 
Table1.1: Classification of adenoviruses. The table indicates the types of each species and the 
common site of infection. Species B is divided into two subspecies B1 and B2. 
27 
 
1.3 Adenovirus structure: 
Adenoviruses are non-enveloped DNA viruses with a 70-100 nm diameter icosahedral 
capsid (Shenk 2001). The capsid consists of 252 morphological units including 240 hexons 
and 12 pentons (Goncalves & De Vries 2006). The fibre protein projects from the 
pentameric penton at each of the 12 vertices. These three proteins (hexon, penton and fibre) 
are the major capsid proteins (Van Oostrum & Burnett 1985; Van Oostrum et al. 1987).  
Four additional proteins pIIIa, pVI, pVIII, and pIX are located on the capsid (Vellinga et al. 
2005). The capsid surrounds a DNA containing core which contains a single copy of DNA 
with proteins such as the terminal protein (TP), polypeptide pV, pVII and pX (Goncalves & 
De Vries 2006; Russell 2000) (Fig 1.2). 
1.4 Antigenic composition of adenoviruses: 
Adenovirus proteins hexon, penton and fibre contain the main antigenic determinants 
(Hierholzer 1995; Horwitz 2001a).  
All adenoviruses except avian and some bovine adenovirus hexons carry the group specific 
determinate α (Norrby 1969). In addition a type specific antigen ε, which reacts with 
neutralizing antibodies, is also carried on the hexon (Madisch et al. 2005). Neutralizing 
antibodies react with the major capsid proteins, hexon, fibre and penton but the main target 
for these antibodies is the hexon (Pichla-Gollon et al. 2007). X-Ray analysis showed that 
adenovirus hexon includes four loops (L1-L4), two of them (L1 and L2) are located on the 
surface of the virion (Rux et al. 2003). L1 contains the hexon hypervariable regions 1-6 
(HVR 1-6) and L2 contains the hypervariable region 7 (HVR7). These HVRs contain more 
than 99% of the type specific variation of the hexon (Crawford-Miksza and Schnurr 
1996b). 
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The fibre knob carries a type specific determinant γ which reacts with haemagglutination 
inhibition antibodies (Norrby 1969). The adenovirus type specificity is determined by this γ 
determinant in addition to the hexon ε determinant. A different determinant δ is also located 
on the fibre of species C and D and may play a role in the haemagglutination reaction 
(Watson et al. 1988). The penton, which is the third major capsid protein, carries an 
antigenic determinant β (Pettersson 1984). 
 
Figure 1.2: Adenovirus structure. Reproduced from (Russell 2000) with permission from the 
publisher. 
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1.5 Adenovirus genome: 
The adenovirus genome is linear, double stranded DNA and 30-38 kbp in size (Ruuskanen 
et al. 2002). There is an inverted terminal repeat (ITR) at each termini and terminal protein 
(TP) attached to the 5' end of the genome (Sussenbach 1984). 
The genome encodes for several transcription units: early units (E1A, E1B, E2, E3 and E4), 
intermediate units and a major late transcription unit (Ruukcanen et al. 2002) (Fig. 1.3). 
 
 
 
Figure 1.3: Adenovirus genome organization. Reproduced from (Russell 2000) with permission 
from the publisher. The regions are indicated in the text by the small letters in brackets. 
 
(a) 
(b) 
(c) 
(d) 
(e) 
(f) 
(g) 
(j) 
(i) 
(k) 
(h) 
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1.5.1 Early regions of the genome: 
The early regions of HAdV genome are divided into five transcription units: E1A, E1B, E2, 
E3 and E4.  
1.5.1.1 E1A: 
Early region 1A (E1A) is the first transcription unit to be activated and encodes different 
spliced proteins (21K and 28K) which regulate the transcription of other genes (Goncalves 
& De Vries 2006).  This region is indicated in Fig 1.3 by (a). 
1.5.1.2 E1B:  
This region encodes two proteins of 19K and 55K molecular weight. Proteins of this region 
interact with p53 (protein 53) and inhibit apoptosis (Russell 2000; Shenk 2001). This 
region is indicated in Fig 1.3 by (b). 
1.5.1.3 E2: 
E2 transcripts unit is divided into two sub-units, E2A and E2B. These two regions encoded 
three proteins: DNA binding protein, precursor terminal protein and DNA polymerase. The 
predicted ORFs of these proteins are located on the complementary strand. E2 proteins are 
required for DNA replication (Ruuskanen et al. 2002; Shenk 2001). E2A region is indicated 
in Fig 1.3 by (c) and E2B (d). 
1.5.1.4 E3: 
E3 interferes with the host immune response and inhibits apoptosis (Russell 2000). Eight 
open reading frames (ORFs) are encoded within the E3 region: 12K, CR1α (conserved 
region 1 α), gp19K (glycoprotein 19K), CR1β, CR1γ, RIDα (receptor internalization and 
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degradation α), RIDβ and 14.8K (Arnold et al. 2010; Horwitz 2004). This region is 
indicated in Fig 1.3 by (e). 
1.5.1.5 E4:  E4 plays a role in regulating gene expression, protein stability and exporting of 
virus mRNA in addition to shutting off host protein synthesis (Russell 2000; Ruuskanen et 
al. 2002). E4 region contains six ORFs: ORF1, ORF2, ORF3, ORF4, 34K, ORF6/7. These 
ORFs are located on the complementary strand (Davison et al. 2003). This region is 
indicated in Fig 1.3 by (f). 
1.5.2 Intermediate regions of the genome: 
Two genes are encoded in this region: Iva2 and IX.  Iva2 plays a role in DNA packing and 
IX is a small capsid protein. Both proteins help in the activation of the major late promoter 
(MLP) (Goncalves & De Vries 2006; Yang et al. 2009).  
1.5.3 Late regions of the genome: 
The major late transcription unit of the genome is divided into five regions L1-L5 and 
encodes mainly structural proteins which are transcribed from the MLP. 
1.5.3.1 L1: Two proteins are encoded by this region, 52/55K which plays a role in DNA 
packaging and virus assembly and pIIIa which is a minor structural protein (Kreivi et al. 
1991). This region is indicated in Fig 1.3 by (g). 
1.5.3.2 L2: Four ORFs corresponding to penton, pX, pV and pVII proteins are encoded by 
this region. The penton is a major capsid protein and contains the RGD motif which 
interacts with cellular integrins and is important in virus internalization (Zubieta et al. 
2005). Other proteins are associated with the DNA and called core proteins (Alestrom et al. 
1984). This region is indicated in Fig 1.3 by (h). 
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1.5.3.3 L3: This transcription unit encodes three proteins pVI, hexon and protease. The pVI 
is a minor capsid protein while the hexon is one of the major capsid proteins. Protease is 
essential in virus assembly by cleaving other proteins (Russell 2009). This region is 
indicated in Fig 1.3 by (i). 
1.5.3.4 L4: L4 region consists of four ORFs, encoding the 100K, 33K, 22K and pVIII 
proteins. The 100K plays a role in virus assembly and activation of late protein synthesis 
(Shenk 2001). The 33K protein is involved in regulating the MLP while the 22K protein 
assists in DNA packaging and the last protein pVIII is a minor structural protein (Russell 
2009). This region is indicated in Fig 1.3 by (j). 
1.5.3.5 L5: Only one ORF corresponding to the fibre protein was identified within this 
region. The fibre is a major capsid protein and consists of a tail, shaft and knob. The fibre 
knob interacts with cellular receptors (Green et al, 1983). This region is indicated in Fig 1.3 
by (k). 
1.5.4 Non-coding features of the genome: 
1.5.4.1 Inverted terminal repeats (ITRs): 
The ITR at each end of adenovirus genome includes conserved sequence motifs which are 
critical for DNA replication (Chen et al. 1990). 
1.5.4.2 Virus-associated RNA (VA RNA): 
Species A, B1, F and G members encode one VA RNA (I) while species B2, C, D and E 
encode two VA RNAs (I & II) which are important in the inhibition of the host antiviral 
defence system (O'Malley et al. 1986). 
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1.6 Replication: 
The replication of adenovirus takes place in the nucleus and the infectious cycle of 
adenovirus virus is divided into early and late phases (Russell 2000). 
1.6.1 Virus attachment and entry into the cell: 
The fibre proteins interact with cellular receptors through the fibre knobs (Leen & Rooney 
2005). Coxsackievirus and adenovirus receptor (CAR) are receptors for most adenovirus 
types of all species except species B (Arnberg 2009). Human adenovirus types 2 and 5 from 
species C (HAdV-C2 and HAdV-C5) can attach also to heparan sulfate proteoglycan 
receptors (Dechecchi et al. 2000; Dechecchi et al. 2001). In addition, sialic acid was found 
to be the receptor for HAdV-D types 8, 19 and 37 of species D (Zhang & Bergelson 2005). 
HAdV-B types 11, 14, 16, 21, 35 and 50 were found to bind to a different receptor which is 
CD46 (membrane cofactor protein) (Arnberg 2009). Species B types also use CD80 and 
CD86 as receptors (Arnberg 2009; Short et al. 2004). The receptors might be one of the 
determinants that affect adenovirus tissue tropism (Russell 2000; Zhang & Bergelson 
2005). 
Another interaction between viral proteins and cellular receptors is important for 
internalization.  This interaction occurs between Arg-Gly-Asp (RGD) sequence of the 
penton protein and αv β3, αv β5 integrins (Ruuskanen et al. 2002). It was found that all 
adenovirus types have the RGD sequence except HAdV-F40 and HAdV-F41 (Albinsson & 
Kidd 1999). The viruses enter the cell by receptor-mediated endocytosis (Leen & Rooney 
2005). The virus particles escape into the cytoplasm after disruption of the endosome 
(Zhang & Bergelson 2005) and reach the nucleus 45 minutes after binding to the receptors 
(Ruuskanen et al. 2002).  
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1.6.2 Early events: 
Early adenovirus gene expression occurs before DNA replication and aims to induce the 
suitable conditions for replication, provide protection from the antiviral response and 
produce gene products for viral replication (Shenk 2001). 
1.6.3 DNA replication:  
The origin of replication is the inverted terminal repeats at the two ends of the genome 
(Goncalves & De Vries 2006). The replication occurs by a strand displacement mechanism 
in two stages. In the first stage one DNA strand is used as template and the new strand is 
synthesized. In the second stage the displaced single strand circularises to form partial 
duplex DNA and the synthesis of the second strand occurs as in the first stage (Shenk 
2001). 
1.6.4 Late events and virus assembly: 
Most of the late mRNAs encode structural proteins. Empty capsid is synthesized and viral 
DNA is then inserted into it. Virion assembly occurs in the nucleus before the virus 
particles are released from the infected cell (Lenaerts et al. 2008) (Fig 1.4). 
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Figure 1.4 . The adenovirus infection pathway. CAR, coxsackie-adenovirus receptor; DBP, DNA-
binding protein; E, early; L, late; MLP,major late promoter; pTP, precursor terminal protein; TP, 
terminal protein. Reproduced from (Lenaerts et al, 2008) with permission from the publisher. 
  1.7 Clinical features: 
1.7.1 Respiratory infections: 
Adenoviruses are one of the commonest causes of acute respiratory tract infections 
especially in children (Jacobs et al. 1971; Kim et al, 2000). It was reported in a ten year 
study that adenoviruses were responsible for 7% of paediatric respiratory tract infections 
(Brandt et al. 1969). In this study, a total of 18,096 outpatients and hospitalized infants and 
children with respiratory tract illness (pneumonia, bronchopneumonia, bronchiolitis, 
nasopharyngitis and bronchitis) were tested. In another study, 9% of the nasal swaps from 
children with upper respiratory tract infection were positive by PCR (Echavarria 2009). 
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HAdV-C types 1, 2, 5, 6 and HAdV-B3 are the common types that associated with upper 
respiratory tract infections (Horwitz 2001a; Singh-Naz et al. 1993; Wesley et al. 1993). 
Symptoms include tonsillitis, pharyngitis, pharyngoconjunctival fever, nasal congestion and 
cough (Echavarria 2009; Horwitz 2001a) which is difficult to distinguish clinically from 
infections caused by other viruses or bacteria (Hierholzer 1995). 
Adenoviruses are among the most common causes of lower respiratory tract infections such 
as pneumonia and bronchiolitis (Pavia 2011). Most of adenovirus lower respiratory tract 
infections are caused by species C types 1, 2 and 5 in addition to species B types 3 and 7 
and these two types are usually isolated from epidemics and might cause severe infections 
in children (Hong et al. 2001; Kim et al. 2003). It was reported by two studies in Argentina 
that adenoviruses are the second most common cause of viral lower respiratory tract 
infections in children (Videla et al. 1998; Videla et al. 1999). In one of these studies 71% 
of acute lower respiratory infections caused by adenoviruses were associated with 
pneumonia and 24% with bronchiolitis (Videla et al. 1998). Pneumonia might be associated 
with extrapulmonary complications such as conjunctivitis, gastroenteritis, encephalitis, 
intussusception and 
 
haemorrhagic cystitis (Smyth 2002) especially in children and the 
immunocompromised (Hierholzer 1995).  
Association of HAdV-E4 and HAdV-B7 with acute respiratory disease (ARD) in military 
recruits has been reported (Lenaerts et al. 2008). Other types such as HAdV-B types 3, 14 
and 21 are also associated with ARD (Van Der Veen & Dijkman 1962). The clinical 
features resemble those of upper respiratory tract infection but fatal pneumonia can occur 
(Horwitz 2001a). Crowding, fatigue and stress are the risk factors of epidemic infection 
(Hayashi & Hogg 2007). Oral vaccine against HAdV-E4 and HAdV-B7 was used in 
military recruits which reduced the ARD morbidity and mortality rates (Purkayastha et al. 
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2005). The vaccine production was stopped for economic reasons and its stocks were 
exhausted in the late 1990s which resulted in an increase of ARD cases in military recruits 
(Gray et al. 2000). 
Pertussis or whooping cough is caused by Bordetella pertussis (Echavarria 2009) but 
adenoviruses were frequently isolated from pertussis patients (Nelson et al. 1975). 
Adenovirus was isolated from 22.4% of pertussis patients and 5% of controls (Nelson et al. 
1975) but no evidence of the responsibility of adenovirus alone for pertussis was found but 
it couls be one of the factors that play a role in pertussis (Horwitz 2001a). 
Adenoviruses were also detected in the middle ear fluid specimens from children with acute 
otitis media and it has been suggested to play role in the enhancement of the inflammation 
in the middle ear (Monobe et al. 2003). 
Adenoviruses are able to establish persistent and latent infections in human tissues such as 
tonsils and adenoids (Garnett et al. 2002; Garnett et al. 2009). It has been also suggested 
that latent infections of adenovirus might play a role in chronic obstructive pulmonary 
disease (COPD) and asthma pathogenesis (Hayashi & Hogg 2007; Wilson 2003) (Fig 1.5). 
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Figure 1.5: Adenovirus infections of the respiratory tract. Reproduced from (Hayashi & Hogg 2007) 
with permission from the publisher. 
 1.7.2 Eye infections: 
HAdV-B3, HAdV-B7 and HAdV-E4 cause mild conjunctivitis as a part of 
pharyngoconjunctival fever or separately (Horwitz 2001a; Wadell 2000). Association 
between types 3, 4, 7 and swimming pool outbreaks were reported (Hierholzer 1995; Jiang 
2006). On the other hand, severe cases of epidemic keratoconjunctivitis (EKC) are caused 
by HAdV-D types 8, 19 and 37 (Aoki & Tagawa 2002; Echavarria 2009). HAdV-D19 
prototype is not associated with ocular infections but other strains such as HAdV-D19C 
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cause these kinds of infections (Robinson et al, 2009b). Newly identified HAdV-D53 and 
HAdV-D54 are also associated with EKC (Ishiko & Aoki 2009; Walsh et al. 2009). 
1.7.3 Gastroenteritis:  
Enteric adenoviruses (HAdV-F40 and HAdV-F41) were first discovered in stools using 
electron microscopy (Flewett et al. 1975). These fastidious adenoviruses were considered 
as the second most common cause of acute gastroenteritis in children after rotavirus (Cukor 
& Blacklow 1984; Uhnoo et al. 1984).  
Most enteric adenoviruses infections occur in children (Uhnoo et al. 1983). In one study, 
85% of children with enteric adenovirus infections were less than 3 years old (Uhnoo et al. 
1983). In a second study, 70% of children were under 2 years old (Uhnoo et al. 1984). 
Other types from species A, B and C can rarely cause acute gastroenteritis (Echavarria 
2009; Wilhelmi et al. 2003). 
1.7.4 Intussusception: 
An association between adenovirus infections and intussusception in infants was reported 
(Bines et al. 2006). Nonenteric adenoviruses were shed by 44.3% of infants with 
intussusception compared to 3.8% in healthy controls which indicates the association 
between nonenteric adenoviruses and intussusception (Hsu et al. 1998). This association 
was more frequent in infants older than one year. 
1.7.5 Haemorrhagic cystitis: 
 HAdV-B types11 and 21 were found to be associated with haemorrhagic cystitis in 
children (Mufson & Belshe 1976). 
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1.7.6 Myocarditis: 
Adenovirus is one of the most common causes of viral myocarditis (Dennert et al. 2008). In 
one study viral genome was found in 239/624 (38%) of myocardial samples from 
myocarditis patients and adenovirus was the most common viral genome (23%) in these 
samples (Bowles et al. 2003). 
1.7.7 Obesity: 
The association between HAdV-D36 and obesity in humans and animals has been reported 
(Atkinson et al. 2005; Dhurandhar et al. 2002). The ability of HAdV-D36 to reduce fatty 
acid oxidation could be the mechanism by which this type of adenovirus induces obesity 
(Wang et al. 2010). 
1.8 Adenovirus in immunocompromised patients: 
The number of immunocompromised individuals with adenovirus infections has increased 
because of the increase of transplant patients and the AIDS epidemic (Hierholzer 1992; 
Kojaoghlanian et al. 2003). These infections may be asymptomatic (Humar et al. 2005) or 
may associate with different clinical features such as pneumonia, hepatitis, haemorrhagic 
cystitis, gastroenteritis and encephalitis (Kojaoghlanian et al. 2003). 
Adenovirus infections are more severe in immunocompromised individuals than in 
immunocompetent and cause morbidity and mortality frequently (Baldwin et al. 2000; Leen 
& Rooney 2005). The fatality rate in immunocompromised individuals with pneumonia is 
60% compare with 15% in normal individuals and 50% in immunocompromised patients 
with hepatitis compare with 10% in normal individuals (Hierholzer 1992). 
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Adenovirus infections in these patients may be primary infections or because of 
reactivation of latent virus (Kojaoghlanian et al. 2003). In transplant patients the infection 
can be acquired from the donor organ (Hayashi & Hogg 2007). It is difficult to distinguish 
between primary and latent infections (Carrigan 1997).  
The overall incidence of adenovirus infections after stem cell transplant is 40%   in 
paediatrics and 10% in adults (Tebruegge & Curtis 2010). 
In bone marrow transplant patients and AIDS patients adenovirus infections occur in 
multiple sites but in solid organ transplant the infection site is usually the transplanted 
organ (Kojaoghlanian et al. 2003). Disseminated infections occur usually in bone marrow 
transplant patients and the most common isolated types are HAdV-A31, HAdV-B11 and 
HAdV-C types 1, 2 and 5 (Hierholzer 1992). 
Adenovirus infections occur usually in paediatric liver transplant recipients but cases of 
infection in adults have been reported (McGrath et al. 1998). The common isolated types 
from liver transplant patients are HAdV-C types 1, 2 and 5 (Kojaoghlanian et al. 2003). 
The disease presents as hepatitis but pneumonia, gastroenteritis and urinary tract infections 
may occur (McGrath et al. 1998). In renal transplant patients most of the cases are caused 
by HAdV-B types 7, 11, 34 and 35 (Hierholzer 1992). Haemorrhagic cystitis and nephritis 
are usually the common features in addition to pneumonia and hepatitis (Kojaoghlanian et 
al. 2003). In cancer patients the most common isolated types are 7 and 11 of species B and 
types 1, 2, 5 and 6 of species C with fatality rate 53.3 % (Hierholzer 1992; Kojaoghlanian 
et al. 2003). 
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Adenovirus can occasionally cause CNS infections such as meningitis and encephalitis 
(Wadell 2000), hepatitis (Cames et al. 1992) and nephritis the these patients (Bruno et al. 
2004). 
1.8.1 Adenovirus infections in AIDS patients: 
Species D adenoviruses are isolated commonly from stool and species B from urine of 
AIDS patients (Hierholzer et al. 1988). Early studies reported that the adenovirus detection 
rate in stool samples of AIDS patients is 29% or less (Khoo et al. 1995). However, in a 
recent study 15/20 (75%) AIDS patients were shedding adenovirus from their 
gastrointestinal tracts and more than one type was detected in 8 cases (53%) (Curlin et al. 
2010).  Real-time PCR was the method of detection in this recent study while older and less 
sensitive methods were used in the earlier study and this could be the reason of the 
difference in the detection rates. Prolonged shedding of adenovirus from the gut of AIDS 
patients was reported by Khoo et al. (1995) including shedding of more than one type 
which increases the chance for these types to undergo recombination and also for mutation 
to occur which might result in new variants or types of adenovirus (Crawford-Miksza and 
Schnurr 1996a; De Jong et al. 1999). 
 Intermediate strains have been frequently isolated from AIDS patients. These strains are 
recombinants which have the hexon of one type and the fibre of another type (Hierholzer et 
al. 1988; Hierholzer 1992). In addition, AIDS patients were the source of nine of the last 14 
described types of adenovirus (De Jong et al. 1999; Ishiko and Aoki 2009; Jones et al. 
2007; Walsh et al. 2009; Walsh et al. 2010a). 
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 1.9 Epidemiology:  
Adenoviruses cause epidemic and endemic infections (Ruuskanen et al. 2002). These 
infections are usually mild, self-limited and associated with type-specific immunity (Walls 
et al. 2003). More serious infections may be found in immunocompromised patients (Leen 
& Rooney 2005). Adenoviruses can infect people of all ages but they are most common in 
children under 5 years (Tebruegge & Curtis 2010). In one study 61.3% of patients with 
adenovirus infections were children under 5 years (Cooper et al. 2000).    
The clinical features vary depending on adenovirus type (Zhang & Bergelson 2005). 
Cooper et al. (2000) reported that A and F species were associated with infant 
gastroenteritis and species D and E were mainly associated with adult conjunctivitis. 
Species C was associated with respiratory infections in young children in addition to 
gastroenteritis. Species B was found in patients with the same syndromes which were 
associated with species C in addition to conjunctivitis.  
The virus can be shed in stools for months to years after primary infection (Fox et al. 
1977). 
Transmission of adenovirus is by faecal-oral and conjunctival routes or by aerosolized 
droplets (Tebruegge & Curtis 2010). In addition, swimming pools can be a route of 
transmission (Jiang 2006). Infections occur throughout the year (Schmitz et al. 1983) but 
some types such as 2, 4, 7 and species F have seasonal variations (Cooper et al. 2000). 
Outbreaks of acute respiratory disease (ARD), keratoconjunctivitis, pharyngoconjunctivitis 
and gastrointestinal infections caused by adenovirus have been reported in schools (Harely 
et al. 2001), day-care centres (Van et al. 1992) swimming pools (Jiang 2006) and military 
recruits (McNeill et al. 2000).  
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1.10 Diagnosis: 
1.10.1 Cell cultures: 
The best cultures for adenovirus isolation are human cells (Ruuskanen et al. 2002). Human 
embryo kidney (HEK) cells are excellent for the growth of the virus but these cultures are 
expensive (Krisher & Menegus 1987). A549 cell lines are also good for isolation for 
samples from all sites (Horwitz 2001a). Other cell cultures such as KB, HeLa and Hep2 are 
also used for adenovirus isolation (Horwitz 2001a). 
The cytopathic effect (CPE) which includes rounding and clustering of the cells can be 
observed after a few days for some types and after two or three weeks for other types 
(Straus 1984). Shell vial technique can be used for a more rapid detection (Van Doornum & 
De Jong 1998). 
The transformed 293 cell lines are used for the isolation of the fastidious enteric adenovirus 
HAdV-F40 and HAdV-F41 (Brown & Petric 1986). Electron microscopy can be used for 
direct detection of these fastidious enteric adenoviruses in the clinical specimens (Horwitz 
2001a). 
1.10.2 Serology: 
Serological methods such as complement fixation (CF), Radioimmunoassay (RIA), 
immunofluorescence (IF) and enzyme-linked immunosorbent assay (ELISA) can be used 
for further identification for the positive results in cell culture. In addition, serum 
neutralization (SN) and haemagglutination inhibition (HI) tests can be used for typing 
(Echavarria 2009; Horwitz 2001a). Some tests can be used for direct detection in the 
clinical specimens such as IF, RIA and ELISA (Hierholzer 1992). However, direct 
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detection in clinical specimens is less sensitive than cell culture isolation and detection 
(Horwitz 2001a). Serology can be used also to test the antibody responses in the patients 
which can be useful for epidemiological studies (Horwitz 2001a). There are some 
limitations of serological tests such as lack or absence of antibodies in 
immunocompromised patients (Raboni et al. 2003) or false positives because of antibodies 
from previous infections (Miller & Howell 1988).  
1.10.3 Detection of the viral DNA: 
Restriction enzymes analyses have been used for adenovirus identification (Hierholzer 
1992). The sensitivity of these methods can be improved by Southern blotting and DNA-
DNA hybridisation (Horwitz 2001a). 
Nowadays, PCR provides a rapid and sensitive technique for adenovirus identification in 
comparison with cell culture which takes a long time to obtain the result and to serological 
methods which are less sensitive than cell culture (Avellon et al. 2001). Different primers 
have been used and derived from different gene regions such as hexon (Allard et al. 1990;  
Cooper et al. 1999; Morris et al. 1996) and fibre ( Bruzzone et al. 2000). Multiplex PCR 
have been developed for identification of more than one organism (Elnifro et al. 2000; 
Grondahl et al. 1999; Jackson et al. 1996). Quantitative real-time PCR have also been 
developed and used to measure the viral load (Garnett et al. 2002; Gu et al. 2003). 
1.11 Treatment: 
There
 
are no approved antiviral agents for the
 
treatment of adenovirus infections (Walls et 
al. 2003). However, cidofovir and ribavirin have been used for treatment of these infections 
(Lenaerts & Naesens 2006). The clinical features that need treatment are adenovirus 
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infections in immunocompromised patients, keratoconjunctivitis and paediatric lower 
respiratory tract infections (Gainotti et al. 2010). 
1.11.1 Cidofovir:  
Cidofovir is one of the acyclic nucleoside phosphonates which needs two phosphorylation 
steps to be active (Cihlar & Chen 1996). The diphosphate form then acts as a nucleotide 
analogue which can inhibit the viral DNA polymerase. The higher affinity to viral DNA 
polymerase, compared to cellular DNA polymerase, is the reason of the antiviral selectivity 
of cidofovir (Lenaerts & Naesens 2006). The classical acyclic nucleoside analogues, such 
as acyclovir are ineffective against adenovirus because the virus do not encode thymidine 
kinase which is important for the first step of the phosphorylation of these compounds (De 
Clercq 2003). 
It has been reported that 31/45 (69%) of patients with adenovirus infection from 10 centres 
were successfully treated with cidofovir after allogeneic haematopoietic stem cell 
transplantation (Ljungman et al. 2003). Hillenkamp et al. (2002) found that topical 1% 
cidofovir has an effect in the treatment of acute adenoviral keratoconjunctivitis but the local 
toxicity limited its frequent use. Cidofovir is described as the most effective antiviral agent 
for adenovirus infections treatment (Lindemans et al. 2011). However, there is a potential 
renal toxicity (Ljungman 2004) and probenecid is another drug which has been used with 
cidofovir to protect the kidney and to increase its plasma levels (Lindemans et al. 2011). 
1.11.2 Ribavirin: 
Ribavirin has multiple mechanisms of action but only some of them may affect adenovirus 
such as enhancing T-cell response and inhibition of cellular inosine monophosphate 
dehydrogenase which results in guanosine triphosphate (GTP) pools reduction (Graci & 
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Cameron 2006; Lenaerts & Naesens 2006). Ribavirin treatment of adenovirus infections 
has had variable success (Kinchington et al. 2005; Ljungman 2004). Morfin et al (2005) 
reported that only species C adenoviruses are susceptible to ribavirin. However, the same 
group found that clinical isolates from species A, B and D isolates are also susceptible to 
this drug (Morfin et al, 2009).  
1.11.3 Immunotherapy: 
Immunotherapy has been used as an alternative treatment of adenovirus infections such as 
intravenous immunoglobulin (Lenaerts & Naesens 2006), adenovirus-specific T cells (Leen 
et al. 2006)  and donor lymphocytes infusions (DLI) (Lindemans et al. 2011). 
1.12 Adenovirus vectors:  
About 70% of gene therapy clinical trials have used viral vectors (Edelstein et al, 2004). 
Adenovirus vectors are the most commonly used vector in these clinical trials (Fig. 1.6). 
These vectors have been used by researchers for many purposes such as delivery of genes 
responsible for the control of cell growth, to correct naturally occurring mutations or to 
stimulate the immune response (Horwitz 2001a). They have also been used experimentally 
as recombinant vaccines for HIV (Barouch and Nabel 2005) and malaria (Bruder et al. 
2010) in addition to gene therapy of cancer, monogenic diseases, cardiovascular diseases 
(Edelstein et al. 2007) and others. 
The first generation of adenovirus recombinant vectors was E1 deleted vectors. The early 
regions E1A, E1B are deleted and expressed by the cell line in which the vector is produced 
(Young et al. 2006). The deletion of these regions prevents the activation of gene 
expression and allows the insert of approximately 5 kb of foreign DNA (Goncalves & De 
Vries 2006). Deletion of E3 genes which is nonessential for replication increases the 
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capacity of the vector to 8 kb (Goncalves & De Vries 2006). The first approved gene 
therapy for head and neck cancer in China is an example of the first generation vectors 
(Perason & Kandachi 2004).  
The second generation of adenovirus vectors was developed by further deletion of the E2A, 
E2B and E4 regions to reduce the immune response (Goncalves & De Vries 2006; Young 
et al. 2006). The third generation vectors (the high capacity or gutless vectors) contain only 
the inverted terminal repeat (ITR) and the packaging sequences. The capacity of these 
vectors is very high (Young et al. 2006). The immune response of this generation is less 
than the first and the second ones and the safety is better (Goncalves & De Vries 2006). 
The advantages of adenovirus as a vector are the ability to produce a large amount of the 
virus in high titre, the wide range of host cells and the ability of adenovirus to insert large 
foreign DNA (Quantin et al. 1992). On the other hand, the innate and pre-existing 
immunity to adenovirus vectors is a big disadvantage of these vectors (Zaiss et al. 2009). 
Another disadvantage is the toxicity effect of the adenovirus with the intravenous 
administration (Young & Mautner 2001). HAdV-C5 is the most commonly used type of 
adenovirus as a vector. However, development of vectors from different adenovirus species 
such as HAdV-B (McVey et al. 2010) and HAdV-D (Baden et al. 2009) is ongoing to 
avoid the pre-existing immunity to HAdV-C5.  Other strategies have been used to avoid the 
pre-existing immunity to adenovirus includes modifying the viral capsid and using helper-
dependent vectors (Zaiss et al. 2009). The possibility of interaction between wild type 
adenoviruses and adenovirus vectors has not been studied.  
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Figure 1.6: Vectors used in the clinical trials of gene therapy. Figure was taken from:  
(http://www.wiley.com//legacy/wileychi/genmed/clinical/) with permission from the publisher 
(Accessed on 4/5/2011).  
 
1.13 Adenovirus persistence and latency: 
Adenovirus can be shed in the stool after acute infection for months or years which 
indicates that adenoviruses are able to establish persistent infections (Fox et al. 1977). 
Persistent adenovirus infection was detected in a lymphoblastoid cell line from a bone 
marrow transplant recipient with B-cell lymphoproliferative disease and adenovirus 
pneumonia (Flomenberg et al. 1996). Andiman & Miller (1982) established chronic 
infection of adenovirus types 5 and 6 in EBV-transformed human lymphocytes. These cells 
contained small amounts of the virus for a long time even after exposure of the cells to 
antibodies which indicates nonlytic infection of adenovirus.  
No infectious adenovirus can be cultured from adenoids and tonsils immediately after 
excision in most of the cases. However, infectious virus could be detected weeks or months 
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later (Rowe et al. 1953; Van Der Veen & Lambriex  1973). Garnett et al. (2002) detected 
group C adenovirus DNA in lymphocytes from 33 of 42 (79%) lymphoid tissue samples by 
using real time PCR even when cultivation failed. They suggested that T lymphocytes 
could be the place of the latent adenovirus in tonsils and adenoids. The same group detected 
HAdV-C in 85% of tested tonsils and adenoids lymphocytes by real- time PCR (Garnett et 
al. 2009). Viral transcripts were detected rarely in samples but mRNA was detected in most 
of the samples after stimulation in cell culture.   
Adenovirus can establish a latent infection in other tissues such as the lung epithelial cells 
(Lichtenstein & Wold 2004). Hayashi (2002) found that latent adenovirus infections may 
play a role in the pathogenesis of chronic obstructive pulmonary disease (COPD). In 
addition, adenovirus DNA was detected by PCR in 78.4% of asthmatic children during 
symptom-free periods. This suggests a possible role of adenovirus in asthma (Marin et al. 
2000).  Reactivation of a latent infection may cause serious infections in 
immunocompromised patients including transplant recipients (Hayashi & Hogg 2007; 
Kojaoghlanian et al. 2003). 
The molecular mechanisms of adenovirus persistence and latency are not clear (Horwitz 
2001a). However, the maintenance of persistent or latent adenovirus infection could be 
related to the ability of the immune response to limit but not eliminate the infection because 
the virus can evade the immune system using different mechanisms (Pereira 1972; Routes 
& Cook 1989). These mechanisms include inhibition of apoptosis by immune-regulatory 
proteins such as E1B-55K, E1B-19K, E4 ORF6 and E3 region proteins (McNees and 
Gooding 2002). It was suggested that E3 promoter is upregulated in persistently infected T 
lymphocytes by cellular activation signals even with no expression of E1A (Mahr et al. 
2003). 
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Pereira (1972) suggested that the maintenance of persistent or latent adenovirus infection 
could be related to incorporation of the viral genome or part of it into the human cells. In 
another study, Green et al. (1979) analysed HAdV-C2 DNA from tonsils by Southern 
blotting using EcoRI which gives 6 fragments with HAdV-C2. However, 4/5 tested 
samples showed the 6 fragments of HAdV-C2 in addition to extra fragments which did not 
resemble any other fragments of other species C types and they suggested that this unusual 
form of DNA detected in tonsils might be an integrated DNA in the cellular genome or 
recombination between two types of the virus. On the other hand, a recent study compared 
HAdV-C2 and HAdV-C5 DNA from two persistently infected cell lines with purified viral 
DNA from non-persistently infected cells using restriction enzymes and Southern blotting. 
Similar fragments were detected with the DNA from persistently infected and non-
persistently infected cells which suggested that DNA extracted from persistently infected 
cell lines was free and not attached to cellular DNA (Zhang et al. 2010). 
1.13.1 DNA methylation and persistence/latency: 
DNA methylation is common in different organisms and involves adding a methyl group to 
the cytosine of the CpG dinucleotides (Doerfler 1981). This DNA modification suppresses 
gene expression by different ways such as preventing the transcription factors from binding 
to specific sequences such as promoters or by binding of specific proteins to the methylated 
sites which results in transcription suppression (Hoelzer et al. 2008; Razen and Cedar 
1991). Methylation of specific promoters in Epstein-Barr virus (EBV) helps the virus to 
escape the immune response and plays a role in its latency (Ambinder et al. 1999; Tao & 
Robertson 2003). 
Adenovirus DNA is not methylated in general (Gunthert et al. 1976) and no DNA 
methylation was found in the major late promoter region of HAdV-C2 isolated from 
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infected cells between 1 and 48 hours after infection (Kämmer & Doerfler 1995). However, 
adenovirus DNA integrated into the host cell genome becomes highly methylated (Doerfler 
et al. 2001). In vitro methylation of a specific site on the adenovirus major late promoter 
(MLP) resulted in inhibition of transcription factors binding (Watt & Molloy 1988). This 
mechanism could be used by adenovirus to establish latent or persistent infections and 
needs further investigation.     
1.13.2 Adenovirus latent infection and chronic obstructive pulmonary disease 
(COPD): 
Chronic obstructive pulmonary disease (COPD) is associated with irreversible limitation of 
airflow and inflammatory response of the lung (MacNee 2003; Singh 2003). The main risk 
factor for the development of COPD is smoking. Respiratory infection in childhood such as 
adenovirus infections is another risk factor (Hayashi 2002). Many studies found that 
adenovirus infections amplify the inflammation induced by cigarette smoking in COPD 
patients and this increase in the inflammatory response is not because smoker patients are 
more susceptible to these infections than other patients (Hayashi 2002; MacNee 2003; 
Singh 2003). 
Adenovirus E1A DNA fragment was found in integrated form in chromosome 19 of lung 
epithelial cells in five out of nine patients with COPD (Hayashi et al. 2000). In addition, 
more copy numbers of E1A of adenovirus DNA was detected in epilithia of COPD smoker 
patients than in smoker controls (Matsuse et al. 1992). Adenovirus is able to establish 
persistent or latent infections and these infections might be the origin of E1A which has 
been found to play a role in COPD pathogenesis (Hayashi 2002; Hayashi & Hogg 2007).   
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The latent infection of adenovirus caused inflammation response and increase in 
macrophage and lymphocytes in animal models after exposure to cigarette smoke and this 
response was more than the response caused by cigarette smoke in animals without 
adenovirus infection (Vitalis 1998). It was found that E1A regulates the expression of 
inflammatory mediators such as interleukin IL8 in response to stimulation of environmental 
particles in COPD patients. (Hayashi & Hogg 2007; Higashimoto et al 2002). 
1.14 Adenovirus genome stability: 
Understanding of the genome stability of adenovirus is important for vaccine and vector 
development. Adenovirus can undergo antigenic shifts (recombination) and antigenic drifts 
(mutations) (Crawford-Miksza and Schnurr 1996a). Recombination has been well 
documented in adenoviruses (Robinsons et al. 2009a; Walsh et al. 2009; Wigand & Adrian 
1989). Historically, the intermediate strains, which have hexon of one type and fibre of 
different type, used to be detected by the conflicting results of the serum neutralization  
(SN) and haemagglutination inhibition (HI) tests (Hierholzer 1992). Limited sequencing of 
the hexon and fibre has been used to detect this kind of recombination (Madisch et al. 
2005; Madisch et al. 2006). In addition, sequencing of other regions of adenovirus genome 
revealed hot spots of recombination within some genes such as hexon and penton 
(Robinson et al. 2009a; Walsh et al. 2009). Moreover, recombination events in other 
coding and non-coding regions have been detected using full genome sequencing and 
analysis (Walsh et al. 2009). 
Sixteen field isolates of species C adenovirus were sequenced and analysed in four genome 
regions: hexon, fibre, DNA polymerase and E1A regions. Many mismatches were observed 
in the DNA polymerase and E1A regions which indicated recombination events in these 
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non-structural regions (Lukashev et al. 2008). In the same study, similarity plot analysis of 
the full length genome of types from different adenovirus species suggested that 
recombination between types within the same species had occurred in the origin of 
adenovirus types from species B, C and D.  
Coinfections of more than one type of adenovirus have been reported which gives these 
types the opportunity to interact and for recombination to occur (Echavarria et al. 2006; 
Vora et al. 2006). This could be observed in special cases such as AIDS patients from 
whom many types of adenovirus were identified especially from species D (De Jong et al. 
1999). All these findings suggest that recombination plays an important role in adenovirus 
evolution.  
The changes in the adenovirus genome may result in more virulent variants (Walsh et al. 
2010). In addition it could result in the emergence of new types of adenovirus such as 
HAdV-D53 (Walsh et al. 2009). It could also change the neutralizing epitopes such as 
HAdV-B55 (Walsh et al. 2010a) or the tropism such as HAdV-D56 (Robinson et al. 2010). 
On the other hand, recent studies suggest that adenovirus genome is stable over long 
periods of time. These reports used the full genome sequencing to compare prototype 
strains which were isolated in the 1950s and recently isolated field strains. 
Full genome sequencing of three strains of HAdV-C was carried out (Seto et al. 2010a). 
One of the isolates was representing the prototype which was isolated in 1953. The second 
was a laboratory strain which was circulating in laboratories for over 39 years. The third 
strain was a field strain which was isolated in 1998. The comparison of these strains 
revealed very limited changes and no recombination events which indicate that HAdV-C5 
genome is stable over long period of time. 
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Four strains of HAdV-B3 were analysed in another study (Mahadevan et al. 2010). One 
strain was the prototype strain which was isolated in 1953.  Two other recent clinical 
strains from China and one from USA were also analysed. In addition, a laboratory strain 
(isolated in 2005) was included in the analysis. The full genome sequencing and 
comparisons of these strains revealed also that HAdV-B3 is stable over more than 50 years. 
Comparisons of prototypes, vaccine strains and field strains of HAdV-B7 and HAdV-E4 
showed limited changes over a long period of time also suggests that adenovirus genome is 
stable (Purkayastha et al. 2005). This indicates that old vaccines produced from these 
strains could be effective for a long period of time (Seto et al. 2010b). 
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1.15 Aims of the project: 
There are two main parts of this research project: 
1- With the recent use of adenovirus as a vector for gene and vaccine therapy in many 
clinical trials and the possible need of a vaccine against specific types of HAdV in the 
future, more information about their genome stability is needed. This will help in assessing 
possible recombination between wild type adenovirus and vector or vaccine strains. This 
will also give a better understanding of adenovirus evolution. 
The first aim of this research project is to study the genome stability of two species of 
adenovirus D and B. Two groups of adenovirus clinical isolates will be investigated by 
sequencing and phylogenetic analysis of different genome regions: 
- The first group contains HAdV-D isolates collected from AIDS patients and most of 
them had contradictory typing results of the hexon L2 and fibre knob genome 
regions in addition to some with unknown hexon L2 and/or fibre knob regions.  
Sequencing and phylogenetic analysis of the hexon L1, fibre shaft and penton 
regions will be performed to detected any intergene recombination between the 
hexon, fibre and penton regions or any intragene recombination within these three 
regions. This analysis will help also to detect possible new types of adenovirus. The 
genomes of these possible types will be fully sequenced and analysed.  
- The second group contains HAdV-B isolates from a 15 months simultaneous 
outbreak of HAdVB3 and HAdVB7 occurring in the Manchester area in addition to 
types 3 & 7 isolates from different years following the outbreak and isolates from 
different types of HAdV-B.  Sequencing and phylogenetic analysis of the hexon L2, 
fibre knob, penton, DNA polymerase and E1A regions will be performed to 
investigate recombination events between species B types in these regions, 
especially the outbreak isolates which had the chance to interact because they were 
circulating in the same region and at the same time. Another aim of this part of the 
study is to detect any change in the clustering patterns over time.    
2- Adenoviruses are able to establish persistent and latent infections in human tissues. 
Studying of adenovirus persistence and latency is important because the nature and 
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mechanisms of this persistence and latency is not clear and reactivation of these latent 
viruses may cause severe infections in immunocompromised patients. In addition, these 
latent infections may play a role in the pathogenicity of some respiratory infections. 
Moreover, recombination between adenovirus vectors and latent adenoviruses may occur. 
The aim of this part of the research project is to provide a good understanding of 
adenovirus persistence and latency in human tonsillar and adenoid tissue.  
The tonsillar and adenoid tissues will be collected from the operating theatre after excision. 
Lymphocytes will be isolated and stored in aliquots in liquid nitrogen. Samples will be 
examined for evidence of adenovirus infection and viral load will be determined by real-
time PCR then sequencing procedure and phylogenetic analysis will be used for virus 
typing. In addition, one of the possible mechanisms of latency which is DNA methylation 
will be investigated.  
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2. Materials and Methods 
2.1 Materials: 
AdEasy
TM
 virus purification kit was supplied by Agilent Technologies, USA. 
Benzonase® endonuclease was supplied by Merck KGaA, Germany. 
Big Dye® Terminator v.1.1, 5X Big Dye sequencing buffer, Hi Di TM Formamide, 
TaqMan® Universal PCR  Master Mix, TaqMan® Probe, MicroAmp™ 48 and 96-well 
plates with optical caps were supplied by Applied Biosystems, UK. 
Deoxynucleoside triphosphates and EasyLadder I were supplied by Bioline Ltd., UK. 
E-Gel®  2% agarose gels and adenovirus 2 DNA were supplied by Invitrogen, UK. 
Ethanol was supplied by Fisher Scientific, UK. 
ExoSAP-IT
TM
 PCR clean up reagent was supplied by USB Corporation, USA. 
FastRead® disposable counting slides were supplied by Immune Systems Ltd, UK. 
HAdV-C2 whole genome DNA was supplied by Gibco, UK.  
Minimum essential media Eagle, L-glutamine-penicillin-streptomycin stabilised solution, 
Hank’s Balanced Salt Solution 10X, 1M HEPES buffer, 10mg/ml gentamicin solution, 
antibiotic-antymycotic mixture 100X, fetal calf serum, NaCl, Tris-Cl, EDTA, phenol-
chloroform-isoamyl alcohol, chloroform, sodium acetate, dimethyl sulfoxide and 10X 
trypsin-EDTA solution were supplied by Sigma-Aldrich, UK.  
Nuclease-free sterile distilled water was supplied by Promega Corporation, UK. 
Oligonucleotide primers were purchased from Eurofins MWG Operon, UK. 
Plasmid (pCR®2.1-TOPO) was provided by Dr. Robert J. Cooper. 
QIAamp® DNA Mini Kit, HotStar® Taq polymerases and appropriate PCR Buffer, 
proteinase K and EpiTect® Bisulfite kit were supplied by Qiagen Ltd., UK. 
Tissue sieve was supplied by Bello Glass, USA. 
59 
 
2.2 Clinical samples and isolates: 
2.2.1 Species D clinical isolates from AIDS patients: 
A total of 31 clinical isolates from AIDS patients and their contacts collected between 1986 
and 1994 were kindly supplied by Mr. Andrew Bailey, Diagnostic Virology Laboratories, 
Manchester Royal infirmary, Manchester, UK. They include 20 isolates from 6 HIV 
patients, 2 isolates from 2 contacts of AIDS patients and 9 isolates where their case sources 
have not been recorded. These isolates were typed previously using serum neutralization 
(SN) by Mr. Andrew Bailey. There were also typed by phylogenetic analysis of the hexon 
L2 and fibre knob regions (Al Qurashi, 2009).  
2.2.2 Species B clinical isolates: 
A total of 96 isolates of HAdVB were kindly supplied by Mr. Andrew Bailey who had 
typed them by SN. Twenty seven HAdV-B3 & 35 HAdV-B7 were collected during a 15 
month outbreak between December 1983 and February 1985 and a further 23 isolates of 
HAdV-B3 & HAdV-B7 were collected from 1986-1997. In addition, 11 isolates of other 
types of HAdV-B (HAdV-B11, HAdV-B16, HAdV-B21 and HAdV-B35) were included in 
this study. All samples were collected in Manchester.  
2.2.3 Tonsils and adenoids samples: 
Tonsils and adenoids (106 right and left tonsils and 10 adenoids) were obtained from 57 
patients (31 female and 26 male with age range 1-16 years) who underwent routine 
tonsillectomies and/or adenoidectomies at St. Mary’s Hospital and Royal Manchester 
Children’s Hospital, Manchester, UK. The study has ethical approval: REC reference 
number 07/H1011/70. The patient or the legal guardians of the patient read and signed a 
consent form and received a leaflet of information about the research project.  
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2.3 Methods: 
2.3.1 Lymphocyte isolation from tonsils and adenoids: 
The tissues were prepared as described by Garnett et al (2002) by collecting them in HH5 
media containing 25mM HEPES, Hank’s balanced salt solution 1X, 5% fetal calf serum, 
0.05 mg/ml gentamicin and 1% antibiotic antimycotic mixture (10,000 units/ml penicillin 
G, 10 mg/ml streptomycin sulfate and 25 µg/ml amphotericin B in a proprietary citrate 
buffer). Tissues were processed within 3 hours of collection. The right and left tonsils and 
the adenoids were processed separately when they were available from the same patient. 
2.3.1.1 Enzymatic disruption:  
Tissues were minced into small pieces using sterile scissors and scalpel and transferred into 
a bottle containing 0.25 % trypsin in PBSA (8g/L NaCl, 0.2g/L KCl, 2.89g/L Na2HPO4 
6H2O and 0.2g/L KH2PO4). The bottle was incubated at 37° C on a rotating wheel for 
various times (30 minutes, 1 hour, 3 hours and overnight). 
2.3.1.2  Mechanical disruption: 
The tissue was washed by PBS buffer, minced into small pieces using sterile scissors and 
scalpel and pushed through cotton muslin into 10 ml of HH5 media using the plunger from 
a sterile plastic syringe to produce single cell suspension. The cotton muslin was rinsed by 
another 10 ml of HH5 medium and this wash together with the first suspension were 
transferred into a 50 ml centrifuge tube. The cells were centrifuged at 2000 rpm for five 
minutes, washed in 15 ml of HH5 medium and finally suspended in 10 ml HH5 media.  
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A second mechanical disruption method was applied using the same procedure except the 
single cell suspension was produced by pushing the tissues through a stainless steel tissue 
sieve instead of the cotton muslin. 
The cells were counted using FastRead disposable counting slides and stored in liquid 
nitrogen in aliquots of 1 × 10
8
 cells per ml of freezing medium containing 90% fetal calf 
serum and 10% dimethyl sulfoxide (DMSO). Cells were prepared for DNA extraction by 
thawing aliquots, washing and resuspending cells in 3 ml of HH5 medium and DNA was 
extracted from 5 × 10
6
 cells. 
2.3.2 DNA Extraction from lymphocytes and virus isolates: 
DNA was extracted using QIAamp DNA mini kit according to manufacturer's instructions. 
Briefly, 20µl of Protease was added to the sample (5 × 10
6
 cells or 200µl of the isolates) in 
1.5 ml microcentrifuge tube, followed by 200µl of buffer AL. After incubation at  56 ºC for 
10 minutes, the tube was centrifuging briefly before adding 200µl  of ethanol and 
centrifuged again. The mixture was applied to a QIAamp Spin Column and centrifuged at 
8000 rpm for 1 minute. The filtrate was discarded and QIAamp Spin Column was placed in 
a clean 2 ml collection tube.  
The column was washed with 500µl of buffer AW1 by centrifugation at 8000 rpm for 1 
minute followed by washing in 500µl of buffer AW2 and  centrifuging  at 14000 rpm for 3 
minute. Finally, the DNA was eluted from the column with 150µl buffer AE (10 mM Tris 
HCl; 0.5 mM EDTA; pH 9.0) by incubating at room temperature for 1 minute and then 
centrifuging at 8000 rpm for 1 minute. The eluted DNA was stored at -20ºC. The 
composition of some of the above mentioned buffers has not been released by the 
manufacturer.     
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2.3.3 Polymerase chain reaction (PCR): 
2.3.3.1 PCR contamination prevention: 
Three different rooms were used for PCR to reduce the risk of contamination. A DNA-free 
room where the master mix and the reagents were prepared. Ultra-violet (UV) was applied 
before and after using the room. A sample preparation room where the DNA was extracted 
and added to the master mix and UV was also applied before and after use. Finally, a third 
room was for the amplification process by the thermo cycler machine and for running gels. 
Also, cabinets were used for the preparation of reagents and addition of extracted samples 
and plugged tips were used throughout.  
2.3.3.2 Primers:  
Nested PCR (Lu and Erdman 2006) was used to amplify the hexon L1 region including the 
highly variable regions (HVR1-6) of the genome of tonsils and adenoids samples and 
species D clinical isolates. The external primers were AdhexF1: 5’TIC TTT GAC ATI CGI 
GGI GTI CTI GA3’ (Position 19135–19160 corresponds to HAdV-C2: J01917) and 
AdhexR1: 5’CTG TCI ACI GCC TGR TTC CAC A3’ (Position 20009–20030). The 
internal primers were: AdhexF2: 5’GGY CCY AGY TTY AAR CCC TAY TC3’ (Position 
19165–19187) and AdhexR2 5’GGT TCT GTC ICC CAG AGA RTC IAG CA3’ (Position 
19960–19985). These internal primers generate an amplicon of 820bp. 
To amplify the fibre knob and part of the fibre shaft region in species D, primers 
FiDL/ADD2 were used. Two sets of primers were used to amplify a central fragment of 
species D penton including the hypervariable region (HVR) and RGD regions: P1D set of 
primers containing P1DL/P1DR and P2D set of primers containing P2DL/P2DR (Table 
2.1).  
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Fragments from different genome regions of species B clinical isolates where amplified by 
PCR using different sets of primers. HSAd1, HSAd2 primers were used to amplify the 
hexon L2 region (HVR7). The fibre knob was the target of a second set of primers FiBR, 
FiBL. Different primers (AdPOL1F/AdPOL1R, AdPOL2F/AdPOL2R) were used to 
amplify two fragments of the DNA polymerase gene. Fragments of E1A region were 
amplified using primers modified to be specific for HAdV-B subspecies B1 (AdE1B-
F/AdE1B1-R) and B2 (AdE1B-F/AdE1B2-R) of HAdV. Different primers (P1BL/P1BR, 
P2BL/B2BR) were used to amplify two fragments of the penton region (Table 2.2). The 
modified primers parameters were tested using an online software Primer3 (Rozen & 
Skaletsky 1999, http://frodo.wi.mit.edu/primer3/). Mobyle@Pasture portal (Rice et al, 
2000, http://mobyle.pasteur.fr/cgi-bin/portal.py?#forms::merger) was used to merge the two 
sequenced fragments when two sets of primers were used.  
Tables 2.1 and 2.2 summarise the above mentioned primers:   
Primer Target 
region 
Sequence 5’-3’ Amplicon 
size (bp) 
Primers 
position 
(HAdV-D9, 
AJ854486) 
Reference 
FiDL 
 
ADD2 
Fibre ATGTCTCACTCAAGGTGGGA 
 
GCTGGTGTAAAAATCAATAAAGA 
1000 31092-31111 
 
32044 -32066 
Madisch 
et al. 
(2005) 
P1DL 
 
P1DR 
Penton  ACTACCAAAACGACCACAGC 
 
CCTCATACATGATTCTGAAGC 
599  14303-14323 
 
14699-14683 
Madisch 
et al. 
(2007) 
P2DL 
 
P2DR 
TTCGCAAGAAGC AACCTTT 
 
TCTTGCATGAGGTCCGG 
423 13724-13743 
 
14276-14294 
 
Table 2.1: Primers used for HAdV-D isolates genome regions amplification. The table summarises: 
 primer name, target region, primer sequence, amplicon size, primer position and reference.
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Primer Target 
region 
Sequence 5’-3’ Amplicon 
size (bp) 
Primers position 
(HAdV-B3: AY599834) 
Reference 
HSAd1 
HSAd2 
Hexon L2 
(HVR7) 
ATGTACTACAACAGCACTGGCAACATGGG 
GCGTTGCGGTGGTGGTTAAATGGGTTTACGTTGTCCAT 
 
629  19879-19910  
20470- 20507 
Sarantis et al 
2004 
FiBL 
FiBR 
Fibre  TACCCCTATGAAGATGAAAGCA 
GGAGGCAAAATAACTACTCG 
 
987  31362-31384 
32343-32363 
 
Madisch et al, 
2005 
AdPOL1F 
AdPOL1R 
  
DNA 
polymerase 
GCAAAAGTGTCCCTGACCATGAC 
GTGGAAACCTACACCTGGATGGG 
 
653  
 
 
7143-7166 
7772-7795 
Modified from 
Lukashev et al, 
2008 
AdPOL2F 
AdPOL2R  
TGGCGAGGTCATAGGCGAT 
GGTAGCGCCCAAGGGRCAC 
683  7684-7703 
8347-8366 
AdE1B-F 
AdE1B1-R 
E1A CTGYGGGGTKAACGGYTA 
CTGGGAGCAGCTGAAATGGA 
830  87-105 
896-916 
Modified from 
Lukashev et al, 
2008 
AdE1B-F 
AdE1B2-R 
CTGYGGGGTKAACGGYTA 
TTGRGTTCCGTGGACTGTGA 
 
822  87-107 
888 -908 
P1BL 
P1BR 
 
Penton  TACGAGAGCGTGATGCAGC 
CGAACTTAACACCAATGTCAC   
597  
 
13965-13984 
14541-14562 
Madisch et al, 
2007 
P2BL 
P2BR 
GTGCAGAACAATGACTTTACC  
AGGAACGTTTTCACTGACGG 
1196 14190-14211 
15366-15386 
 
Table 2.2: Primers used for HAdV-B isolates genome regions amplification. The table summarises: primer name, target region, primer 
sequence, amplicon size, primer position and reference. 
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2.3.3.3 PCR sensitivity: 
The sensitivity of the nested PCR only was determined because it was used to amplify the 
DNA from tonsils and adenoids while the other primers were used to amplify DNA from 
isolates. Plasmid DNA containing the 140 bp HAdV-C2 PCR product of AdRJC1/AdRJC2 
primers,  of known copy number together with HAdV-C2 whole genome DNA of unknown 
copy number were used to assess the sensitivity of the nested PCR. Primers AdRJC1: 5'-
GAC ATG ACT TTC GAG GTC GAT CCC ATG GA-3' (Position  21589-21617 
corresponds to HAdV-C2: J01917) and AdRJC2: 5'-CCG GCT GAG AAG GGT GTG 
CGC AGG TA-3' (Position 21703-21728 ) (Cooper et al 1999) target the highly conserved 
region of  the carboxyl end of the hexon gene and amplify a 140 bp product.  
2.3.3.4 Gel-based PCR: 
Each PCR reaction contained 10mM Tris-HCl pH 8.3, 50mM KCl, 1.5 mM MgCl2, 0.2 µM 
of each primer, 0.2 mM of each deoxynucleoside triphosphate (dNTP), 1.25U of HotStar 
Taq DNA Polymerase in a total volume of 50µl. Every PCR run included an extraction 
control, negative control (distilled H2O) and a positive DNA control. Positive controls are 
DNA extracts from isolates typed previously using both serum neutralization (SN) and 
sequencing of the hexon L2 region. Amplification was carried out using GenAmp® PCR 
system 9700 thermal cycler (Applied Biosystems) . 
For AdRJC1/AdRJC2 primers the following cycling conditions were used: 
Initial denaturing at 94ºC for 7 minutes, followed by 40 cycles of denaturing at 94 ºC for 30 
seconds, annealing at 55ºC for 30 seconds and extension at 72 ºC for 45 seconds. Finally, 
there was further extension step of 72 ºC for 3 minutes. 
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Nested PCR was carried out using the external primers AdhexF1/AdhexR1 and the internal 
primers AdhexF2/AdhexR2. The internal amplification was performed using 0.5μl of the 
amplicons obtained from the external reaction. Both amplification programmes started with 
15 minutes activation at 95°C followed by 40 cycles of 1 minute at 94°C, 1 minute at 45°C 
and 2 minutes at 72°C, followed by final extension of 72°C for 5 minutes. 
The cycling conditions for the penton primers for species B (P1BL/P1BR, P2BL/B2BR)  
and species D (P1DL/P1DR , P2DL/P2DR) were:  15 minutes of activation  at 95°C 
followed by 40 cycles of 20 seconds at 94°C, 20 seconds at 57°C and 40 seconds at 72°C 
and final extension of  72°C for 5 minutes.  
For all other primers the following cycling conditions were used: 
Initial denaturing at 95ºC for 15 minutes followed by 40 cycles of denaturing at 95 ºC for 1 
minute, annealing at 51ºC for 1 minute and extension at 72 ºC for 1 minute. The final step 
was an incubation period for 72 ºC for 3 minutes. 
2.3.3.5 Detection of PCR products by 2% E-Gel electrophoresis: 
The PCR products were run on 2% agarose E-Gel and the molecular weight of the products 
was estimated using a quantitative DNA ladder which consists of five linear double strand 
DNA fragments ranging from 100 bp to 2000 bp. The gel then was visualized and 
photographed with AlphaImager 2200 (Alpha Innotech, USA). 
2.3.3.6 Real-Time PCR: 
Real-time PCR was used for quantitative analysis of HAdVs in lymphocytes from tonsils 
and adenoids. AdRJC1 and AdRJC2 primers (2.3.3.3) were used in this assay together with 
TaqMan probe: 5’FAM-CAC CGC GGC GTC AT-MGB3’ (position 21679-21692 
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corresponds to HAdV-C2: J01917; designed by Dr. Malcolm Guiver and used routinely in 
the Diagnostic Virology Laboratories, Manchester Royal infirmary). The amplification was 
carried out using TaqMan® Universal PCR Master Mix with AmpErase® Uracil N-
glycosylase (UNG) (containing dNTPs, MgCl2 and Taq DNA polymerase), 0.2µM of 
TaqMan probe, 0.3µM of each primer and 2µl of DNA in a final volume of 20µl. 
The reactions were performed in a 48-well plate using Applied Biosystems StepOne™ 
Real-Time PCR System and the following conditions were used: 
One cycle of 50 ºC for 2 minutes then 1 cycle of 95 ºC for 10 minutes followed by 50 
cycles of 95 ºC for 15 second and 60 ºC for 1minute. 
Ten-fold serial dilutions (10
-5
-10
-10
) of purified plasmid DNA containing the target region 
of the adenovirus genome were used to determine the sensitivity of the assay. Some of the 
higher dilutions were run on four replicates and the lower dilutions were run in three 
replicates. Negative controls were included in all runs.   
The cycle threshold (Ct) value, which is the number of cycles required for the fluorescent 
signal to exceed the background level, was determined for each replicate. A standard curve 
was constructed by plotting the Ct values against the starting quantities of plasmid DNA. 
2.3.4 Sequencing: 
2.3.4.1 PCR and product purification: 
The amplified PCR products were purified from unconsumed dNTPs and primers using 
ExoSAP-IT PCR clean up reagent based on Exonuclease I/Shrimp Alkaline Phosphatase 
Method. Briefly, 5µl of PCR product was mixed with 2µl of the clean up reagent in a 96 
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well plate. The mixture was incubated for 15 minutes at 37°C to degrade remaining primers 
and nucleotides then 15 minutes at 80°C for inactivation of the reagent. 
2.3.4.2 Sequencing reaction: 
Two sequences reactions were prepared and both strands of DNA were sequenced 
separately. The sequencing reaction contains sequencing buffer, Big Dye ((fluorescent dye-
labeled dideoxy terminators), forward or reverse primers (0.5µM) and 1µl of purified PCR 
product in final volume of 20µl.  The sequencing reaction was carried out in GeneAmp
® 
 
PCR System 9700 Thermal cycler (Applied Biosystems ) and the following conditions 
were used: an initial denaturing cycle of  96 ºC for 60 seconds, followed by 25 cycles of 96 
ºC for 10 seconds, 50 ºC for 5 seconds and 60 ºC for 4 minutes.  
2.3.4.3 Purification of sequencing reaction products: 
Sequenced products were purified using the ethanol/sodium acetate clean up method. Fifty 
microliter of 100% ethanol and 2 µl of sodium acetate pH 4.6 were added to each well then 
the plate was sealed. The plate was inverted three times for mixing and centrifuged at 
2000g for 20minutes in plate centrifuge. The plate was then inverted on absorbent paper 
and centrifuged at 150g for 1 minute. To each well, 150µl of 70% ethanol was added and 
the plate was centrifuged again at 2000g for 5 minutes, inverted on absorbent paper and 
centrifuged at 150g for 1 minute. The plate was then sealed and stored at -20 ºC in the dark 
until use.  
2.3.4.4 Sequencing analysis: 
The samples were removed from -20 ºC and left at room temperature for 5 minutes. Hi- Di 
formamide (20µl) was added to each well and the plate heated in a thermal cycler at 50 ºC 
for 5 minutes. The plate was put in ABI PRISM
®
 3100 Genetic Analyzer (Applied 
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Biosystems) to carry out the sequencing analysis and data collection was done by 3100 
Data Collection software and ABI PRISM Sequencing Analysis software (Applied 
Biosystems). Sequencher software v 4.0.5 (Gene Codes Corporation) was used to assemble 
the forward and reverse sequences. 
2.3.5 Phylogenetic Analysis: 
The sequences of the targeted regions of adenovirus prototypes in addition to the sequenced 
samples or isolates were used to build phylogenetic trees by DNA distance neighbor joining 
method. BioEdit v7.0.5 (Hall, 1999) was used for sequence editing. ClustlX v1.83 
(Thompson et al. 1997) was used for calculating the sequence alignments. Phylogenetic 
trees were constructed by the neighbour-joining method using Phylo-win software v2 
(Galtier et al. 1996) by the DNA distance neighbour joining method and a Kimura two 
parameter substitution model. Bootstrap analysis was performed with 1000 
pseudoreplicates. The phylogenetic trees were drawn by TreeView v1.6.6 (Page, 1996). 
The accession numbers of the sequences which were used to construct the phylogenetic 
trees for species B are shown in Table 2.3. Those used to construct the phylogenetic trees 
for the hexon, fibre and penton are shown in Table 2.4.  
HAdV-B type Accession number 
HAdV-B3 GB (Prototype) AY599834 
HAdV-B3 NHRC 1276 (Reference strain) AY599836 
HAdV-B7 GOMEN (Prototype) AY594255 
HAdV-B7 NHRC 1315 (Reference strain) AY601634 
HAdV-B11 (Prototype) AY163756 
HAdV-B14  (Prototype) AY803294 
HAdV-B16  (Prototype) AY601636 
HAdV-B21  (Prototype) AY601633 
HAdV-B34  (Prototype) AY737797 
HAdV-B35  (Prototype) AC_000019 
HAdV-B50  (Prototype) AY737798 
HAdV-B55  (Prototype) FJ643676 
Table 2.3: HAdV-B types used in the phylogenetic analysis and their GenBank accession numbers. 
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Type Accession numbers Type Accession numbers 
Hexon Fibre Penton Hexon Fibre Penton 
1  X67709 AB108423 DQ375462  29 AB330110 AJ811451 DQ375474  
2  J01917 J01917 J01917  30  AB330111 AJ831473 AJ296010  
3  X76549 X01998 Z29487  31  X74661 X76548 DQ375459  
4  X84646 X76547 AY594254  32  DQ149629 AJ811452 DQ375475  
5  X02997 M18369 AC_000008  33  AB330114 AJ811453 DQ375476  
6  X67710 AB108424 HQ413315 34  AB018426 AB073168 AY737797  
7  X76551 AF104384 AC_000018  35  AB018427 U32664 AC_000019  
8  X74663 AB162768 AJ249343  36  AB330117 AJ811454 DQ375477  
9  AB330090 X74659 AF217407  37  X98360 U69132 AF118437  
10  AB330091 AJ811442 DQ375463  38  AB330119 AJ811455 DQ375478  
11  AB018424 AY163756 AC_000015  39  DQ149634 AJ811456 DQ375479  
12  X73487 X73487 AC_000005  40  L19443 M28822 M86665  
13  AB330094 AJ811443 AJ296009  41  X51783 M60327 AF105145  
14  AB018425 AB065116 AY803294  42  AB330123 AJ811457 DQ375480  
15  AB330096 X72934 DQ375464  43  AB330124 AJ811458 DQ375481  
16  X74662 U06106 DQ375460  44  DQ149637 AJ811459 DQ375482  
17  AB330098 Y14241 AF108105  45  AB330126 AJ811460 DQ375483  
18 AB330099 AJ841699 DQ375458  46 AB330127 AJ811461 AY875648  
19 AB448771 U69131 DQ375465  47 AB330128 AJ811462 DQ375484  
20 AB330101 AJ811444 DQ375466  48 U20821 AJ811463 DQ375485  
21 AB330102 U06107 DQ375461  49 AB330130 AJ811464 DQ375486  
22 AB330103 AJ811445 DQ375467  50 AB330131 AJ811465 AY737798  
23 AB330104 AJ811446 DQ375468  51 AB330132 AJ811460 DQ375487  
24 AB330105 AJ811447 DQ375469  52 DQ923122 DQ923122 DQ923122  
25 AB330106 AJ811448 DQ375470  53 FJ169625  FJ169625  FJ169625  
26 AB330107 AJ811449 DQ375471  54 AB448770  AB448770  AB448770  
27 AB330108 AJ811450 DQ375472  55 FJ643676  FJ643676  FJ643676  
28 AB330109 Y14242 DQ375473  56 HM770721 HM770721 HM770721 
 
Table 2.4: Adenovirus types and accession numbers used for hexon L1, fibre shafts and partial 
penton phylogenetic trees construction. 
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2.3.6 Recombination analysis: 
BootScan and SimPlot recombination analysis was performed using SimPlot version 3.5.1 
(Lole et al. 1999) with the following parameters: window size of 200 bp, step size of 20 bp, 
100 repetitions and neighbour-joining algorithm. 
2.3.7 DNA methylation detection in tonsils and adenoids samples: 
A methyl group is added to the carbon 5 position of cytosine in CpG dinucleotides during 
DNA methylation. DNA treatment with sodium bisulfite converts unmethylated cytosine 
residues into uracil and leaves methylated cytosine unchanged. In the sense strand, the 
methylated cytosine will be amplified by PCR as cytosine while the uracil, formerly 
unmethylated cytosine, will be amplified as thymine. The methylation status can be 
determined by PCR amplification and sequencing of the target region  
2.3.7.1 Bisulfite treatment and clean up of DNA for methylation analysis: 
DNA was extracted as described previously (2.3.2) then treated with sodium bisulfite. 
EpiTect Bisulfite kit from Qiagen was used for bisulfite conversion and cleanup of DNA 
according to manufacturer's instructions: 
2.3.7.1.1 Bisulfite conversion: Bisulfite mix (85μl) was added to 20μl of DNA solution 
(containing 1μg of DNA) in a 200μl PCR tube and 35μl of DNA protect buffer was added. 
The conversion reaction was carried out in Techne TC-5000 thermal cycler (Techne, UK) 
and the following conditions were used: 
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Step                                     Time                                            Temperature 
Denaturation                       5 min                                                   95°C 
Incubation                           25 min                                                 60°C 
Denaturation                       5 min                                                   95°C 
Incubation                           85 min                                                 60°C 
Denaturation                       5 min                                                   95°C 
Incubation                          175 min                                                60°C 
Hold                                  Indefinite                                               20°C 
 
2.3.7.1.2 Clean up converted DNA: The PCR tubes were centrifuged and the bisulfite 
reactions were transferred to 1.5 ml tubes and 560µl of buffer BL was added. The solutions 
was mixed and centrifuged briefly. The mixture of each tube was transferred to a EpiTect 
Spin Column and centrifuged at 14,000 rpm for 1 minute. The filtrate was discarded and 
EpiTect Spin Column was placed in a collection tube. The column was washed with 500µl 
of buffer BW by centrifugation at 14,000 rpm for 1 minute followed by adding 500µl of 
buffer BD and incubation for 15ºC at room temperature and centrifuged again at 14000 rpm 
for 1 minute. The filtrate was discarded and EpiTect Spin Column was placed in a 
collection tube. The washing step with buffer BW was repeated twice. Finally, the DNA 
was eluted from the column with 20µl buffer EB by centrifuging at 12,000 rpm for 1 
minute. The eluted DNA was stored at -20 ºC. (Buffers BL, BW and BD compositions are 
not released by manufacturer). 
2.3.7.2 Bisulfite specific PCR and direct sequencing: 
2.3.7.2.1 Primers: 
Methyl Primer Express® Software v1.0 (Applied Biosystems) was used to design specific 
PCR primers to amplify the bisulfite converted DNA. Semi-nested PCR was used to 
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amplify the E1A promoter region (position 387-808 corresponds to HAdV-C2: J01917) and 
the major late promoter (MLP) region (position 5808-6237) of HAdV-C. 
2.3.7.2.1.1 E1A region primers:   
Bisulfite treatment of the DNA will convert unmethylated cytosine into uracil and leaves 
methylated cytosine unchanged and result in two strands of DNA with different 
hybridization properties.  Non- methylation specific (bisulfite-specific) primers flanking the 
potential sites of methylation (CpG dinucleotides) have been designed for each strand. All 
cytosine which are not in CpG (Fig 2.1A) were substituted into thymine by the software 
before designing the primers to mimic bisulfite treated DNA (Fig 2.1). 
One forward and two reverse primers were designed : 
METE1-F: TTT AGG TGT TTT TTT TAG GTG TT 
METE1-R1: AAA AAA TTA TCA ACC AAT ACC TCT (Inner) 
METE1-R2: AAA AAA TAA ATA AAT CAA TCC CTT (Outer) 
 
A:  
CCCAGGTGTTTTTCTCAGGTGTTTTCCGCGTTCCGGGTCAAAGTTGGCGTTTTATTATTATAGTCA
GCTGACGCGCAGTGTATTTATACCCGGTGAGTTCCTCAAGAGGCCACTCTTGAGTGCCAGCGAGTA
GAGTTTTCTCCTCCGAGCCGCTCCGACACCGGGACTGAAAATGAGACATATTATCTGCCACGGAGG
TGTTATTACCGAAGAAATGGCCGCCAGTCTTTTGGACCAGCTGATCGAAGAGGTACTGGCTGATAA
TCTTCCACCTCCTAGCCATTTTGAACCACCTACCCTTCACGAACTGTATGATTTAGACGTGACGGC
CCCCGAAGATCCCAACGAGGAGGCGGTTTCGCAGATTTTTCCCGAGTCTGTAATGTTGGCGGTGCA
GGAAGGGATTGACTTATTCACTTTTC 
B:  
TTTAGGTGTTTTTTTTAGGTGTTTTTCGCGTTTCGGGTTAAAGTTGGCGTTTTATTATTATAGTTA
GTTGACGCGTAGTGTATTTATATTCGGTGAGTTTTTTAAGAGGTTATTTTTGAGTGTTAGCGAGTA
GAGTTTTTTTTTTCGAGTCGTTTCGATATCGGGATTGAAAATGAGATATATTATTTGTTACGGAGG
TGTTATTATCGAAGAAATGGTCGTTAGTTTTTTGGATTAGTTGATCGAAGAGGTATTGGTTGATAA
TTTTTTATTTTTTAGTTATTTTGAATTATTTATTTTTTACGAATTGTATGATTTAGACGTGACGGT
TTTCGAAGATTTTAACGAGGAGGCGGTTTCGTAGATTTTTTTCGAGTTTGTAATGTTGGCGGTGTA
GGAAGGGATTGATTTATTTATTTTTT 
 
Figure 2.1: Bisulfite specific primer designing of E1A promoter region. A: Initial nucleotide 
sequence. B:  Bisulfite modification of DNA. Forward primers are indicated in blue colour and 
reverse primers are indicated in red colour. TATA box underlined. 
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2.3.7.2.1.2 MLP region primers:   
Two forward and one reverse primers were designed (Fig 2.2):  
MLP1F: TAG AAA TTY GGA TTA TTT TGA G  (Outer) 
MLP1R: CAA ACT TAA CAA CAA AAA AAT TAT C  
 MLP1Fb: GTT GTT TAT TAG GGG GTT TAT T  (Inner) 
A: 
TAGAAACTCGGACCACTCTGAGACGAAGGCTCGCGTCCAGGCCAGCACGAAGGAGGCTAAGTGGGA
GGGGTAGCGGTCGTTGTCCACTAGGGGGTCCACTCGCTCCAGGGTGTGAAGACACATGTCGCCCTC
TTCGGCATCAAGGAAGGTGATTGGTTTATAGGTGTAGGCCACGTGACCGGGTGTTCCTGAAGGGGG
GCTATAAAAGGGGGTGGGGGCGCGTTCGTCCTCACTCTCTTCCGCATCGCTGTCTGCGAGGGCCAG
CTGTTGGGGTGAGTACTCCCTCTCAAAAGCGGGCATGACTTCTGCGCTAAGATTGTCAGTTTCCAA
AAACGAGGAGGATTTGATATTCACCTGGCCCGCGGTGATGCCTTTGAGGGTGGCCGCGTCCATCTG
GTCAGAAAAGACAATCTTTTTGTTGTCAAGCTTG 
B: 
TAGAAATTCGGATTATTTTGAGACGAAGGTTCGCGTTTAGGTTAGTACGAAGGAGGTTAAGTGGGA
GGGGTAGCGGTCGTTGTTTATTAGGGGGTTTATTCGTTTTAGGGTGTGAAGATATATGTCGTTTTT
TTCGGTATTAAGGAAGGTGATTGGTTTATAGGTGTAGGTTACGTGATCGGGTGTTTTTGAAGGGGG
GTTATAAAAGGGGGTGGGGGCGCGTTCGTTTTTATTTTTTTTCGTATCGTTGTTTGCGAGGGTTAG
TTGTTGGGGTGAGTATTTTTTTTTAAAAGCGGGTATGATTTTTGCGTTAAGATTGTTAGTTTTTAA
AAACGAGGAGGATTTGATATTTATTTGGTTCGCGGTGATGTTTTTGAGGGTGGTCGCGTTTATTTG
GTTAGAAAAGATAATTTTTTTGTTGTTAAGTTTG 
Figure 2.2: Bisulfite specific primer designing of MLP region. A: Initial nucleotide sequence. B:  
Bisulfite modification of DNA. Forward primers are indicated in blue colour and reverse primers 
are indicated in red colour. TATA box underlined.  
 
2.3.7.2.2 Bisulfite specific PCR: 
For E1A region, one forward primer and two reverse primers were used. In the first 
reaction the forward and the outer reverse primer were used to amplify the bisulfite 
converted DNA then 1µl of the PCR product was amplified in the second reaction using the 
same forward primer with the inner reverse primer.  
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For MLP region, two forward primers MLP1F, MLP1Fb and one reverse primer MLP1R 
were used. In the first reaction the outer forward and the reverse primer were used to 
amplify the bisulfite converted DNA then 1µl of the PCR product was amplified in the 
second reaction using the inner forward primer with the reverse primer. 
PCR reaction mixture was as described in 2.3.3.4 and the first round amplification 
programme started with 15 minutes activation at 95°C then 5 cycles of 30 seconds at 95°C, 
90 seconds at 56°C for E1A  and 58°C for MLP and 90 seconds at 72°C.  The second round 
of amplification was for 25 cycles of 30 seconds at 95°C, 90 seconds at 54°C for E1A and 
56°C for MLP and 90 seconds at 72°C and the last step was the final extension of 72°C for 
4 minutes. 
2.3.7.2.3 PCR products purification and sequencing: 
PCR products purification and sequencing reaction were carried out as described previously 
(2.3.4). The second reaction forward and reverse primers of the semi-nested PCR were used 
in the sequencing reaction. 
2.3.8 Full genome sequencing analysis of 3 HAdV-D clinical isolates from AIDS 
patients: 
2.3.8.1 Virus Culture: 
Attempts to cultivate isolates Aids4, Aids28, Aids23, Aids25, Aids58 and Aids59 were 
carried out. HEp-2 cells were cultured in Eagle’s minimum essential media supplemented 
with10% fetal calf serum and 5% L-glutamine-penicillin-streptomycin in culture tubes 
incubated at 37ºC with 5% CO2. When cells reach 80-90% confluency, the growth media 
was replaced with maintenance media and 50 µl of the virus stock was added. Infected 
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tubes were incubated until most cells showed cytopathic effect (CPE). Virus was then 
passaged in 25 cm
2
 and 75 cm
2
 flasks.  
A total of 6 flasks per virus were infected and ~ 90 ml of the infected media was used for 
virus purification. 
2.3.8.2 Virus purification: 
Cultivation was successful for isolates Aids25, Aids59 and Aids32. Virus purification was 
performed using AdEasy virus purification kit according to the manufacturer's instructions. 
Briefly, the recovered infected medium and cells were centrifuged for 15 minutes to 
remove cell debris. Benzonase endonuclease was added to the supernatant (final 
concentration 12.5 U/ml)  and incubated for 37ºC for 30 minutes. 
The benzonaze treated supernatant was filtered through a 0.45 µm filter using 50 ml 
syringe. A special filter unit (Sartobind) with a membrane that can bind virus particles was 
prepared by wetting it using phosphate buffered saline (PBS). Loading buffer was added to 
the filtered benzonaze treated supernatant and virus suspension was passed slowly through 
the Sartobind unit. Washing buffer was passed through the unit to wash the captured virus 
particles. Finally, 5 ml of the elution buffer was used to elute the purified virus from the 
filter unit. Figure 2.3 summarises this protocol. 
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Figure 2.3. Virus purification protocol (Modified from AdEasy virus purification manual, Agilent 
Technologies, 2010).  
2.3.8.3  SDS treatment and phenol/chloroform DNA extraction from the purified virus 
preparation for full genome sequencing: 
DNA was extracted by the method described by Le et al, (2001). Briefly, 5 ml of 2% SDS 
solution (containing 12.5 mM EDTA, 150 mM NaCl and 100 mM Tris-Cl) and 200 µl 
proteinase K was added to purified virus eluate and incubated for 30 minutes at 50ºC. 
Phenol chloroform extraction: Equal volume of phenol-chloroform-isoamyl alcohol was 
added to the SDS treated solution. The tube contents were mixed and centrifuged for 2 
minutes at 14,000 rpm. The aqueous (top) phase containing DNA was transferred to a new 
tube. An equal volume of chloroform was added and mixed and the tube was centrifuged at 
14,000 rpm for 2 minutes. The top phase was transferred to a new tube again. DNA was 
precipitated by adding 1/10 volume of 3M sodium acetate (pH 5.2) and two volumes of 
100% ethanol and holding at -20ºC for 1 hour. The precipitated DNA was centrifuged for 
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20 minutes at 14,000 rpm and the supernatant discarded. After washing with 70% ethanol 
the DNA pellet was dried at room temperature then dissolved in 100 µl of TE buffer (1 mM 
EDTA and 10 mM Tris-Cl, pH 8).  
2.3.8.4 DNA concentration measurement: 
NanoDrop spectrophotometer (NanoDrop Technologies) was used to determine the viral 
DNA concentration by measuring the optical density of the DNA at a wavelength of 
260nm. The A260/A280 ratio was used to estimate the relative purity of the DNA. 
2.3.8.5 Full genome sequencing:  
Two samples of Aids59 and Aids25 DNA extracts were subjected to sequencing while one 
sample of Aids32 extract was sequenced. Sequencing was carried out using the 454 GS 
FLX Titanium system (Roche) at the University of Liverpool Centre for Genomic 
Research. Briefly, the DNA was sheared and separated into single-stranded fragments. 
Adaptors were added to both ends of each fragment. Fragments were captured by DNA 
capture beads then amplified using emulsion PCR. Amplified fragments were sequenced by 
pyrosequencing. GS De Novo Assembler 2.0.00.20 (Roche) was used for genomic 
fragments assembly. The assembled contigs were ordered according to the completely 
sequenced HAdV-D genomes available in the GenBank. 
2.3.8.6 Direct sequencing of the inverted terminal repeats (ITR) and Aids32 genome 
gaps sequencing: 
The available sequences of HAdV-D terminal repeats in the GenBank and the sequences 
resulted from the full genome sequencing were used to design primers to confirm the 
sequences of the ITRs which are inverted sequences at each end of the genome (Table 2.5).  
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Primers Sequence 5’-3’ 
ITR1F CCCCACAAAGTAAACAAAAGTT 
ITR1R GAAATCTCTACTCGCTGGCACT 
ITR2F CGTAATGACCAAAGGTCTAAAAA 
ITR2R TCATCAATAATATACCCCACAAAG 
 
Table 2.5: Primers used for ITR amplification. 
 
Some fragments in Aids32 genome was amplified and sequenced to fill in the gaps between 
contigs generated by the full genome sequencing. Primers (Table 2.6) were designed 
manually from the full genome sequence of Aids32.  
 PCR was carried out as described in 2.3.3.4 for HSAd1/ HSAd1 primers. PCR products 
purification and sequencing was performed as described previously (2.3.4). 
Primers Sequence 5’-3’ 
Aid32-1F   TCTTGCAGGGAAGCAAAGTT 
Aid32-1R AGCACCAGCAGGATGAGTCT 
Aid32-2F CCCGTAGTCTGGAGAAGCAT 
Aid32-2R CTCGTTCGGCTCGAAATC 
Aid32-3F ACTGGTGTTGGACCAGAAGC 
Aid32-3R GCCAATGTAGTTTGGCCTGT 
Aid32-4F CATCGCCTCACCTATGAGC 
Aid32-4R CCTTTCAAGGTGTGGAGGAA 
Aid32-5F TAGCTTCGAGCAGTGGCTCT 
Aid32-5R CCCTGGGGCTCTAGTGACTT 
 
Table 2.6: Primers used for Aids32 regions amplification. 
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2.3.8.7 Genome annotation and sequencing analysis: 
Genome annotation was carried out manually and using the IGS Annotation Engine  
(http://ae.igs.umaryland.edu/cgi/index.cgi). Open reading frames were searched against 
available database in GenBank and confirmed by the NCBI ORFider 
(http://www.ncbi.nlm.nih.gov/projects/gorf/). Splice sites were predicted manually by 
comparison to annotated genomes available in the GenBank. 
Multiple sequence alignments of the proteins and the nucleotide sequences of the coding 
regions were performed using ClustalX v 1.83 (Thompson et al. 1997). Full genome 
nucleotide sequence alignment was performed by Clustal Algorithm implemented in 
BioEdit software v7.0.5 (Hall, 1999). Phylogenetic trees were constructed as described 
previously (2.3.5). 
The percent identities for the proteins were obtained by BLASTP and confirmed by 
calculations from the alignments using BioEdit software. Manual annotation was performed 
for some of the HAdV-D genomes which are not fully annotated to use them in the percent 
identities calculations. The percent identities of the nucleotide sequences of the protein 
coding regions were obtained by BLASTN and confirmed by calculations from the 
alignments using BioEdit software  
A program, mVISTA LAGAN (http://www.genome.lbl.gov/vista/lagan/submit.shtml) was 
used for global pairwise alignment (Brudno et al, 2003). 
Recombination analysis was performed for genome regions as described in 2.3.6.  
HAdV full genome sequences  with the following accession numbers were used in the full 
genome analysis: HAdV-C1, AF534906; HAdV-C2, J01917; HAdV-B3, AY599834; 
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HAdV-E4, AY599837; HAdV-C5, AY339865; HAdV-B7,  AY594255; HAdV-D8, 
AB448767; HAdV-D9, AJ854486; HAdV-B11, AY163756; HAdV-A12, X73487; HAdV-
B14, AY803294; HAdV-B16, AY601636; HAdV-D17, AF108105; HAdV-A18, 
GU191019; HAdV-D19, AB448771; HAdV-B21, AY601633; HAdV-D22, FJ404771; 
HAdV-D26, EF153474; HAdV-D28, FJ824826; HAdV-D29, AB562587; HAdV-A31, 
AM749299; HAdV-B34,  AY737797; HAdV-B35,  AY128640; HAdV- D36, GQ384080; 
HAdV-D37, AB448775; HAdV-F40, L19443; HAdV-F41, DQ315364; HAdV-D46, 
 AY875648; HAdV-D49, DQ393829; HAdV-B50, AY737798; HAdV-D48, EF153473; 
HAdV-G52, DQ923122; HAdV-D53, AB605243; HAdV-D54, AB448770; HAdV-B55, 
FJ643676; HAdV-D56, HM770721.                      
The following accession numbers have been used for the full hexon phylogenetic analysis: 
HAdV types 1 to 51 accession numbers: AB330082 to AB330132 and the above mentioned 
full genome accession numbers for the rest of HAdVs. 
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3. Results: 
3.1 Molecular analysis of HAdV-D isolates from AIDS patients: 
3.1.1 Previous typing results of AIDS isolates: 
A total of 31 clinical isolates from AIDS patients were typed previously by Al Qurashi 
(2009) using sequencing and phylogenetic analysis of the hexon L2 region (including 
HVR7) and fibre knob region. These isolates were found to be from HAdV-D species and 
28 of them had contradictory typing results in these two regions so they are clearly 
intermediate strains. Two isolates appear to be completely new and one isolate (Aids32) 
was typed as HAdV-D23 variant in both hexon L2 and fibre knob regions. Some of the 
isolates had an identical sequence to the reference strains but others had varying degrees of 
divergence from the reference strains in these two regions. Two isolates (Aids23 &Aids25) 
had unknown hexon L2 region (U1) and unknown fibre knob region (HU3). A further two 
unknown fibre knob regions were found in 4 isolates, HU1 in isolates Aids4 and Aids28 
and HU2 in isolates Aids58 and Aids59.  
Table 3.1 summarises the previous typing results of these isolates. In this part of the study, 
these isolates have been characterized further by sequencing and phylogenetic analysis of 
the hexon L1 (including HVR1-6), fibre shaft and penton regions. 
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Table3.1: Previous typing results of the hexon L2 and fibre knob regions of intermediate strains. 
The table summarises the phylogenetic typing results of the isolates, year of isolation and the case 
number. NR: not recorded. c: HIV negative partner of an HIV positive patient (Al Qurashi 2009). 
 
Case Year isolated Isolate 
Previous Typing Results 
Hexon L2 
(HVR7) 
Fibre knob 
19 1993 
Aids27, Aids38,  19v3 H9v1 
Aids48 19v3 H9v3 
10 
1992 Aids57 19v3 H9v1 
1993 
Aids39 
17v1 
H9v1 
Aids24 H9v2 
Aids18, Aids51, Aids50 
H29v1 
1994 Aids2, Aids13 
17 
1992 Aids54 
19v3 
H23v1 
1993 Aids31, Aids34 H49v2 
24 
1993 
Aids32 23v1 23v1 
Aids28 
26v3 HU1 
1994 Aids4 
57 1993 Aids22 17v1 H9v1 
74 1993 Aids23, Aids25 U1 HU3 
c14 1993 Aids15 17v1 H22v1 
c15 1993 Aids20 17v1 H9v4 
NR 
 
1986 Aids72 44v1 H38v1 
1992 Aids58, Aids59 20v1 HU2 
1992 Aids61 19v3 H9v1 
1993 Aids16, Aids17 19v3 H43p 
1993 Aids21 17v1 H9v1 
1994 Aids7 20p H22v2 
1994 Aids14 19v3 H9v1 
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3.1.2 PCR of HAdV-D clinical isolates: 
3.1.2.1 Positive control:  
DNA extracted from HAdV-D9 isolate was used as a positive control to test different sets 
of primers targeting different regions of HAdV-D genome. This isolate was typed 
previously by serum neutralization (SN). It was typed also by Al Qurashi (2009) using 
sequencing and phylogenetic analysis of the hexon L2 region.  
3.1.2.2 Primers AdhexF1/AdhexR1 and AdhexF2/AdhexR2: 
The target region of these primers is the hexon L1 region. Serial 10-fold dilutions of 
HAdV-D9 were prepared and 10
-1
 and 10
-2
 dilutions were tested using these nested PCR 
primers. The product size of the internal reaction (AdhexF2/AdhexR2 primers) was 748 bp 
(Fig 3.1). 
 
 
Figure 3.1: Agarose gel electrophoretogram of serial dilutions of HAdV-D9 DNA with 
AdhexF2/AdhexR2 primers. Lane 1: Blank. Lane 2: Quantitative DNA ladder, lane 3: Negative 
control, lanes 4 and 5: 10
-1
 and 10
-2
 dilutions of HAdV-D9 DNA.  
 
3.1.2.3 Primers FiDL/ADD2: 
These primers target the fibre knob and part of the fibre shaft regions of HAdV-D. Two 
dilutions (10
-1
 and 10
-2
) of DNA extracted from the HAdV-D9 isolate was amplified and 
clear bands of 1000 bp appeared on the gel (Fig 3.2). 
< 748 bp 
2000 bp > 
1000 bp > 
500 bp   > 
250 bp   > 
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Figure 3.2: Agarose gel electrophoretogram of serial dilutions of HAdV-D9 DNA with FiDL/ADD2 
primers. Lane 1: Blank. Lane 2: Quantitative DNA ladder, lane 3: Negative control, lanes 4 and 5: 
10
-1
 and  10
-2
 dilutions of HAdV-D9 DNA.  
 
3.1.2.4 Primers P1DL/P1DR and P2DL/P2DR: 
Two sets of primers were used to amplify two overlapping fragments of the penton region 
of HAdV-D. Serial 10-fold dilutions of HAdV-D9 were prepared and 10
-1
 and 10
-2
 dilutions 
were tested using these primers. The products of the first set of primers had a size of 599 bp 
and the products of the second set had a size of 407 bp as expected (Fig 3.3).  
 
 
Figure 3.3: Agarose gel electrophoretogram of serial dilutions of HAdV-D9 DNA with P1DL/P1DR 
and P2DL/P2DR primers. Lane 1: Blank. Lane 2: Quantitative DNA ladder, lane 3: Negative 
control, Lanes 4 and 5: 10
-1
 and  10
-2
 dilutions of HAdV-D9 DNA amplified using P1DL/P1DR 
primers and lanes 6 and 7: 10
-1
 and  10
-2
 dilutions of HAdV-D9 DNA amplified using P2DL/P2DR 
primers .  
 
 
 
< 1000 bp 
< 599 bp 
< 407 bp 
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3.1.3 Sequencing and phylogenetic analysis of the hexon L1 region (HVR1-6) of 
isolates from AIDS patients: 
The phylogenetic analysis of the hexon L1 region (nucleotide positions 394-924 of the full 
hexon of HAdV-D9, AJ854486) showed that all intermediate strains belong to HAdV-D 
and have the same typing results as the L2 region of the hexon gene. Some of the isolates 
had identical sequences to reference strains but others have varying degrees of divergence 
from these reference strains. In addition, two isolates had an unidentified type in this 
region. The phylogenetic trees of the nucleotide and amino acid sequences of these strains 
in the L1 region are shown in Figure 3.4 and Figure 3.5. The bootstrap percentage values 
(not shown on trees for clarity) were higher than 70% for most the branches of tested 
isolates in L1 region trees and this was applicable to all subsequent trees in this study. 
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Figure 3.4: Phylogenetic tree of nucleotide sequences of hexon L1 region (nucleotide positions 394-
924 of the full hexon of HAdV-D9) of the clinical isolates and all HAdV-D types. Only one 
example of each variant has been used in the tree.  
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Figure 3.5: Phylogenetic tree of amino acid sequences of hexon L1 region of the clinical isolates 
and HAdV-D types. Only one example of each variant has been used in the tree.  
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3.1.3.1 Hexon L1 type 17:  
Two variants (17v1 and 17v2) were detected by sequencing of the L1 region, both of them 
had the same sequence in the L2 region (17v1). Eight isolates were typed as 17v1. This 
variant diverged from the reference sequence HAdV-D17 by 0.75% in nucleotide and 
0.56% in amino acid sequences. The divergence was caused by 4 substitutions resulting in 
one amino acid change D135G. BLASTN results showed 100% similarity with one variant 
of HAdV-D17 (EF195772). 
Three isolates were typed as 17v2. They varied from the reference sequence by 3.93 % in 
both nucleotide and amino acid sequences. This divergence was caused by 3 nucleotide 
substitutions resulting in one amino acid change. A further 6 amino acids were deleted as 
the result of an 18 nucleotide deletion in alignment position 125-142 (Fig 3.6). The 
sequence of this variant has not been reported previously. 
3.1.3.2 Hexon L1 type 19:  
One variant (19v3) of HAdV-D19 was detected in 11 isolates from three AIDS patients and 
3 patients whose HIV status is not recorded. This variant differed from the reference 
sequence by 7 nucleotides (1.26% divergence) and 4 amino acids (2.16% divergence). 
BLASTN results showed 100% similarity to many HAdV-D19 clinical variants previously 
reported e.g. strain A (AB448772) and strain C (EF121005).  
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Figure 3.6: Nucleotide and amino acid alignment of the hexon L1 region of HAdV-D17 reference 
strain with isolate Aids13 as an example of variant 17v2.  Amino acid changes are indicated in the 
boxes. 
3.1.3.3 Hexon L1 type 20:  
Isolate Aids7 had the same sequence as the reference strain of type 20 in both L1 and L2 
regions. Two other isolates (Aids58 and Aids59) were typed as 20v1 which varied from 
HAdV-D20 reference strains by 7.32% in the nucleotide sequence and 9.04% in the amino 
acid sequence. Twenty one of 39 nucleotide substitutions were clustered at the beginning of 
10 20 30 40 50 60 70 80
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
HAdV-D17 CCCAGTCAGTGGGTTGCCAAAGAAAATGGTCAGGGAACTGATAAGACACATACTTATGGCTCAGCTGCCATGGGAGGAAG
 P  S  Q  W  V  A  K  E  N  G  Q  G  T  D  K  T  H  T  Y  G  S  A  A  M  G  G  S 
Aids13v2 .................................................................C..............
 P  S  Q  W  V  A  K  E  N  G  Q  G  T  D  K  T  H  T  Y  G  S  A  A  M  G  G  S 
90 100 110 120 130 140 150 160
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
HAdV-D17 CAACATCACCATTGAAGGTTTAGTAATTGGAACTGATGAAAAAGCTGAGGATGGCAAAAAAGATATTTTTGCAAATAAAC
 N  I  T  I  E  G  L  V  I  G  T  D  E  K  A  E  D  G  K  K  D  I  F  A  N  K 
Aids13v2 ............................................------------------..................
 N  I  T  I  E  G  L  V  I  G  T  D  E  K  D  I  F  A  N  K 
170 180 190 200 210 220 230 240
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
HAdV-D17 TTTATCAGCCAGAACCTCAAGTAGGTGAAGAAAACTGGCAAGAGTCTGAAGCCTTCTATGGAGGCAGAGCTCTTAAGAAA
 L  Y  Q  P  E  P  Q  V  G  E  E  N  W  Q  E  S  E  A  F  Y  G  G  R  A  L  K  K 
Aids13v2 .......A........................................................................
 L  Y  Q  P  E  P  Q  V  G  E  E  N  W  Q  E  S  E  A  F  Y  G  G  R  A  L  K  K 
250 260 270 280 290 300 310 320
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
HAdV-D17 GACACAAAAATGAAGCCCTGCTATGGCTCATTTGCAAGACCTACCAATGAAAAAGGCGGACAAGCTAAATTTAAGCCAGT
 D  T  K  M  K  P  C  Y  G  S  F  A  R  P  T  N  E  K  G  G  Q  A  K  F  K  P  V 
Aids13v2 ................................................................................
 D  T  K  M  K  P  C  Y  G  S  F  A  R  P  T  N  E  K  G  G  Q  A  K  F  K  P  V 
330 340 350 360 370 380 390 400
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
HAdV-D17 GGAAGAGGGGCAGCAACCTAAAGATTATGACATAGATTTGGCTTTCTTTGACACACCTGGAGGCACCATCACAGGAGGCA
 E  E  G  Q  Q  P  K  D  Y  D  I  D  L  A  F  F  D  T  P  G  G  T  I  T  G  G 
Aids13v2 ................................................................................
 E  E  G  Q  Q  P  K  D  Y  D  I  D  L  A  F  F  D  T  P  G  G  T  I  T  G  G 
410 420 430 440 450 460 470 480
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
HAdV-D17 CAGACGAAGAATATAAAGCAGACATTGTGTTGTACACTGAAAATGTCAACCTTGAAACCCCAGACACCCACGTGGTATAC
 T  D  E  E  Y  K  A  D  I  V  L  Y  T  E  N  V  N  L  E  T  P  D  T  H  V  V  Y 
Aids13v2 ...G............................................................................
 T  G  E  E  Y  K  A  D  I  V  L  Y  T  E  N  V  N  L  E  T  P  D  T  H  V  V  Y 
490 500 510 520 530
....|....|....|....|....|....|....|....|....|....|....
HAdV-D17 AAGCCAGGAAAAGAGGATGACAGTTCAGAAGTAAATTTGACACAGCAGTCCATG
 K  P  G  K  E  D  D  S  S  E  V  N  L  T  Q  Q  S  M 
Aids13v2 ......................................................
 K  P  G  K  E  D  D  S  S  E  V  N  L  T  Q  Q  S  M 
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the L1 region which includes HVR1 (Fig 3.7) resulting in 10/16 of the amino acid changes. 
The sequence of this variant has not been reported in the GenBank previously. 
 
 
Figure 3.7: Nucleotide and amino acid alignment of the hexon L1 region of HAdV-D20 reference 
strain with isolate Aids59 as an example of 20v1. Amino acid changes are indicated in the boxes. 
 
 
 
 
10 20 30 40 50 60 70 80
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
Ad20 TCCAGTCAGTGGCTTGCAAAAGATACCAATGCTGCTGGTCAACCAGATA-AAACTCACACCTATGGCGTTGCAGCCATGG
 S  S  Q  W  L  A  K  D  T  N  A  A  G  Q  P  D  K  T  H  T  Y  G  V  A  A  M 
Aids59v1 ............GAGCAG...A.A..T.C..G..GA..-...TG.C..GG....G..T..T...................
 S  S  Q  W  E  Q  K  K  T  T  G  G  G  N  D  M  E  T  H  T  Y  G  V  A  A  M 
90 100 110 120 130 140 150 160
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
Ad20 GTGGAGAAGACATTACAGAAAAGGGTCTTCAAATTGGCATTGATGAAACTAAAGAAGAAAATAACAAGATATTTGCCAAT
 G  G  E  D  I  T  E  K  G  L  Q  I  G  I  D  E  T  K  E  E  N  N  K  I  F  A  N 
Aids59v1 .........................C..................................................AG.C
 G  G  E  D  I  T  E  K  G  L  Q  I  G  I  D  E  T  K  E  E  N  N  K  I  F  A  D 
170 180 190 200 210 220 230 240
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
Ad20 GAAATATACCAACCAGAACCTCAAGTGGGAGAAGAAAACTGGCAGGAAACATTTGTTTTTTATGGCGGTAGAGCTCTTAA
 E  I  Y  Q  P  E  P  Q  V  G  E  E  N  W  Q  E  T  F  V  F  Y  G  G  R  A  L  K 
Aids59v1 A...C..T........................................................................
 K  T  F  Q  P  E  P  Q  V  G  E  E  N  W  Q  E  T  F  V  F  Y  G  G  R  A  L  K 
250 260 270 280 290 300 310 320
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
Ad20 GAAGGATACCAAAATGAAACCATGCTATGGCTCATTTGCCAGACCTACTAATGAAAAGGGAGGTCAGGCTAAATTTGTAC
 K  D  T  K  M  K  P  C  Y  G  S  F  A  R  P  T  N  E  K  G  G  Q  A  K  F  V 
Aids59v1 ......C.........................................................................
 K  D  T  K  M  K  P  C  Y  G  S  F  A  R  P  T  N  E  K  G  G  Q  A  K  F  V 
330 340 350 360 370 380 390 400
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
Ad20 TTGATCAGGAAGGAAAGCCAACTAAAAATCATGACATCACAATGGCTTTCTTTGATACTCCTGGTGGGCAATTAAATGGA
 L  D  Q  E  G  K  P  T  K  N  H  D  I  T  M  A  F  F  D  T  P  G  G  Q  L  N  G 
Aids59v1 ....C.............................T................................A.....G......
 L  D  Q  E  G  K  P  T  K  N  H  D  I  T  M  A  F  F  D  T  P  G  G  Q  L  N  G 
410 420 430 440 450 460 470 480
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
Ad20 AAAGATGAACTTAAGGCAGACATTGTCATGTACACTGAAAATGTCAACCTGGAAACACCTGACACCCATGTTGTTTACAA
 K  D  E  L  K  A  D  I  V  M  Y  T  E  N  V  N  L  E  T  P  D  T  H  V  V  Y  K 
Aids59v1 ........G........................................................G..............
 K  D  E  L  K  A  D  I  V  M  Y  T  E  N  V  N  L  E  T  P  D  T  H  V  V  Y  K 
490 500 510 520 530
....|....|....|....|....|....|....|....|....|....|..
Ad20 ACCTGGAAAAGAGGATGACAGTTCAGAAATCAATTTGGTTCAACAGTCCATG
 P  G  K  E  D  D  S  S  E  I  N  L  V  Q  Q  S  M 
Aids59v1 ........CTTCA.......................................
 P  G  T  S  D  D  S  S  E  I  N  L  V  Q  Q  S  M 
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3.1.3.4 Hexon L1 type 23v1: 
Isolate Aids32 clustered with HAdV-D23 in both nucleotide and amino acid trees with a 
single nucleotide change (T495G) that did not result in an amino acid change. The 
sequence of this variant has not been reported previously. 
 
3.1.3.5 Hexon L1 type 26v3: Isolates Aids4 and Aids28 from patient 24 were typed as 
HAdV-D26 variants. They had an identical sequence with 10.93% nucleotide divergence 
and 8.06% amino acid divergence from the reference strain. This included three deletions 
of one (alignment position 415), three (alignment position 44-46) and five (alignment 
position 426-430) nucleotides resulting in a total of three amino acid deletions (Fig 3.8). 
The sequence of this variant has not been reported previously. 
3.1.3.6 Hexon L1 type 44v1: Isolate Aids72 varied from HAdV-D44 by only one 
nucleotide (T288C)  which did not result in an amino acid change. BLASTN results 
showed one hit with 100% similarity with HAdV-D44 variant (EF151417). 
3.1.3.7 Unidentified Hexon L1 type U1: 
Isolates Aids23 and Aids25 had an unidentified L2 sequence in the previous typing. The 
sequence of L1 of these two isolates (U1) although clearly from species D, could not be 
identified with existing types. The nucleotide phylogenetic tree of L1 region showed U1 
clustering with HAdV-D types 17, 10, 26, 45, 13, 37 and 30 but not branching off any of 
them. The nucleotide divergences between U1 and these types were: 20.58%, 32%, 26.2%, 
36.8%, 38.4%, 36.8% and 30.9% respectively. In the amino acid phylogenetic tree U1 was 
clustering with HAdV-D types 17, 10, 26, 45, 27, 28 and 19 and the amino acid 
divergences were: 19.79%, 31.4%, 24.6%, 31.4%, 29.4%, 22.41% and 28.2% respectively.  
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Figure 3.8: Nucleotide and amino acid alignment of the hexon L1 region of HAdV-D26 reference 
strain with isolate Aids28 as an example of 26v3. Amino acid changes are indicated in the boxes. 
 
 
 
 
 
10 20 30 40 50 60 70 80
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
HAdV-D26 CCCAGTCAGTGGGAAACAAAAGAAAAGCAAGGAACTACTGGAGGAGTGCAGCAAGAAAAAGATGTCACAAAAACATTTGG
 P  S  Q  W  E  T  K  E  K  Q  G  T  T  G  G  V  Q  Q  E  K  D  V  T  K  T  F  G 
Aids28v3 ..A.....A.............................C....---.C..AACG..........................
 P  S  Q  W  E  T  K  E  K  Q  G  T  T  G  V  Q  T  E  K  D  V  T  K  T  F  G 
90 100 110 120 130 140 150 160
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
HAdV-D26 TGTGGCTGCCACCGGCGGAATTAATATAACAAACCAGGGTCTGTTACTAGGAACTGACGAAACCGCTGAGAATGGCAAAA
 V  A  A  T  G  G  I  N  I  T  N  Q  G  L  L  L  G  T  D  E  T  A  E  N  G  K 
Aids28v3 ......C.....T..............T....................T........T....AA..C..A..........
 V  A  A  T  G  G  I  N  I  T  N  Q  G  L  L  L  G  T  D  E  K  A  E  N  G  K 
170 180 190 200 210 220 230 240
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
HAdV-D26 AAGACATTTATGCAGACAAGACTTTCCAGCCAGAACCTCAAGTTGGAGAAGAAAACTGGCAGGAAAATGAAGCCTTCTAT
 K  D  I  Y  A  D  K  T  F  Q  P  E  P  Q  V  G  E  E  N  W  Q  E  N  E  A  F  Y 
Aids28v3 .........................T..A....................G.......................A.....C
 K  D  I  Y  A  D  K  T  F  Q  P  E  P  Q  V  G  E  E  N  W  Q  E  N  E  A  F  Y 
250 260 270 280 290 300 310 320
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
HAdV-D26 GGAGGAAGGGCTCTTAAAAAGGACACTAAAATGAAACCATGCTATGGATCTTTTGCTAGACCTACTAATGAGAAAGGAGG
 G  G  R  A  L  K  K  D  T  K  M  K  P  C  Y  G  S  F  A  R  P  T  N  E  K  G  G 
Aids28v3 .....C..A........G........C.....................................................
 G  G  R  A  L  K  K  D  T  K  M  K  P  C  Y  G  S  F  A  R  P  T  N  E  K  G  G 
330 340 350 360 370 380 390 400
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
HAdV-D26 TCAGGCAAAGTTCAAACCAGTTAATGAAGGAGAACAACCTAAAGATCTGGATATAGATTTTGCTTACTTTGACGTCCCTG
 Q  A  K  F  K  P  V  N  E  G  E  Q  P  K  D  L  D  I  D  F  A  Y  F  D  V  P 
Aids28v3 ....................................G........A...........................ACT..A.
 Q  A  K  F  K  P  V  N  E  G  E  Q  P  K  E  L  D  I  D  F  A  Y  F  D  T  P 
410 420 430 440 450 460 470 480
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
HAdV-D26 GCGGAAGTCCTCCAGCAGGTGGTAGTGGGGAAGAATACAAAGCAGATATAATTTTGTACACTGAAAATGTTAATCTTGAA
 G  G  S  P  P  A  G  G  S  G  E  E  Y  K  A  D  I  I  L  Y  T  E  N  V  N  L  E 
Aids28v3 .T..C.A.ATAA..-..A.GAAC..-----......TA..G........C..........................G...
 G  G  N  I  T  Q  G  T  E  E  L  K  A  D  I  I  L  Y  T  E  N  V  N  L  E 
490 500 510 520 530 540 550
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|...
HAdV-D26 ACACCAGACACTCATGTGGTTTACAAGCCAGGAACTTCAGATAACAGTTCAGAAATCAATCTGGTTCAGCAGTCCATG
 T  P  D  T  H  V  V  Y  K  P  G  T  S  D  N  S  S  E  I  N  L  V  Q  Q  S  M 
Aids28v3 ....................A.....................G...................T...............
 T  P  D  T  H  V  V  Y  K  P  G  T  S  D  D  S  S  E  I  N  L  V  Q  Q  S  M 
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Table 3.2 summarises the typing results of the hexon L1 region of the clinical isolates. 
Type Variant 
Accession 
number 
Sequence 
divergence 
from tree 
reference strain 
(%) 
Amino acid changes 
nt aa 
17 
v1 EF195772 0.75 0.56 D135G 
v2 
 
3.93 3.93 
K41-, A42-, E43-, D44-, G45-, 
K46-, D135G 
19 v3 
EF121005
 
AB448772
  
1.26 2.16 T74S, G170A, E177Q, C104G 
20 
Prototype AB330101
 
0 0 None 
v1  7.32 9.04 
L5E, A6Q, D8K, N10T, A11G, 
A12G, Q14N, P15D, D16M, 
K17E, N53D, E54K, I55T, 
Y56F, K163T, E164S 
23 v1  0.20 0 None 
26 v3  10.93 8.6 
G15-, Q18T, T48K, D122E, 
V132T, S136N, P137I, P138T, 
A139Q, G141-, S142-, G143T, 
Y146L, N175D 
44 v1 EF151417
 
0.19 0 None 
 
Table 3.2: Summary of hexon L1 (HVR1-6) phylogenetic analysis of HAdV-D variants. The table 
summarises types, variants, BLASTN accession number, and nucleotide and amino acid 
divergences. nt: nucleotide, aa: amino acid. 
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3.1.4 Sequencing and phylogenetic analysis of the partial fibre shaft region of isolates 
from AIDS patients: 
The phylogenetic analysis of partial fibre shaft region (nucleotide positions 202-552 of the 
full fibre of HAdV-D9, AJ854486) showed that all the isolates had the same typing results 
in the fibre shaft and fibre knob regions. This typing differed from the hexon L1 and L2 
typing confirming that all these isolates except Aids32 are intermediate strains. Some of the 
isolates had the same sequence as the reference strains but others have varying degrees of 
divergence whilst others could not be typed beyond species D. The phylogenetic trees of 
the nucleotide and amino acid sequences of these strains in the fibre shaft region are 
illustrated in Figure 3.9 and Figure 3.10. 
3.1.4.1 Fibre shaft type H9: 
Four fibre shaft variants of HAdV-D9 were detected in different isolates. H9v1 showed 5 
nucleotide (1.42%) and 3 amino acid (2.56%) substitutions from the reference strain. H9v2 
also showed 5 nucleotide substitutions (1.42%) which resulted in only 2 amino acid 
changes (1.71%). The nucleotide divergence of H9v3 and H9v4 from the reference strain 
was 1.71% (6 nucleotides) but they differed from each other by one nucleotide which 
resulted in different divergence in amino acid level, 3.42% for H9v3 and 2.56% for H9v4. 
The amino acid sequences for H9v1 and H9v4 are identical. However, they are different in 
one nucleotide (Fig 3.11). None of these sequence variants have been reported previously. 
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Figure 3.9: Phylogenetic tree of nucleotide sequences of partial fibre shaft region (nucleotide 
positions 202-552 of the full fibre of HAdV-D9) of the clinical isolates and all HAdV-D types. 
Only one example of each variant has been used in the tree. 
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Figure 3.10: Phylogenetic tree of amino acid sequences of partial fibre shaft region of the clinical 
isolates and all HAdV-D types. Only one example of each variant has been used in the tree. 
 
 
 
 
 
0.1
HAdV-D36
HAdV-D28
HAdV-D43
Aids16H43p
Aids25HU3
Aids28HU1
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Figure 3.11: Nucleotide and amino acid sequence alignment of the fibre shaft region HAdV-9 with 
examples of detected variants. Amino acid changes are indicated in the boxes. 
 
10 20 30 40 50 60 70 80
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
HAdV-D9 GGTCTCACTTTGCAAGATGGAACTGGAAAACTAACAGTCAATGCTGATCCACCTTTGCAACTTACAAACAACAAATTAGG
 G  L  T  L  Q  D  G  T  G  K  L  T  V  N  A  D  P  P  L  Q  L  T  N  N  K  L  G 
Aids39H9v1 ...............C................................................................
 G  L  T  L  Q  H  G  T  G  K  L  T  V  N  A  D  P  P  L  Q  L  T  N  N  K  L  G 
Aids24H9v2 ................................................................................
 G  L  T  L  Q  D  G  T  G  K  L  T  V  N  A  D  P  P  L  Q  L  T  N  N  K  L  G 
Aids48H9v3 ...............C................................................................
 G  L  T  L  Q  H  G  T  G  K  L  T  V  N  A  D  P  P  L  Q  L  T  N  N  K  L  G 
Aids20H9v4 ...............C................................................................
 G  L  T  L  Q  H  G  T  G  K  L  T  V  N  A  D  P  P  L  Q  L  T  N  N  K  L  G 
90 100 110 120 130 140 150 160
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
HAdV-D9 GATTGCTTTGGACGCTCCATTTGATGTTATAGATAATAAACTCACATTGTTAGCGGGCCATGGCTTGTCTATTATAACAA
 I  A  L  D  A  P  F  D  V  I  D  N  K  L  T  L  L  A  G  H  G  L  S  I  I  T 
Aids39H9v1 ................................................................................
 I  A  L  D  A  P  F  D  V  I  D  N  K  L  T  L  L  A  G  H  G  L  S  I  I  T 
Aids24H9v2 .................................C..............................................
 I  A  L  D  A  P  F  D  V  I  D  N  K  L  T  L  L  A  G  H  G  L  S  I  I  T 
Aids48H9v3 .................................A..............................................
 I  A  L  D  A  P  F  D  V  I  E  N  K  L  T  L  L  A  G  H  G  L  S  I  I  T 
Aids20H9v4 .................................C..............................................
 I  A  L  D  A  P  F  D  V  I  D  N  K  L  T  L  L  A  G  H  G  L  S  I  I  T 
170 180 190 200 210 220 230 240
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
HAdV-D9 AAGAAACATCAACACTGCCTGGCTTGAGGAATACTCTTGTAGTATTAACTGGAAAGGGTATTGGAACAGAATCAACAGAT
 K  E  T  S  T  L  P  G  L  R  N  T  L  V  V  L  T  G  K  G  I  G  T  E  S  T  D 
Aids39H9v1 ...........................TT...................................................
 K  E  T  S  T  L  P  G  L  I  N  T  L  V  V  L  T  G  K  G  I  G  T  E  S  T  D 
Aids24H9v2 ...........................TT...................................................
 K  E  T  S  T  L  P  G  L  I  N  T  L  V  V  L  T  G  K  G  I  G  T  E  S  T  D 
Aids48H9v3 ...........................TT...................................................
 K  E  T  S  T  L  P  G  L  I  N  T  L  V  V  L  T  G  K  G  I  G  T  E  S  T  D 
Aids20H9v4 ...........................TT...................................................
 K  E  T  S  T  L  P  G  L  I  N  T  L  V  V  L  T  G  K  G  I  G  T  E  S  T  D 
250 260 270 280 290 300 310 320
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
HAdV-D9 AATGGCGGAACGGTATGTGTTAGAGTTGGAGAAGGTGGCGGCTTATCATTTAATAATGATGGAGACTTGGTAGCATTTAA
 N  G  G  T  V  C  V  R  V  G  E  G  G  G  L  S  F  N  N  D  G  D  L  V  A  F  N 
Aids39H9v1 ..........GC....................................................................
 N  G  G  S  V  C  V  R  V  G  E  G  G  G  L  S  F  N  N  D  G  D  L  V  A  F  N 
Aids24H9v2 ..........GC....................................................................
 N  G  G  S  V  C  V  R  V  G  E  G  G  G  L  S  F  N  N  D  G  D  L  V  A  F  N 
Aids48H9v3 ..........GC....................................................................
 N  G  G  S  V  C  V  R  V  G  E  G  G  G  L  S  F  N  N  D  G  D  L  V  A  F  N 
Aids20H9v4 ..........GC....................................................................
 N  G  G  S  V  C  V  R  V  G  E  G  G  G  L  S  F  N  N  D  G  D  L  V  A  F  N 
330 340 350
....|....|....|....|....|....|.
HAdV-D9 TAAAAAAGAAGATAAGCGCACCCTATGGACA
 K  K  E  D  K  R  T  L  W  T 
Aids39H9v1 ...............................
 K  K  E  D  K  R  T  L  W  T 
Aids24H9v2 ...............................
 K  K  E  D  K  R  T  L  W  T 
Aids48H9v3 ...............................
 K  K  E  D  K  R  T  L  W  T 
Aids20H9v4 ...............................
 K  K  E  D  K  R  T  L  W  T 
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3.1.4.2 Fibre shaft type H22: 
Two isolates were typed as H22 in the fibre shaft region. One of them (Aids15) is identical 
to the prototype H22p. However, the fibre knob of this isolate differed from the prototype. 
The fibre shaft of the second isolate Aids7 (H22v1) varied from the prototype by 3 
nucleotides (C205T, A213G, C254G, 0.86% divergence) resulting in one amino acid 
change A82G and has not been reported previously. The fibre knob of isolate Aids7 is also 
different from the reference strain.  
3.1.4.3 Fibre shaft type H23: 
One variant H23v1 was detected in isolates Aids54 and Aids32. It showed 5.1% nucleotide 
divergence and 5.64% amino acid divergence from the reference strain and has not been 
reported previously (Fig 3.12). In the fibre knob region the sequence was also different 
from the reference strain.  
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Figure 3.12: Nucleotide and amino acid alignment of the fibre shaft region of HAdV-D23 reference 
strain with isolate Aids54. Amino acid changes are indicated in the boxes. 
3.1.4.4 Fibre shaft type H29v1: 
This variant was detected in 5 clinical isolates and differed from the reference strain by 3 
nucleotide substitutions (C15A, A16C, C311T, 0.81%) each of which resulted in an amino 
acid change (D5E, K6Q, S104F, 2.42% divergence).  BLASTN search showed 100% 
similarity with some HAdV-D29 variants such as FM210545. 
3.1.4.5 Fibre shaft sequences identical to the reference strain: 
Fibre shaft type H38p was detected in isolate Aids72 and was found to be identical to the 
reference strain. However the fibre knob sequence was different from the reference strain. 
10 20 30 40 50 60 70 80
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
HAdV-D23 GGGCTGACTGTGGAACAAGATAGTGGAAACCTAAAGGTGAACACTAAAGCTCCCTTGCAAGTTGCAGCTGATAAACAATT
 G  L  T  V  E  Q  D  S  G  N  L  K  V  N  T  K  A  P  L  Q  V  A  A  D  K  Q  L 
Aids54H23v1 ..A..........................T............C..................................GC.
 G  L  T  V  E  Q  D  S  G  N  L  K  V  N  P  K  A  P  L  Q  V  A  A  D  K  Q  L 
90 100 110 120 130 140 150 160
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
HAdV-D23 GGAAATTGCACTGGCTGATCCATTTGAAGTCAGTAAAGGCAGGCTTGGTATAAAAGCAGGTCATGGATTGAAAGTCATTG
 E  I  A  L  A  D  P  F  E  V  S  K  G  R  L  G  I  K  A  G  H  G  L  K  V  I 
Aids54H23v1 ............A............C....G.....T....A......................................
 E  I  A  L  A  D  P  F  Q  V  S  N  G  K  L  G  I  K  A  G  H  G  L  K  V  I 
170 180 190 200 210 220 230 240
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
HAdV-D23 ACAATTCAATTTCTGGTTTAGAAGGCTTGGTAGGCACGCTTGTAGTTTTGACTGGTCATGGAATTGGCACTGAAAACTTG
 D  N  S  I  S  G  L  E  G  L  V  G  T  L  V  V  L  T  G  H  G  I  G  T  E  N  L 
Aids54H23v1 ....C..............G..............T.T.....................G.....................
 D  N  S  I  S  G  L  E  G  L  V  G  M  L  V  V  L  T  G  Q  G  I  G  T  E  N  L 
250 260 270 280 290 300 310 320
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
HAdV-D23 CTTAACAATGATGGATCGAGCAGAGGAGTTGGAATAAACGTAAGACTTGGAAAAGATGGAGGTTTATCCTTTGATAAAAA
 L  N  N  D  G  S  S  R  G  V  G  I  N  V  R  L  G  K  D  G  G  L  S  F  D  K  K 
Aids54H23v1 .......G......G..A..............................................................
 L  N  S  D  G  S  S  R  G  V  G  I  N  V  R  L  G  K  D  G  G  L  S  F  D  K  K 
330 340 350 360 370
....|....|....|....|....|....|....|....|....|....|..
HAdV-D23 GGGTGATTTAGTAGCATGGAATAAAAAATATGATACTCGCACCCTTTGGACA
 G  D  L  V  A  W  N  K  K  Y  D  T  R  T  L  W  T 
Aids54H23v1 .....................C...........C..................
 G  D  L  V  A  W  N  K  K  Y  D  T  R  T  L  W  T 
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Two isolates (Aids16 and Aids17) were typed as H43p in the fibre shaft region with 
sequences identical to the reference strain. Both isolates also have a fibre knob sequence 
identical to the reference strain. 
H49p was detected in two isolates (Aids31 and Aids34) with the same sequence as the 
reference strain in the fibre shaft region but the fibre knob sequence of these two isolates 
(H49v2) was not identical to the reference strain. 
3.1.4.6 Unidentified fibre shafts: 
3.1.4.6.1 HU1: 
Isolates Aids4 and Aids28 previously shown to have an untyped fibre knob HU1 also had 
an unidentified fibre shaft sequence (HU1). The phylogenetic tree showed HU1 clustering 
with HAdV-D types 28, 43 and 45 but not branching off any of them. The closest types 
were HAdV-D43 and HAdV-D28 with 8.83% nucleotide and 9.4% amino acid divergences 
for both of them. 
3.1.4.6.2 HU2: 
HU2 is an unidentified sequence detected in two isolates (Aids58 and Aids59), both of 
them previously shown to have an identical unknown fibre knob HU2. Fibre shaft sequence 
HU2 clusters with HAdV-D types 22, 15 and 42 but was not identical to any of them with 
nucleotide divergences 16.81%, 17.95% and 18.81% respectively and amino acid 
divergence of 19.66% for all of them. 
3.1.4.6.3 HU3: 
Aids23 and Aids25 had the unidentified fibre shaft sequence HU3 and had also been shown 
to have an untyped fibre knob HU3. This unidentified fibre shaft was at the same 
phylogenetic cluster  with HU1 and HAdV-D types 28, 43 and 45 but not branching off any 
of them.  The closest type was HAdV-D43 with 8.26% nucleotide and 8.55% amino acid 
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divergence. HU3 differed from HU1 by only 0.57% in the nucleotide sequence and 1.71% 
in the amino acid sequence.  
The fibre shafts typing results of all clinical isolates are summarised in Table 3.3 
 
Table 3.3: Summary of fibre shafts phylogenetic analysis of HAdV-D variants. The table 
summarises types, variants, BLASTN accession number, and nucleotide and amino acids 
divergence. nt: nucleotide, aa: amino acid. 
 
 
 
 
Fibre 
shaft 
Type 
Variant 
Accession 
number 
Sequence divergence from 
tree reference strain (%) Amino acid changes 
nt aa 
H9 
v1  1.42 2.56 D6H, R63I, T84S 
v2  1.42 1.71 R63I, T84S 
v3  1.71 3.42 
D6H, D38E, R63I, 
T84S 
v4  1.71 2.56 D6H, R63I, T84S 
H22 
Prototype AJ811445 0 0 None 
v1  0.86 0.86 A82G 
H23 v1  5.11 5.64 
T15P, E36Q, K39N, 
P41K, T66M, H73Q, 
D83S 
H29 v1 FM210545 0.81 2.42 D5E, K6Q, S104F 
H38 Prototype AJ811455 0 0 None 
H43 Prototype AJ811458 0 0 None 
H49 Prototype AJ811464 0 0 None 
HU1   
8.83(Ad43) 
8.83(Ad28) 
9.4(Ad43) 
9.4(Ad28) 
 
HU2   
17.95(Ad15) 
18.81(Ad42) 
16.81(Ad22) 
19.66(Ad15) 
19.66(Ad42) 
19.66(Ad22) 
 
HU3   
8.26(Ad43) 
0.57(HU1) 
 
8.55(Ad43) 
1.71 (HU1) 
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3.1.5 Sequencing and phylogenetic analysis of the partial penton region of isolates 
from AIDS patients: 
Various penton types of HAdV-D were detected in the clinical isolates by phylogenetic 
analysis of the partial penton sequence containing the penton variable regions, HVR and 
RGD loop (nucleotide positions 250-1168 of the full penton sequence of HAdV-D9, 
AJ854486). Three of the isolates (Aids31, Aids34 and Aids54) had the same sequence of 
the reference strains HAdV-D19C. This strain is significantly different from the HAdV-
D19 prototype in the penton region. One isolate (Aids72) had the same penton sequence as 
the HAdV-D44 prototype. The rest of the isolates had untyped pentons (PU1-PU10) in both 
nucleotide and amino acid phylogenetic analysis (Fig 3.13 and Fig 3.14).    
The available full penton sequences of some HAdV-D types in GenBank were used for 
multi-sequence alignment analysis using mVISTA software to compare the full penton 
sequences by aligning HAdV-D9 against a penton from each phylogenetic cluster of the 
amino acid tree (Fig 3.15). The analysis showed that the whole penton sequence is 
conserved except the two variable regions HVR and the RGD loop. This structure of the 
HAdV penton sequences in addition to the well known recombination in the HVR and 
RGD penton regions of HAdV-D types suggests that the high number of unidentified 
penton types of the clinical isolates could be a result of intra-penton recombination between 
the penton variable regions (HVR and RGD). Separate phylogenetic analysis was carried 
out for each penton variable region to investigate this possibility further.  
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Figure 3.13: Phylogenetic tree of nucleotide sequences of the penton region (nucleotide positions 
250-1168 of the full penton sequence of HAdV-D9) of the clinical isolates and all HAdV-D types. 
Only one example of each variant has been used in the tree. 
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Figure 3.14: Phylogenetic tree of amino acid sequences of the penton region of the clinical isolates 
and all HAdV-D types. Only one example of each variant has been used in the tree. Cluster 
numbering according to Madisch et al. 2005. 
 
 
 
 
0.1
HAdV-D33
Aids32PU5
HAdV-D51
HAdV-D19
HAdV-D23
Aids25PU2
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Figure 3.15: Pairwise sequence alignment comparison of HAdV-D9 full penton sequence with six 
other types from species D  using mVISTA . The percent of sequence homology is reflected in the 
height of each data point along the y-axis and the genome position along the x-axis.  
 3.1.5.1 Sequencing and phylogenetic analysis of the penton HVR of isolates from 
AIDS patients: 
3.1.5.1.1 Identified penton HVR types: 
The phylogenetic analysis of the nucleotide sequences (nucleotide positions 351-547 of full 
penton  sequence of HAdV-D9) of this region (Fig 3.16) showed one isolate (Aids72) had 
an identical sequence to the prototype HAdV-D44 and two isolates (Aids58 and Aids59) 
were variants of  HAdV-D15 or HAdV-D42 that are identical in this region. The two 
nucleotide difference (C69T; A174G; 1.02%) did not result in an amino acid change. This 
variant has not been reported previously. Isolates Aids32 showed a 1% nucleotide 
divergence from HAdV-D32, a type that has an identical amino acid HVR sequence to 
HAdV-D13 and HAdV-D44, and resulted in a single amino acid change (K25E). Several 
HAdV-D types have identical amino acid sequences (Fig 3.17) including for example 
HAdV-D types 15, 22, 37, 42 and 53. Twelve isolates had sequences identical to the 
HAdV-D19C reference strain.  
HVR1 RGD loop 
HAdV-D48 
HAdV-D22 
HAdV-D36 
HAdV-D37 
HAdV-D49 
HAdV-D19 
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Figure 3.16: Phylogenetic tree of nucleotide sequences of the penton HVR region (nucleotide 
positions 351-547 of full penton  sequence of HAdV-D9) of the clinical isolates and all HAdV-D 
types. Only one example of each variant has been used in the tree. 
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Figure 3.17: Phylogenetic tree of amino acid sequences of the penton HVR region of the clinical 
isolates and all HAdV-D types. Only one example of each variant has been used in the tree. 
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3.1.5.1.2 Unidentified penton HVR types: 
Four unidentified penton HVR types were detected and none of them have been reported 
previously. 
3.1.5.1.2.1 HVR U1: 
Isolates Aids4 and Aids28 had an unidentified penton HVR sequence (U1). The closest 
types to U1 were HAdV-D28 and HAdV-D33 (both of which have an identical amino acid 
sequence) with 5.5% divergence resulting in 3 amino acid changes (Table 3.4). 
3.1.5.1.2.2 HVR U2: 
This unidentified type was detected in two isolates (Aids23 and Aids25) and clustered in 
the nucleotide phylogenetic tree with HAdV-D types 15, 22, 37, 38, 42 and 53. The closest 
types were 15 and 42 which had an identical nucleotide sequence in this region and differed 
from U2 by 4 nucleotides (2.03%). At the amino acid level, HAdV-D types 15, 22, 37, 42 
and 53 are identical in the HVR and differed from U2 by 2 amino acids (Table 3.4). 
3.1.5.1.2.3 HVR U3: 
Nine isolates had this unidentified sequence which clustered with HAdV-D types 17, 19C, 
29, 43 and the unidentified sequence U4. A further isolate (Aids15) differed from U3 by a 
single nucleotide (U3v1). The closest type was HAdV-D29 in the nucleotide level with 
3.55% divergence from U3 and 3.05% divergence from U3v1. In the amino acid level, both 
U3 and U3v1 were identical and differed from HAdV-D29 and HAdV-D17 (both have an 
identical amino acid sequence) by 3 amino acids (4.62% divergence).   
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3.1.5.1.2.4 HVRU4: 
This unidentified type was detected in isolate Aids20 which clustered with HAdV-D types 
17, 19C, 29, 43 and the unidentified sequences U3 and U3v1. The closest type was HAdV-
D29 at the nucleotide level with 5.08% divergence. However, HAdV-D types 8 and 30 with 
identical amino acid sequences were closest to U4 and differed by 2 amino acids (3.08% 
divergence) comparing to HAdV-D29 which differed from U4 by 4 amino acids. 
The penton HVR region typing results are summarised in Table 3.4. 
HVR 
variant 
Accession 
number 
Sequence divergence from tree reference strain (%) Amino acid 
changes nt aa 
19C EF121005 0 0 None 
15/42 v1  1.02 0 (Ad15/Ad22/Ad37/Ad42/Ad53) None 
32 v1  1.0 (Ad32) 1.6 (Ad13/Ad44/Ad32) K25E 
44p DQ375482 0 0 None 
U1  5.5 
(Ad28/Ad33) 
4.62 (Ad28/Ad33) D12P, 
A13V, S14N 
U2  2.03 
(Ad15/Ad42) 
3.08 
(Ad15/Ad22/Ad37/Ad42/Ad53) 
N14D, Q24E 
U3  3.55 (Ad29) 4.62 (Ad17/Ad29) E12A, A13E, 
E24D U3v1  3.05% (Ad29) 
U4  5.08(Ad29) 3.08 (Ad8/Ad30) K20M, 
E24D 
 
Table 3.4: Summary of penton HVR phylogenetic analysis of HAdV-D variants. The table 
summarises types, variants, BLASTN accession number, and nucleotide and amino acids 
divergence. nt: nucleotide, aa: amino acid. 
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3.1.5.2 Sequencing and phylogenetic analysis of the penton RGD loop of isolates from 
AIDS patients:  
3.1.5.2.1 Identified penton RGD types: 
Phylogenetic  analysis of the RGD region (nucleotide positions 746-1168 of HAdV-D9 full 
penton sequence) showed one isolate (Aids72) had an identical sequence to the prototype 
HAdV-D44 and three isolates (Aids31, Aids34, Aids54) had identical sequences to HAdV-
D19C (Fig 3.18 & Fig 3.19).   
Three penton RGD variants (9v1, 9v2 and 9v3) of HAdV-D9 were detected in 8 isolates. 
Each of the three variants varied from the reference strain by two different nucleotides 
(0.47%). These nucleotide substitutions resulted in two amino acid changes (L127H & 
C134S) in 9v3 only. The amino acid sequence of 9v1 and 9v2 was identical to the reference 
strain HAdV-D9 which is also identical to HAdV-D10 and HAdV-D26 in this region.  
One variant of HAdV-D36 was detected in isolate Aids15. This variant differed from the 
reference strain by 7 nucleotides (C15A; T36C; T78C; C84T; T90C; C93A; G167T; 1.7%) 
but only a single amino acid change (G56V; 0.7%).  
Two variants of HAdV-D42 were detected. RGD 42v1 was detected in 7 isolates and 
showed 2 nucleotide substitutions (G354A; G387C; 0.48%) from the reference strain, 
neither of which resulted in an amino acid change. The second variant 42v2 was detected in 
one isolate only and varied from the reference strain by 4 nucleotides (G129C; C209T; 
G349C; G378C; 0.96%) and one amino acid change (K43N). 
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Figure 3.18: Phylogenetic tree of nucleotide sequences of penton RGD region (nucleotide positions 
746-1168 of HAdV-D9 full penton sequence) of the clinical isolates and all HAdV-D types. Only 
one example of each variant has been used in the tree. 
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Figure 3.19: Phylogenetic tree of amino acid sequences of the penton RGD region of the clinical 
isolates and all HAdV-D types. Only one example of each variant has been used in the tree. 
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3.1.5.2.2 Unidentified penton RGD types: 
3.1.5.2.2.1 RGD U1: 
This unidentified type was detected in two isolates (Aids4 and Aids28) and clustered in the 
nucleotide phylogenetic tree with HAdV-D types 25, 29, 36, 43 and 46. The closest type 
was 43 which differed from U1 by 32 nucleotides (5.39% divergence) resulting in 5 amino 
acid changes (3.52% divergence) from both HAdV-D43 and HAdVD36 that have an 
identical amino acid sequence in this region (Fig 3.19). 
3.1.5.2.2.2 RGD U2: 
This type of penton RGD region was detected in isolates Aids23 and Aids25 which 
clustered with HAdV-D types 24, 27 and 48 in the nucleotide phylogenetic tree. The closest 
type at the nucleotide level was 48 with 4.07% nucleotide divergence resulting in 3 amino 
acid changes (2.16% divergence) from both HAdV-D48 and HAdV-D27 that have an 
identical amino acid sequence in this region. 
3.1.5.2.2.3 RGD U3: 
This unidentified type was detected in isolate Aids7 which clustered with HAdV-D47 but 
varied from it by 19 nucleotide substitutions (4.55%) which resulted in 4 amino acid 
changes (3.6% divergence).   
3.1.5.2.2.4 RGD U4: 
This unidentified type was detected in two isolates (Aids58 and Aids59) and clustered in 
the nucleotide phylogenetic tree with HAdV-D types 15, 20, 28, 37, 45 and 53. The closest 
type was HAdV-D28 with 19.81% nucleotide divergence resulting from 6 nucleotide 
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substitutions and 78 nucleotide deletions. HAdV-D types 37 and 53 had identical amino 
acid sequences in this region and diverged from U4 by 19.86%. The 78 nucleotide deletion 
from U4 resulted in a 26 amino acid deletion in this region including the RGD motif (Arg-
Gly-Asp) itself. A further single amino acid change resulted from nucleotide substitutions 
between U4 and HAdV-D37/53 while two amino acid changes resulted from the nucleotide 
substitutions between U4 and HAdV-D28. 
3.1.5.2.2.5 RGD U5: 
Isolates Aids32 had the unidentified penton RGD sequence (U5). The phylogenetic tree 
showed U5 clustering with HAdV-D types 19, 23, 33 and 51. The closest type was HAdV-
D23 with 5.3% nucleotide divergence resulting in one amino acid change and four amino 
acid deletions (3.6% divergence). 
The penton RGD region typing results of all clinical isolates are summarised in Table 3.5. 
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RGD variant Accession 
number 
Sequence divergence from tree reference 
strain (%) 
Amino acids 
change 
nt aa 
9v1  0.47 0 (Ad9/Ad10/Ad26) None 
9v2  0.47 0 (Ad9/Ad10/Ad26) None 
9v3  0.47 1.42 (Ad9/Ad10/Ad26) L127H, C134S 
19C EF121005 0 0 None 
36v1  1.7 0.7 (Ad36/Ad43) G56V 
42v1  0.48 0 (Ad22/Ad42) None 
42v2  0.96 0.72 (Ad22/Ad42) K43N 
44p DQ375482 0 0 None 
U1  5.39 (Ad43) 3.52 (Ad36/Ad43) T34V, K35A, 
D39E, T62I, E77G 
U2  4.07 (Ad48) 2.16 (Ad27/Ad48) S66T, H67Y, I68V 
U3  4.55 (Ad47) 3.6 (Ad47) A52G, G91D, 
D99G, S123L 
U4  19.81(Ad28) 19.86 (Ad37/Ad53) V24E 
26 amino acids 
deleted 
U5  5.3 (Ad23) 3.6 (Ad23) A54-, G55-, G56-, 
E57-, E73G 
 
Table 3.5: Summary of penton RGD loop phylogenetic analysis of HAdV-D variants. The table 
summarises types, variants, BLASTN accession number, and nucleotide and amino acids 
divergence. nt: nucleotide, aa: amino acid. 
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3.1.5.3 Intra-penton recombination: 
The phylogenetic analysis of the penton HVR and RGD regions showed that the possible 
new penton types (PU1-PU10) included 3 (PU1, PU2, PU9) that appear to be genuine new 
types. A further 3 (PU7, PU10, PU10v1) appear to be the result of recombination between 
two previously known types. The remaining 5 (PU3, PU4, PU5, PU6, PU8) suggest 
recombination between one known type and one previously unknown type (Table 3.6).  
Penton Isolates HVR 
region 
RGD 
region 
P44p Aids72 44p 44p 
P19C Aids31, Aids34, Aids54 19C 19C 
PU1 Aids4, Aids28 U1 U1 
PU2 Aids23, Aids25 U2 U2 
PU3 Aids15 U3v1 36v1 
PU4 Aids58, Aids59 15/42v1 U4 
PU5 Aids32 32v1 U5 
PU6 Aids2, Aids13, Aids18, Aids21, Aids22,  Aids24, 
Aids48,  Aids51 
U3 9v1 
PU7 Aids50 19C 9v2 
PU8 Aids20 U4 9v3 
PU9 Aids7 U3 U3 
PU10 Aids14, Aids16, Aids17,  Aids27, Aids38, Aids57,  
Ais61  
19C 42v1 
PU10v1 Aids39 19C 42v2 
 
Table 3.6: Summary of typing results of penton HVR and RGD regions of the clinical isolates. 
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3.1.5.3.1 Recombination in penton type PU7: 
The phylogenetic analysis of the PU7 HVR and the sequences alignment showed that this 
region is identical to that of HAdV-D19C while the analysis and the alignment of the PU7 
RGD region showed that this is a variant of HAdV-D9. This conflicting result of the two 
variable regions of the same penton indicates recombination in this unidentified penton 
type.  
PU7 penton was compared to HAdV-D19C and HAdV-D9 penton sequences in BootScan 
and SimPlot analysis. BootScan  (Fig 3.20) shows two peaks in the HVR and RGD region 
loci supporting the possibility of recombination in PU7 between HVR of HAdV-D19C and 
RGD of HAdV-D9. Further support of recombination comes from a SimPlot analysis (Fig 
3.21) showing that the HAdV-D19C sequence has a higher similarity level to PU7 in the 
HVR1 region of the alignment and HAdV-D9 was more similar to PU7 in the RGD loop 
region. Similar results were obtained when PU10 (19C/42v1) and PU10v1 (19C/42v2) 
were analysed.  
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Figure 3.20: BootScan analysis of the partial penton gene. Aids50PU7 was compared to HAdV-
D19C (green), HAdV-D9 (red) and other HAdV-D types (different colours). The nucleotide 
position is given on the x axis, and the percentage of permuted trees is given on the y axis. 
 
  
Figure 3.21: Similarity plots of the partial penton gene. Aids50PU7 was compared to HAdV-D19C 
(green), HAdV-D9 (red) and other HAdV-D types (different colours). The nucleotide position is 
given on the x axis, and the percentage of nucleotide sequence similarity is given on the y axis.  
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3.1.6 Multiple recombination events in the genomes of the clinical isolates from AIDS 
patients: 
The previously reported typing results of the hexon  L2 (HVR7) and the fibre knob regions 
of the clinical isolates (Al Qurashi, 2009) in addition to the typing results of the hexon L1 
(HVR1-6) and the partial fibre shaft  showed recombination events between the hexon and 
fibre of the intermediate strains. Further recombination events occurred with the penton and 
within the penton itself between HVR and RGD regions in most of the isolates (Table 3.7). 
Different types and variants were isolated from the same patients over time in some cases. 
For example, in patient 10 several changes occurred between 1992 and 1994. In 1992, 
isolate Aids57 had an identical hexon sequence to HAdV-D19C. However, 1993 and 1994 
isolates from this patients had variants of HAdV-D17 in the hexon region. The fibre regions 
of the isolates from this patient were variants of H9 or H29. The penton of all isolates from 
this patient were unknown previously. In two isolates the penton was a result of 
recombination between Ad19C HVR region and Ad42 RGD region. In one isolate the 
recombination was between Ad19C HVR and Ad9v2 RGD. In the rest of the isolates the 
recombination was between previously unknown HVR (U3) and the Ad9v1 RGD region. 
Only the fibre was changed over time in isolates from patient 17 which had Ad23 fibre in 
1992 then Ad49 fibre in 1993. 
Patient 24 was infected with isolate Aids32 with Ad23 hexon and fibre but subsequently 
was replaced by isolates Aids4 and Aids28 with a Ad26 hexon but previously unknown 
fibre and penton. Isolates Aids58 and Aids59 had a Ad20 hexon with untyped fibre region 
(Ad20v1HU2) and untyped penton RGD region U4 with Ad15/42 variant in the penton 
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HVR. In patient 74, isolates Aids23 and Aids25 appear to represent a completely new 
adenovirus type. 
 
Table 3.7: Summary of previous and current typing results of intermediate isolates in different 
genome regions. The table summarises the phylogenetic typing results of the isolates, year of 
isolation and case number. N/R: not recorded. 
 
 
Case Year 
isolated 
Isolate Hexon 
L2 
(HVR7) 
Hexon 
L1 
( HVR1-
6) 
Fibre 
knob 
Fibre 
shaft 
Penton 
HVR 
Penton 
RGD 
19 1993 Aids27, Aids38 19C 19C H9v1 9v1 19C 42v1 
Aids48 19C 19C H9v3 9v3 U3 9v1 
10 1992 Aids57 19C 19C H9v1 9v1 19C 42v1 
1993 Aids39 17v1 17v1 H9v1 9v1 19C 42v2 
Aids24 17v1 17v1 H9v2 9v2 U3 9v1 
Aids18, Aids51 17v1 17v1 H29v1 29v1 U3 9v1 
Aids50 17v1 17v2 H29v1 29v1 19C 9v2 
1994 Aids2, Aids13 17v1 17v2 H29v1 29v1 U3 9v1 
17 1992 Aids54 19C 19C H23v1 23v1 19C 19C 
1993 Aids31, Aids34 19C 19C H49v2 49p 19C 19C 
24 1993 Aids32 23v1 23v1 23v1 23v1 32v1 U5 
Aids28 26v3 26v3 HU1 HU1 U1 U1 
1994 Aids4 26v3 26v3 HU1 HU1 U1 U1 
57 1993 Aids22 17v1 17v1 H9v1 9v1 U3 9v1 
74 1993 Aids23, Aids25 U1 U1 HU3 HU3 U2 U2 
c14 1993 Aids15 17v1 17v1 H22v1 22p U3v1 36v1 
c15 1993 Aids20 17v1 17v1 H9v4 9v4 U4 9v3 
N/R 
 
1986 Aids72 44v1 44v1 H38v1 38p 44p 44p 
1992 Aids58, Aids59 20v1 20v1 HU2 HU2 15/42v1 U4 
1992 Aids61 19C 19C H9v1 9v1 19C 42v1 
1993 Aids16, Aids17 19C 19C H43p 43p 19C 42v1 
1993 Aids21 17v1 17v1 H9v1 9v1 U3 9v1 
1994 Aids7 20p 20p H22v2 22v1 U3 U3 
1994 Aids14 19C 19C H9v1 9v1 19C 42v1 
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3.2. Molecular analysis of the full genomes of isolates Aids25, Aids59 and 
Aids32: 
Sequencing and phylogenetic analysis of the clinical isolates from AIDS patients showed 
that some of these isolates might represent new types of adenovirus. Cultivation was carried 
out for these isolates in order to sequence their full genomes. Isolates Aids25, Aids59 and 
Aids32 were cultivated successfully and DNA extracts of these isolates were subjected to 
full genome sequencing analysis. 
Two samples of the purified DNA of isolates Aids25 and Aids59 were subjected to full 
genome sequencing. The A260/A280 ratio of Aids25 DNA was 1.87 and the sequencing 
runs resulted in 68,605 reads totalling 21,625,446 nucleotides with an average length of 
311 bp per read. The A260/A280 ratio of Aids59 DNA was 1.90. The two sequence runs of 
Aids59 DNA resulted in 53,648 reads totalling 14,515,089 nucleotides with an average 
length of 271 bp per read. The individual sequences of Aids25 and Aids59 were then 
assembled into contigs. 
Purified DNA of Aids32 with A260/A280 ratio of 1.86 was submitted for sequencing. Only 
one sequencing run generated 34178 reads totalling 12,453,550 nucleotides with an average 
length of 364 bp per read. The individual sequences were then assembled into contigs. Gaps 
between contigs of Aids32were filled by PCR amplification with primers designed from the 
generated sequences.  
The full genome sequencing and analysis of Aids25 and Aids59 has been submitted to the 
GenBank (accession numbers: JN162671 & JN162672 respectively). 
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3.2.1 General features of the genome: 
The genome lengths of Aids25, Aids59 and Aids32 were found to be 35127 bp, 35103 bp 
and 35029 bp and the G+C contents were 57.39%, 56.97% and 56.80% respectively. These 
data are similar to other members of HAdV-D. The base compositions of these isolates are 
shown in Table 3.8. 
Isolates A C G T 
Aids25 22.36% 28.61% 28.78% 20.25% 
Aids59 22.61% 28.41% 28.56% 20.42% 
Aids32 22.65% 28.33% 28.48% 20.54% 
Table 3.8: Base composition of isolates Aids25, Aids59 and Aids32. 
3.2.2 Gene coding features:  
Four early, two intermediate and five late transcription units have been identified in the full 
genome sequences of Aids25, Aids59 and Aids32 which is similar to other HAdV genomes 
organization (Fig 3.22). Thirty nine predicted coding sequences are included within 
genome regions (Table 3.9).  
 
Figure 3.22: Transcriptional map of Aids25. Protein coding region are identified by solid arrows. 
Aids59 and Aids32 genome have the same organization. 
 
E1A  E1B                                        L1             L2                 L3                          L4               E3         L5 
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Region Gene 
product 
Aids25 Aid59 Aids32 
Location Protein 
length 
Location Protein 
length 
Location Protein 
length 
E1A 21 K 562-925, 
1205-1413 
191 571-934, 
1214-1422 
191 560-923, 
1203-1411 
191 
28 K 562-1111, 
1205-1413 
253 571-1120, 
1214-1422 
253 560-1109, 
1203-1411 
253 
E1B 19K 1569- 2114 182 1578- 2123 182 1558- 2103 182 
55 K 1874- 3358 495 1883- 3367 495 1863- 3347 495 
Inter- 
mediate 
IX 3449-3850 134 3455-3853 133 3435-3833 133 
Iva2 3900-5230, 
5509-5521c 
448 3900-5230, 
5509-5521c 
448 3883-5216, 
5492-5504c 
448 
E2B DNA 
Pol 
5003-8275c 1091 5003-8275c 1091 4986-8258c 1091 
L1 13.6 K 7781-8161, 
9366- 9371 
129 7781-8161, 
9372-9377 
129 7764-8144, 
9355-9360 
129 
E2B pTP 8317-10212, 
13467-13475c 
635 8323-10218, 
13491-13499c 
635 8306-10201, 
13476-13484c 
635 
L1 52/55 K 10629-11744 372 10633-11754 374 10616-11734 373 
pIIIa 11770-13446 559 11780-13468 563 11760-13454 565 
L2 Penton 13502-15052 517 13526-15004 493 13511-15052 514 
pVII 15059-15646 196 15011-15592 194 15059-15643 195 
pV 15682-16674 331 15628-16623 332 15679-16677 332 
pX 16707-16928 74 16656-16877 74 16710-16931 74 
L3 pVI 16987-17691 235 16936-17637 234 16990-17691 234 
Hexon 17760-20603 948 17681-20539 943 17765-20557 931 
Protease 20609-21235 209 20545-21171 209 20563-21189 209 
E2A DBP 21285-22760c 492 21221-22687c 489 21238-22704c 489 
L4 100 K 22777-24966 730 22704-24899 732 22721-24907 729 
33 K 24749-24992, 
25162-25448 
177 24685-24925, 
25095-25381 
176 24696-24933, 
25103-25383 
173 
22 K 24749-25162 138 24685-25095 137 24696-25103 136 
pVIII 25500-26180 227 25430-26110 227 25431-26111 227 
E3 12.2 K 26184-26501 106 26114-26431 106 26115-26432 106 
CR 1 α 26458-27048 197 26388-26981 198 26389-26982 198 
gp 19 K 27048-27518 156 26981-27454 157 26982-27455 157 
CR 1 β 27541-28785 412 27477-28718 411 27479-28633 382 
CR 1 γ 28815-29663 283 28748-29584 279 28663-29505 281 
RID α 29673-29945 91 29595-29867 91 29515-29787 91 
RID β 29951-30334 128 29873-30259 129 29793-30176 128 
14.8 K 30330-30719 130 30255-30644 130 30172-30558 129 
 U-exon 30811-30957c 49 30750-30896c 49 30668-30814c 49 
L5 Fiber 30973-32052 360 30910-32021 370 30828-31954 375 
E4 ORF 6/7 32743- 33042c 150 32559-33011c 151 32492-32944c 151 
34 K 32334- 33209c 292 32303-33178c 292 32236-33111c 292 
ORF 4 33142-33501c 120 33111-33470c 120 33044-33403c 120 
ORF 3 33507-33857c 117 33476-33826c 117 33409-33759c 117 
ORF 2 33857-34246c 130 33826-34215c 130 33759-34148c 130 
ORF 1 34290-34664c 125 34259-34633c 125 34192-34566c 125 
Table 3.9: Genome organization of Aids25, Aids59 and Aids32. c: complementary strand. DNA 
plo: DNA polymerase, pTP: precursor terminal protein, DBP:  DNA binding protein, CR1: 
conserved region 1, gp19K: glycoprotein 19K, RID: receptor internalization and degradation. 
 
125 
 
3.2.3 Non-coding features: 
3.2.3.1 Virus-associated RNA (VA RNA): 
HAdV-D members have two VA RNAs which play a role in host antiviral defence 
inhibition. VA RNA I and VA RNA II coding sequences have been identified in Aids25, 
Aids59 and Aids32 genomes with similar sequences to other VA RNAs of other HAdV-D 
types. The locations of these VA RNAs are shown in Table 3.10. 
 
Isolate VA RNA I location VA RNA II location 
Aids25 10241-10403 10461-10611 
Aids59 10247-10407 10465-10615 
Aids32 10230-10390 10448-10598 
 Table 3.10: VA RNA I and VA RNA II locations. 
 
3.2.3.2 Inverted terminal repeats (ITR): 
The 5’ and 3’ ends of Aids25, Aids59 and Aids32 genomes are composed of inverted 
terminal repeat (ITR) sequences of 151 bp, 147 bp and 148 bp respectively. ITRs contain 
conserved sequence motifs which are critical for DNA replication. One of these motifs is 
the core origin. Other motifs bind transcription factors and enhance DNA replication such 
as the nuclear factors I and III (NFI and NFIII) binding sites. However, NFI is missing from 
these isolates and from all HAdV-D types. There are also binding sites for cellular factors 
such as the stimulatory protein 1 (Sp1) and the activating transcription factor (ATF) which 
play role in the efficiency of viral DNA replication (Fig 3.23).  
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Figure 3.23: Inverted terminal repeats (ITRs) alignment of selected HAdVs from different species 
and isolates Aids25, Aids59 and Aids32. Core origin, nuclear factors III (NFIII), 
stimulatory protein 1 (Sp1) and the activating transcription factor (ATF) motifs marked. 
 
 
 
     Sp1 
NF III Core origin 
ATF 
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3.2.4 Full genome phylogenetic analysis: 
The phylogenetic analysis of the nucleotide sequences of Aids25, Aids59 and Aids32 full 
genomes with all HAdVs where full genome sequences are available in the GenBank 
showed that these isolates clearly belong to HAdV-D species (Fig 3.24). Aids25 was close 
to HAdV-D48. However, the divergence between Aids25 and HAdV-D48 is 5.9% which is 
higher than the divergence between existing types of species D. Aids59 did not cluster with 
any other type. Aids32 was close to HAdV-D29. However, the divergence between them 
was 7.1% which is higher than the divergence between existing types of HAdV-D. The full 
genome phylogenetic analysis indicates that Aids25, Aids59 and Aids32 genomes are not 
identical to any of these fully sequenced HAdV-D types. 
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Figure 3.24: Phylogenetic tree of isolates Aids25, Aids59 and Aids32 full genome nucleotide 
sequences with the completely sequenced HAdV genomes. 
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3.2.5 Full genome pairwise alignment: 
Aids25, Aids59 and Aids32 full genome pairwise alignments with selected types of all 6 
HAdV species were performed using mVISTA software. The comparison of the genomes 
of these isolates with other species members showed that only HAdV-D9 of species D had 
a high level of homology to them compared to types from other species. This confirms that 
Aids25, Aids59 and Aids32 are types of species D adenovirus (Fig 3.25).  
Other pairwise alignments of Aids25, Aids59 and Aids32 full genomes with the completely 
sequenced HAdV-D types were performed.  This comparison showed a high level of 
conservation between the genomes of the isolates and all other HAdV-D types in all 
genome regions except penton, hexon, E3 and fibre regions which are less conserved in all 
species D types (Fig 3.26). The analysis showed that Aids25, Aids59 and Aids32 genomes 
were not identical to any of these fully sequenced HAdV-D types. 
 
Figure 3.25: Pairwise sequence alignment comparison of Aids25 full genome sequence with six types from 
each HAdV species using mVISTA. The percent of sequence homology is reflected in the height of each data 
point along the y-axis and the genome position along the x-axis. Arrows on top display the transcription units 
with the direction of the transcription. Similar results were found for Aids59 and Aids32. 
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Figure 3.26: Pairwise sequence alignment comparison of Aids25 full genome sequence with the completely 
sequenced HAdV-D types using mVISTA. The percent of sequence homology is reflected in the height of 
each data point along the y-axis and the genome position along the x-axis. Arrows on top display the 
transcription units with the direction of the transcription. Similar results were found for Aids59 and Aids32. 
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3.2.6 Detailed analysis of selected genome regions: 
3.2.6.1 E3 region: 
Eight ORFs were predicted within the E3 region of Aids25, Aids59 and Aids32 genomes: 
12.2K, CR1α, gp 19K, CR1β, CR1γ, RIDα, RIDβ and 14.8K. The coding regions of 12.2K, 
gp 19K, RIDα, RIDβ and 14.8K proteins are more conserved in the E3 region of Aids25, 
Aids59 and Aids32 and showed high levels of homology to many HAdV-D types.  
Pairwise alignment of the E3 region with HAdV-D types where E3 sequences are available 
in the GenBank (Fig 3.27) showed that parts of this region, coding for CR 1α, CR 1β and 
CR1γ, are more heterologous than other regions. The figure shows also that Aids25 CR1α 
coding region is more homologous to the same region in HAdV-D28 and 49 than other 
types with 91% homology. The coding region of Aids25 CR1β is very close to the same 
region of HAdV-D48 with 95% homology. Aids25 CR1γ coding region is closer to HAdV-
D28 with 80% homology (Fig 3.27 A).  
The closest type to Aids59 CR1α was HAdV-D29 with 98% homology. However, other 
types such as HAdV-D22, 17 and 53 also had a homology of 97% to this coding region. 
Aids59 CR1β was more close to HAdVD-37 and 19 with 86% homology. Aids59 CR1γ 
was close to HAdV-D15 with 99% homology (Fig 3.27 B). 
The closest type to Aids32 CR1α was HAdV-D29 with 98% homology and other types 
such as HAdV-D22, 17 and 53 also had a homology of 97% to this coding region. CR1β 
did not show a high level of homology with any HAdV-D type and the closest types shared 
only 49% homology with it. Aids32 CR1γ showed 79% homology to HAdV-D37 (Fig 3.27 
C). 
The overall sequences of Aids25, Aids59 and Aids32 E3 regions indicate that these regions 
are unique among HAdV-D.  
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Figure 3.27: Pairwise sequence alignment comparison of E3 regions of Aids25 (A), Aids59 (B) and 
Aids32 (C) with the same region of some of HAdV-D types using mVISTA. The percent of 
sequence homology is reflected in the height of each data point along the y-axis and the genome 
position along the x-axis. Arrows on top of figures indicate coding regions of E3 protiens. 
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3.2.6.2 Penton: 
The full penton sequences are not available for all HAdVs in the GenBank. However, 
sequences of the central fragment of the penton including the two variable regions are 
available. Analysis for this fragment of Aids25, Aids59 and Aids32 penton was presented 
previously in this study (see 3.1.5). This analysis showed that Aids25, Aids59 and Aids32 
had unidentified pentons PU2, PU4 and PU5 respectively.  
The full penton nucleotide sequences of Aids25 shared 89.8-96.6% identity with other 
HAdV-D pentons where full penton sequences are available in GenBank. Aids25 penton 
protein has 517 amino acids and showed 90-97% identity to other HAdV-D penton 
proteins. HAdV-D48 penton is the closest to Aids25 in both amino acid and nucleotide 
sequences. However, BLASTP showed also that Aids25 penton had 98% nucleotide and 
97.7% amino acid homology with adenovirus prime strain HAdV-D17’H30 (AJ296013).  
The Aids 59 penton protein has 493 amino acids and showed 88-94% identity to other 
HAdV-D penton proteins where full penton sequences are available in the GenBank. The 
full penton nucleotide sequences of Aids59 shared 87-94% identity with other HAdV-D 
pentons. HAdV-D types 37 and 53 pentons, which are identical, are the closest to Aids59 in 
both amino acid and nucleotide sequences. The mVISTA pairwise alignment showed that 
Aids59 penton has a similar sequence to HAdV-D37 in all regions except the RGD loop 
(Fig 3.28). The divergence between Aids59 penton and HAdV-D37 was the result of a 78 
nucleotide deletion from Aids59 penton sequence compared to HAdV-D37 and other 
species D penton sequences resulting in a 26 amino acid deletion in RGD loop region 
including the RGD motif (Arg-Gly-Asp). This motif is found in all human adenoviruses 
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except HAdV-F40 and HAdV-F41. Aids59 will be the first reported isolate of species D 
adenovirus with a naturally deleted RGD motif.  
 
 
 
Figure 3.28: Pairwise sequence alignment comparison of full penton of Aids59 sequence with the 
same region of HAdV-D9 and HAdV-D37 using mVISTA. The percent of sequence homology is 
reflected in the height of each data point along the y-axis and the genome position along the x-axis.  
 
The previous comparison of Aids32 partial penton sequences including HVR1 and RGD 
loop with for all HAdV-D types showed that Aids32 has an unidentified penton sequence 
(PU5) which is close to HAdV-D types 23, 33, 19 and 51. The full penton sequences are 
not available for these types in the GenBank except HAdV-D19.  
The intra-penton recombination analysis (see 3.1.5.3) showed that Aids32 penton could be 
a result of recombination between the HVR of HAdV-D32 and unknown RGD loop. The 
closest type to the RGD loop of Aids32 was HAdV-D23 (Fig 3.29). 
 
 
  
Figure 3.29: Pairwise sequence alignment comparison of full penton of Aids32 with HAdV-D23 
and HAdV-D32 using mVISTA. The percent of sequence homology is reflected in the height of 
each data point along the y-axis and the genome position along the x-axis.  
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3.2.6.3 Hexon: 
Aids25, Aids59 and Aids32 hexons, like other HAdV hexons, consist of two loops which 
include seven variable regions (HVR1-6 in loop 1 and HVR7 in loop 2) in addition to 
conserved regions. The HVRs are different in sequence and length. 
The previous phylogenetic analysis of the hexon L1 and L2 regions showed that Aids25 has 
unidentified (U1) sequences in these two regions (see 3.1.3.7). Aids25 hexon nucleotide 
sequence is 2844 bp in length and shared 86.8-91.7% homology with the corresponding 
nucleotide sequence of all other HAdV-D. The deduced amino acid sequence is 948 amino 
acids in length and showed 88-93.9% homology to the corresponding protein of other 
HAdV-D.  
Aids59 was typed as a variant of HAdV-D20 in the hexon L1 and L2 regions (see 3.1.3.3). 
The full hexon sequence of Aids59 showed 87.2-96.2% homology to the corresponding 
nucleotide sequence of other HAdV-D. The deduced amino acid sequence is 943 amino 
acids in length and shared 76.5-98.2% homology with the corresponding protein of other 
HAdV-D. 
The L1 and L2 typing results showed that Aids32 has a very close sequence to HAdV-D23 
L1 and L2 regions (see 3.1.3.4).  Aids32 full hexon showed 87-98% nucleotide and 76-99% 
amino acid homology to the corresponding protein of other HAdV-D. 
3.2.6.3.1 Full hexon Phylogenetic analysis: 
The full hexon sequences are available in the GenBank for all HAdVs. The full length of 
Aids25, Aids59 and Aids32 hexon nucleotide sequences were aligned to the hexon 
sequences of all HAdVs and used to construct the nucleotide phylogenetic tree (Fig 3.30). 
The amino acid phylogenetic tree was constructed from the alignment of Aids25, Aids59 
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and Aids32 amino acid sequences and the amino acid sequences for all HAdV-D (Fig. 
3.31). 
Figure 3.30: Phylogenetic analysis of nucleotide sequences of full hexon of isolates Aids25, Aids59 
and Aids32 and all HAdV types.  
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Figure 3.31: Phylogenetic analysis of amino acid sequences of full hexon of isolates Aids25, Aids59 
and Aids32 and all HAdV-D types.  
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The phylogenetic trees show that Aids25 clustered with HAdV-D28, HAdV-D17, HAdV-
D26, HAdV-D27, HAdV-D45 and HAdV-D10 of species D but was not identical to any of 
them which confirm that Aids25 has a new type of hexon. The nucleotide sequence 
identities to these types were 91.7%, 91.5%, 91.1%, 90.5%, 90.5% and 90.3% respectively. 
Aids25 hexon was located at the same cluster in the amino acids tree with HAdV-D28,  
HAdV-D26, HAdV-D17, HAdV-D27, HAdV-D10 and  HAdV-D45 with 93.9%, 93.2%, 
93.3%, 92.3%, 92.1%  and 91.8% homology respectively. Although Aids25 was branching 
with HAdV-D28 in the amino acid phylogenetic tree, it showed a divergence of 6.1 % 
which is higher that the divergence between the hexons of some existing HAdV-D types. 
The closest type to Aids59 hexon was HAdV-D20 and they were branching together in the 
nucleotide and amino acid phylogenetic trees of the full hexon. However, the divergence of 
3.8% between Aids59 and HAdV-D20 is higher than the divergence between existing types 
of species D.  
 Aids32 was branching with HAdV-D23 in both nucleotide and amino acid phylogenetic 
trees of full hexon with 2% nucleotide and 1% amino acid divergence. 
 
3.2.6.3.2 Full hexon pairwise alignment: 
Figure 3.32 shows a pairwise alignment of Aids25 with the closest types of HAdV-D using 
mVISTA software. The figure shows that the hexon has two variable loops, L1 which 
includes HVR1-6 and L2 which contains HVR7 but the rest of the hexon sequence is 
conserved among HAdV-D types. Low levels of identity across the seven HVRs of Aids25 
and the closest types can be observed which supports that Aids25 has a new type of hexon.  
The pairwise sequence alignment of Aids59 and its closest type HAdV-D20 in addition to 
HAdV-D9 as representative of other HAdV-D types using mVISTA showed that the first 
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part of the hexon which include the HVR1-7 is close to HAdV-D 20 in all variable regions 
except the beginning of L1 region which is HVR1. The second part of the hexon has similar 
level of homology to other HAdV-D types including HAdV-D20 (Fig. 3.33). 
Aids32 hexon pairwise alignment using mVISTA with the closest type HAdV-D23 and 
HAdV-D9 showed a high level of similarity between Aids32 hexon and HAdV-D23 in the 
first part of the hexon but the similarity was lower in the second part of the hexon and was 
at similar level of other HAdV-D hexons such as HAdV-D9 (Fig 3.34). In addition, the 
nucleotide alignment of Aids32 and HAdV-D23 showed 49 substitutions only 4 of them 
were in the first 1284 bp which include HVR1-7 and 45 were in the rest of the sequence 
(1512bp).    
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Figure 3.32: Pairwise sequence alignment comparison of the full hexon sequence of Aids25 with 
the same region of the closest HAdV-D types using mVISTA. The percent of sequence homology is 
reflected in the height of each data point along the y-axis and the genome position along the x-axis. 
Arrows on top display the hexon L1 and L2 regions. 
 
 
Figure 3.33: Pairwise sequence alignment comparison of full hexon of Aids59 sequence with the 
same region of HAdV-D9 and HAdV-D20 using mVISTA. Arrows on top display the hexon L1 and 
L2 regions. 
 
 
 
Figure 3.34: Pairwise sequence alignment comparison of full hexon Aids32 sequence with the same 
region of HAdV-D9 and HAdV-D23 using mVISTA. Arrows on top display the hexon L1 and L2 
regions. 
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3.2.6.3.3 Full hexon recombination analysis: 
3.2.6.3.3.1 Aids25 hexon recombination: 
The above mentioned phylogenetic analysis showed that Aids25 has a unique hexon 
sequence among HAdVs. However, Aids25 was originally typed as HAdV-D17 by serum 
neutralization (SN).  
No recombination event was found between Hexon L1 and Hexon L2 of Aids25. However, 
the nucleotide sequence alignment of Aids25 hexon with the closer types showed a 
fragment of Aids25 with a higher level of similarity to HAdV-D17 than to the other types 
(Fig 3.35). This fragment includes part of the sequence between HVR3 and HVR4 in 
addition to most of HVR4.  
 
 
Figure 3.35: Multi sequence alignment of fragment of Aids25 hexon L1 region with the closest 
HAdV-D types. Aids25 sequence which is similar to HAdV-D17 is indicated in black box. 
 
 
 
 
Aids25 AGATGAAACATATCAGCCAGAACCACAGGTAGGAGAAGAAAACTGGCAAGAAAATGAAGCCTTCTATGGA
HAdV-D17 .A..A..CTT..............T..A.....T.................GTC................
HAdV-D26 ...CA.G..T.TC...........T..A..T.................G.....................
HAdV-D27 T..CA.G.GT.TC...........T..A.......................GTCA..............C
HAdV-D28 .A.CA.......C...........T..A........G..G...................T.........C
Aids25 GGCAGGGCTCTCAAAAAAGAAACAAAAATGAAGCCCTGCTATGGCTCATTTGCCAGACCTACCAATGAAA
HAdV-D17 .....A.....T..G.....C................................A................
HAdV-D26 ..A........T.....G..C..T........A..A........A..T.....T........T.....G.
HAdV-D27 .....A.....T..G..G..C..C..G.....A..A........T..............C..T.......
HAdV-D28 .....A........G....................T..T.....T.........................
Aids25 AAGGCGGACAAGCTAAATTTAAGCCA---GTGGAAGAGGGGCAGCAACCTAAAGACCTTGACATTACATT
HAdV-D17 ..........................---..........................TTA......AGAT..
HAdV-D26 ....A..T..G..A..G..C..A...---..TA.T..A..AG.A...........T..G..T..AGAT..
HAdV-D27 .G..A..T..G..A.....C..AG..CCT.CT.TC..A..AG.A..G.....G..A.....T...GAC..
HAdV-D28 .T..A..T..G..A.....C..AA..CCT.CT.---.A..A...G..........A.........GACC.
Aids25
HAdV-D17
HAdV-D26
HAdV-D27
HAdV-D28
                   <                  HVR3             > 
    <                                           HVR4                                                   > 
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3.2.6.3.3.2 Aids59 hexon recombination: 
The above mentioned mVISTA analysis of Aids59 (Fig 3.33) indicates a possible 
recombination events at the beginning of L1 region of Aids59. The nucleotide alignment of 
the hexon variable regions of Aids59 with HAdV-D types showed that Aids59 HVR1 was 
similar to HAdV-D51 and the other variable regions HVR2-7 were similar to HAdV-D20 
which indicate a recombination event. Figure 3.36 shows a fragment of HAdV-D51 at the 
beginning of HVR1 of Aids59. Another short fragment can be observed between HVR2 
and HVR3 while the rest of the sequence is very close to HAdV-D20.  
The mVISTA alignment showed also that the second part of the hexon which does not 
include HVRs has the same level of similarity of HAdV-D20 and HAdV-D9 and this was 
applicable to many other HAdV-D types.  
The phylogenetic analysis of second part of the hexon (Fig 3.37) showed that Aids59 did 
not branch with HAdV-D20 as the variable regions part of the hexon which also indicates 
the possibility of the recombination event. Aids59 was clustering with HAdV-D45. 
However, the divergence between them was 3% which is more than the divergence between 
many existing HAdV-D types which indicates that Aids59 hexon has unidentified sequence 
in the carboxy-terminal. 
BootScan and SimPlot of full hexon sequences of all HAdVs and Aids59 also showed a 
high similarity level in the first part of the hexon including HVR2-7 to HAdV-D20 while 
the rest of the hexon did not show similarity to any HAdV-D which support possibility of 
recombination event between HAdV-D20 and a yet unknown hexon sequence (Fig 3.38 & 
Fig 3.39). This type of recombination in the hexon is well known among HAdV-D types. 
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Figure 3.36: Multi sequence alignment of nucleotide sequences of the of Aids59  hexon L1 (HVR1-
6) and L2 (HVR7) regions with HAdV-D20 and HAdV-D51. HVRs are indicated by arrows. 
HAdV-D20 CTCCCAAGGGCGCCCCCAACTCCAGTCAGTGGCTTGCAAAAGATACCAATGCTGCTGGTCAACCAGATA-
HAdV-D51 ................................GAGCAG...A.A..T.C..G..GA..-...TG.C..GG
Aids59 .C..A..A..T.....................GAGCAG...A.A..T.C..G..GA..-...TG.C..GG
HAdV-D20 AAACTCACACCTATGGCGTTGCAGCCATGGGTGGAGAAGACATTACAGAAAAGGGTCTTCAAATTGGCAT
HAdV-D51 ....A.......T......G..T..T.....A......A........A..G.T..............A.C
Aids59 ....G..T..T............................................C..............
HAdV-D20 TGATGAAACTAAAGAAGAAAATAACAAGATATTTGCCAATGAAATATACCAACCAGAACCTCAAGTGGGA
HAdV-D51 ...CAC...AGC...T.CTG....ACCA....A...AG.CA...C..T...G..............A...
Aids59 ....................................AG.CA...C..T......................
HAdV-D20 GAAGAAAACTGGCAGGAAACATTTGTTTTTTATGGCGGTAGAGCTCTTAAGAAGGATACCAAAATGAAAC
HAdV-D51 ..G..G........A.....T...AA...C.....A..A..G..............C.....G.......
Aids59 ........................................................C.............
HAdV-D20 CATGCTATGGCTCATTTGCCAGACCTACTAATGAAAAGGGAGGTCAGGCTAAATTTGTACTTGATCAGGA
HAdV-D51 ..........T..........................A.....A.....C...C..AA.AA..GA.CA..
Aids59 ................................................................C.....
HAdV-D20 AGGAAAGCCAACTAAAAATCATGACATCACAATGGCTTTCTTTGATACTCCTGGTGGGCAATTA------
HAdV-D51 T..C..A..C..A...G.GTT......AGATT..........C..C........C..CA..C.TCCAGGC
Aids59 ........................T................................A.....G------
HAdV-D20 ---AATGGAAAAGATGAACTTAAGGCAGACATTGTCATGTACACTGAAAATGTCAACCTGGAAACACCTG
HAdV-D51 AATG..CA...G..A...TAC..A.....T.................G....CTT.T........G..A.
Aids59 ---..............G....................................................
HAdV-D20 ACACCCATGTTGTTTACAAACCTGGAAAAGAGGATGACAGTTCAGAAATCAATTTGGTTCAACAGTCCAT
HAdV-D51 ....T.....A..A........A..C..G..T....CG........GGC...C........G..A.....
Aids59 ....G......................CTTCA......................................
HAdV-D20 GCCCAACAGACCCAACTACATTGGCTTCAGGGACAACTTTGTAGGGCTTATGTATTACAACAGCACTGGC
HAdV-D51 ...A...C.G...................................TT.G.....................
Aids59 ...A..T.........................................C.....................
HAdV-D20 AACATGGGTGTGCTGGCAGGTCAGGCCTCTCAGTTGAATGCTGTGGTAGACTTGCAAGACAGAAACACAG
HAdV-D51 .................T.............................C....................C.
Aids59 ...............................................G..T...................
HAdV-D20 AGCTGTCTTACCAGCTCTTGCTAGATTCGCTGGGTGACAGAACCAGATACTTTAGCATGTGGAACTCTGC
HAdV-D51 ............................T.........................................
Aids59 ....A.......................T.........................................
HAdV-D20 GGTGGACAGCTATGATCCAGATGTCAGGATCATTGAGAATCATGGTGTGGAAGATGAACTTCCAAACTAT
HAdV-D51 ..................C.......................C....................C......
Aids59 ........................T.................C...........................
HAdV-D20 TGCTTCCCATTGGATGGTGCTGGAACTAATGCAGTTTACCAAGGTGTAAAAATTACAGATGGAAATGATG
HAdV-D51 .................CT....C..C.....C.CC..T...........GG.G.....A..TG.G....
Aids59 .................C....................................................
HAdV-D20 GCGATGTCAATGATGACTGGGAAAAAGACACCGCAGTATCTGAACGT
HAdV-D51 .A.C..AGG.AAGC..A......CTT..A.A.AA.C.CG...CC...
Aids59 .T.............................................
       <               HVR1 
             >                  < 
       HVR2                          > 
<            HVR3              > 
    <            HVR4 
         >    <                     HVR5 
            > 
      <                             HVR6                             >                      
     <                       HVR7 
          > 
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Figure 3.37: Phylogenetic analysis of nucleotide sequences of carboxy-terminal of Aids25, Aids59 
and Aids32 hexon (Position: 1484-end of hexon) and the same region of all HAdV types.  
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Figure 3.38: BootScan analysis of the full hexon gene , Comparison of isolate Aids59 with HAdV 
types . Red colour indicates HAdV-D20, green colour indicates other HAdV-D types. The 
nucleotide position is given on the x axis, and the percentage of permuted trees is given on 
the y axis. 
 
 
 
 
 
 
 
Figure. 3.39: Similarity plots of the nucleotide sequences of the full hexon gene. Aids59 was 
compared to all HAdV-D types. Red colour indicates HAdV-D20 and green colour indicates other 
HAdV-D types. The nucleotide position is given on the x axis, and the percentage of nucleotide 
sequence similarity is given on the y axis.  
 
                    L1 (HVR1-6)           L2 (HVR7) 
                    L1 (HVR1-6)           L2 (HVR7) 
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3.2.6.3.3.3 Aids32 hexon recombination: 
BootScan and SimPlot of full hexon sequences of all HAdVs and Aids32 showed a high 
similarity level in the first part of the hexon of Aids32 to HAdV-D23 which include the 
HVR1-7. However, the rest of the hexon did not show similarity to any HAdVs and the 
divergence between Aids23 hexon and the closest type in this region was 3% which is 
higher than the divergence between existing types of HAdV-D. This indicates the 
possibility of a recombination event between HAdV-D23 and an unknown hexon sequence 
(Fig 3.40 & Fig 3.41). 
The phylogenetic analysis of the second part of the hexon (Fig 3.37) showes that this part 
of the hexon did not cluster with any other HAdV while the first part was very close to 
HAdV-D23 which also supports the possibility of the above mentioned recombination 
event. 
 
 
 
Figure 3.40: BootScan analysis of the full hexon gene , Comparison of isolate Aids32 with all 
HAdV-D types . Red colour indicates HAdV-D23 and green colour indicates other HAdV-D types. 
The nucleotide position is given on the x axis, and the percentage of permuted trees is given on 
the y axis. 
 
                    L1 (HVR1-6)           L2 (HVR7) 
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Figure 3.41: Similarity plots of the nucleotide sequences of the full hexon gene. Aids32 was 
compared to all HAdV-D types. Red colour indicates HAdV-D23 and green colour indicates other 
HAdV-D types. The nucleotide position is given on the x axis, and the percentage of nucleotide 
sequence similarity is given on the y axis.  
 
3.2.6.4 Fibre: 
The fibre genes of Aids25, Aids59 and Aids32, like all other HAdVs, can be divided into 
three regions: tail at the amino-terminal, middle shaft and knob at the carboxy-terminal. 
The previous typing results of fibre knob and fibre shafts showed that Aids25 had an 
unidentified sequence (HU3) and Aids59 had an unidentified sequence (HU2) in these two 
regions (see 3.1.4.6).  
Only some of the HAdV-D full fibre sequences are available in the GenBank and the 
phylogenetic analysis of the whole fibre of Aids25 with these sequences showed Aids25 
fibre clustering with HAdV-D28 with 82.5% nucleotide and amino acid homology (Fig 
3.42). The divergence of the full Aids25 fibre from the closest type HAdV-D28 is higher 
than the divergence between the fibres of existing HadV-D types such as HAdV-D19 and 
HAdV-D37 which confirm that Aids25 fibre is new type of fibre. 
                    L1 (HVR1-6)           L2 (HVR7) 
148 
 
Aids59 fibre was clustering with HAdV-D22 with 77% nucleotide and 75% amino acid 
homology but with a long distance which indicates a big divergence and confirmed the 
previous typing results of fibre knob and partial fibre shafts which showed that Aids59 has 
an unidentified fibre sequence. 
The previous typing results of the partial fibre sequences (shafts and knobs) showed that 
HAdV-D23 is the closest type to Aids32 fibre region sequence with 92% nucleotide and 
94% amino acid identity (see 3.1.4.3). The full fibre sequence is not available for HAdV-
D23 shaft so that Aids32 fibre clustered with HAdV-D46 which showed 78% nucleotide 
and 76% amino acids homology to Aids32 fibre.  
Aids25, Aids59 and Aids32 amino acids sequence like all HAdV-D fibres contain 
conserved motifs between the tail and the shaft (GVLSL) and also between the shaft and 
the knob (TLWT).  
The FNPVYPYG motif which interacts with the penton can be observed in the three fibre 
tails. The two flexibility loops which appear in all HAdVs fibre shafts except HAdV-D are 
absent from Aids25, Aids59 and Aids32 fibre shafts. The heparan sulphate-binding site 
which has been observed only in in HAdV-C fibre shafts cannot be seen in the fibre shafts 
of the three isolates. The KRLR motif could be detected in Aids25, Aids59 and Aids32 
fibres. This motif plays a role in the assembly by transferring the fibre to the nucleus. Fibre 
knobs of the three isolates contain Tyr and Lys amino acids which are important for sialic 
acid binding and present in all HAdV-D fibre knobs.  
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Figure 3.42: Phylogenetic analysis of amino acid sequences of the full fibre of isolates Aids25, 
Aids59 and Aids32 with HAdV-D types which full fibre sequences available in the GenBank.  
 
 
 
 
 
 
 
 
 
 
 
0.1
HAdV-D29
HAdV-D17
HAdV-D19
HAdV-D37
HAdV-D15
HAdV-D9
HAdV-D56
HAdV-D54
HAdV-D8
HAdV-D53
HAdV-D26
HAdV-D28
Aids25
HAdV-D48
HAdV-D49
HAdV-D46
Aids32
HAdV-D36
HAdV-D22
Aids59
150 
 
3.3 Molecular analysis analysis of HAdV-B clinical isolates: 
DNA extracts of 96 clinical isolates of HAdV-B species were amplified and sequenced then 
phylogenetic analysis of the hexon L2, fibre knob, penton, E1A and DNA polymerase 
regions was performed. Sixty two of the isolates (27 HAdV-B3 and 35 HAdV-B7) were 
collected between December 1983 and February 1985 during a 15 month simultaneous 
outbreak in the Manchester area. These isolates were chosen because they were circulating 
at the same time and in the same geographic area providing an opportunity for 
recombination events. A further analysis was carried out for 23 isolates of HAdV3 and 
HAdV7 collected in different years following the outbreak in addition to 11 isolates of 
other types of HAdV-B (HAdV-B11, HAdV-B16, HAdV-B21 and HAdV-B35). The 
reference strains HAdV-B3 NHRC 1267 and HAdV-B7 NHRC 1315 were included in the 
phylogenetic analysis because they are among the main reference strains that have been 
used elsewhere in the phylogenetic analysis of HAdV-B and because most of the isolates in 
this analysis clustered close to them in all genome regions. 
3.3.1 PCR of HAdV-B clinical isolates: 
3.3.1.1 Positive controls:  
DNA extracted from HAdV-B3 and HAdV-B35 isolates were used as positive controls to 
test different sets of primers targeting different regions of HAdV-B genome. These two 
isolates were typed previously by serum neutralization (SN). They were typed also by Al 
Qurashi (2009) using sequencing and phylogenetic analysis of the hexon L2 region.  
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3.3.1.2 Primers HSAd1/HSAd2: 
The target of these primers is the hexon L2 region including HVR7. Dilutions of 10
-1
 and 
10
-2
 of HAdV-B3 were tested using these primers. Clear bands of the expected size (629 bp) 
appeared on the gel (Fig 3.43A). 
3.3.1.3 Primers FiBL/FiBR: 
These primers target the fibre knob region of HAdV-B. Two dilutions (10
-1
 and 10
-2
 ) of 
DNA extracted from the HAdV-B3 isolate was amplified and clear bands of the expected 
size (987 bp) appeared on the gel (Fig 3.43B). 
A: 
 
 
   
 
Figure 3.43: Agarose gel electrophoretogram of HAdV-B3 DNA. A: With HSAd1/HSAd2 
primers. B: With FiBL/FiBR primers. Lane 1: Quantitative DNA ladder, lane 2: Negative control, 
lanes 3 and 4: 10
-1
 and 10
-2
 dilutions of HAdV-B3 DNA.  
3.3.1.4 Primers P1BL/P1BR and P2BL/P2BR: 
Two dilutions of 10
-1
 and 10
-2
 of HAdV-B3 DNA are amplified by two sets of primers that 
target two overlapping fragments of the penton region of HAdV-B. The products of the first 
set of primers had the expected size of 597 bp and the products of the second set had the 
expected size of 1196 bp (Fig 3.44).  
 
< 987 bp 
< 629 bp 
B: 
2000 bp> 
1000 bp> 
500  bp> 
250  bp> 
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Figure 3.44: Agarose gel electrophoretogram of HAdV-B3 DNA with P1BL/P1BR and P2BL/P2BR 
primers. Lane 1: Blank, lane 2: Negative control, lanes 3 and 4: 10
-1
 and 10
-2
 dilutions of HAdV-B3 
DNA amplified using P1BL/P1BR primers. Lane M: Quantitative DNA Ladder, lanes 5 and 6: 10
-1
 
and 10
-2
 dilutions of HAdV-B3 DNA amplified using P2BL/P2BR primers. 
 
3.3.1.5 Primers AdE1B-F/AdE1B1-R, AdE1B2-R: 
The forward AdE1B-F and the first reverse primer AdE1B1-R target the E1A region of 
species B1 (Types: 3, 7, 16, 21, 50). Two dilutions (10
-1
 and 10
-2
) of HAdV-B3 DNA were 
tested using these primers. Bands with the expected size of 822bp appeared on the gel. The 
same forward primer with the second reverse prime AdE1B2-R targeted the E1A region of 
species B2 (Types: 11, 14, 34, 35, 55). HAdV-B35 DNA from 10
-1
 and 10
-2
 dilutions was 
amplified using these primers and bands of the expected 830 bp products were visible on 
the gel (Fig 3.45). 
 
 
Figure 3.45: Agarose gel electrophoretogram of HAdV-B35 and HAdV-B3 DNA with AdE1B-
F/AdE1B1-R, AdE1B2-R primers. Lane 1: Blank, lane 2: Negative control, lanes 3 and 4:   10
-1
 and 
10
-2
 dilutions of HAdV-B35 DNA amplified using AdE1B-F/AdE1B2-R primers. Lane M: 
Quantitative DNA Ladder, lanes 5 and 6: 10
-1
 and 10
-2
 dilutions of HAdV-B3 DNA amplified using 
AdE1B-F/AdE1B1-R primers. 
< 1196 bp 
597 bp> 
< 822 bp  830 bp> 
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3.3.1.6 Primers AdPOL1F/AdPOL1R and AdPOL2F/AdPOL2R: 
Two sets of primers were used to amplify two overlapping fragments of the DNA 
polymerase region of HAdV-B3. Figure 3.46 shows that bands with expected sizes (653 bp 
for AdPOL1F/AdPOL1R and 683 bp for AdPOL2F/AdPOL2R) appeared on the gel with 
10
-1
 and 10
-2
 dilutions.   
 
Figure 3.46: Agarose gel electrophoretogram of HAdV-B3 DNA with AdPOL1F/AdPOL1R and 
AdPOL2F/AdPOL2R primers. Lane 1: Blank, lane 2: Negative control, lanes 3 and 4: 10
-1
 and 10
-2
 
dilutions of HAdV-B3 DNA amplified using AdPOL1F/AdPOL1R primers. Lane M: Quantitative 
DNA ladder, lanes 5 and 6: 10
-1
 and 10
-2
 dilutions of HAdV-B3 DNA amplified using 
AdPOL2F/AdPOL2R primers. 
 
3.3.2 Sequencing and phylogenetic analysis of HAdV-B3 and HAdV-B7 clinical 
isolates from the 1983-1985 outbreak: 
The phylogenetic analysis of the hexon L2 region (Fig 3.47A) showed that HAdV-B3 
clinical isolates grouped in two major clusters I and II. The first cluster (I) contained 11 
isolates which were  identical to HAdV-B3 prototype (GB strain) while the second cluster 
(II) contained 16 isolates and these isolates were identical to the reference strain HAdV-B3 
NHRC 1276 (AY599836). HAdV-B7 isolates grouped in one cluster and divided into two 
variants which differ from the prototype HAdV-B7 (Gomen) by 4.56 and 5.05%. However, 
these isolates were very close to the reference strain HAdV-B7 NHRC 1315 (AY601634). 
< 683 bp 653 bp> 
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Only one isolate belonged to v2  and differed from the rest of the isolates (34 isolates) by 
one nucleotide.  
The phylogenetic analysis of the clinical isolates in the fibre knob region showed the same 
clustering patterns as in the hexon L2 region and no mismatches were observed between the 
isolates in these two regions (Fig 3.47B). The isolates of HAdV-B3 grouped in two clusters 
and most of cluster I isolates had the same sequences as the prototype. The second cluster 
contains two variants which were very close to the reference strain NHRC 1276. HAdV-B7 
isolates were identical or very close to the reference strain NHRC 1315. 
The clustering patterns of the HAdV-B clinical isolates in the penton region were the same 
as in the hexon L2 and fibre knob regions (Fig 3.47C). Two clusters of HAdV-B3 were 
detected as with the hexon L2 and fibre knob regions. All of the isolates in cluster I were 
identical to the prototype. Two variants of cluster II isolates were detected and all of them 
were very close to HAdV-B3 NHRC 1276 reference isolate. All HAdV-B7 isolates 
nucleotide sequences were closer to the reference strain HAdV-B7 NHRC 1315 than the 
prototype. 
In the E1A phylogenetic tree, HAdV-B3 and HAdV-B7 clinical isolates grouped in similar 
clusters to the hexon L2, fibre knob and penton regions trees (Fig 3.48A). HAdV-B3 cluster 
I isolates were identical or very similar to HAdV-B3 prototype. Most of the isolates in the 
second cluster II belonged to v1 which is identical to reference strain HAdV-B3 NHRC 
1276. Two other variants have been detected and were very close to the reference strain. 
HAdV-B7 isolates were identical or very close to the reference strain HAdV-B NHRC 
1315. 
Most of the clinical isolates in the DNA polymerase region grouped at the same clusters as 
the previous four genome regions except one of HAdV-B7 isolates (84-F6) which had 
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different grouping patterns (Fig 3.48B). Two clusters of HAdV-B3 isolates were detected. 
The isolates in the first cluster were identical to the prototype HAdV-B3 while the second 
cluster isolates were very close to the reference strain NHRC 1276. 
HAdV-B7 clustered close to the reference strain NHRC 1315 and can be divided into 
different variants which differed from the reference strain by 0.1-0.3% nucleotide 
divergence. One isolate (84-F6; v4) was clustered with the rest of HAdV-B7 isolates and 
the reference strain NHRC 1315 in the hexon L2, fibre knob, penton and E1A regions. 
However, this isolate shifted in the DNA polymerase region to a different cluster and 
became closer to HAdV-B3 prototype with (8 nucleotides; 0.75%) divergence comparing to 
(10 nucleotides; 1.03%) and (18 nucleotides; 1.58%) divergence from NHRC1315 
reference strain and HAdV-B7 prototype respectively (Fig 3.49). At the amino acid level, 
isolate 84-F8 was closer to HAdV-B7 NHRC 1315 reference strain and differed from it by 
4 amino acids comparing to 6 and 11 amino acids from HAdV-B3 and HAdV-B7 
prototypes.     
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Figure 3.47: Phylogenetic trees of nucleotide sequences of HAdV-B3 & 7 clinical isolates from the 
outbreak. A: hexon L2. B: Fibre knob. C: penton. Only one example of each variant has been used 
in the tree and the numbers of isolates are in square brackets. 
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Figure 3.48: Phylogenetic trees of nucleotide sequences of HAdV-B3 & 7 clinical isolates from the 
outbreak. A: E1A and B: DNA polymerase. Only one example of each variant has been used in the 
tree tree and the numbers of isolates are in square brackets. The isolate that changed its clustering 
patterns is underlined.  
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Figure 3.49: Nucleotide sequence alignment of the DNA polymerase region of isolate 84-F6 with 
HAdV-B7/NHRC 1315 reference strain and HAdV-B3 prototype.  
 
 
 
Ad7/84-F6 ATCAAGTACTATCTGAACCTCCCTCACGCCCTCCAAAAGATCATGCAAGTTAATCTCCTGACACTGCCTACTAACCTGAC 80
HAdV-B7/NHRC1315 .........C.......................G................C............................. 80
HAdV-B3 ................................................................................ 80
Ad7/84-F6 TCCGCAGCGTCTCAGGACCCTGGACAGCTCCGGCCTGCGCGCTCTCGTCCTCGAGCTCCGCCCCTGCCGCGCCGAGGTCT 160
HAdV-B7/NHRC1315 ......................................A......................................... 160
HAdV-B3 ................................................................................ 160
Ad7/84-F6 GGACTTGCCTCCCGCGAGGGCTCGTCAGCATGACCACCATCGAGACAGAAGATGGTCATGCCGATGCAGACAACATAGTA 240
HAdV-B7/NHRC1315 ................................................................................ 240
HAdV-B3 ................................................................................ 240
Ad7/84-F6 GAGCGCCAGGTACAAACGCCAGGCCTCAATTTTCCACTGAAATTTCTCGTCAAAGGAAGTCAGGTACAACTCATTCATGA 320
HAdV-B7/NHRC1315 ................................................................................ 320
HAdV-B3 A.....G........G..............................................................A. 320
Ad7/84-F6 GGTGCATCCCGTGAATCGCTGCGAGTACTGCGGCCGTCTGTACAAGCACAAGCATGAATGCTCGGCGCGTCGCAGGGAGT 400
HAdV-B7/NHRC1315 ................................................................................ 400
HAdV-B3 ................................................................................ 400
Ad7/84-F6 TCTACTTCCATCACATCAACAGCCATTCCTCCAACTGGTGGCAGGAGATCCAGTTCTTCCCGATTGGCTCTCATCCTCGC 480
HAdV-B7/NHRC1315 ................................................................................ 480
HAdV-B3 ................................................................................ 480
Ad7/84-F6 ACAGAAAGGCTCTTCCTCACCTACGATGTGGAAACCTACACCTGGATGGGGTCCTTTGGCAAGCAGCTAATCCCCTTCAT 560
HAdV-B7/NHRC1315 ................................................................................ 560
HAdV-B3 ..............T................................................................. 560
Ad7/84-F6 GCTGGTCATGAAACTCTCTGGAGACCAGCGGCTCGTCAACATCGCCTATGACCTCGCCATAAAACTCAAGTGGGATCGCT 640
HAdV-B7/NHRC1315 ............................................................G.....T............. 640
HAdV-B3 ................................................................................ 640
Ad7/84-F6 GGCGGCAGGACCCCCAAACCTTCTATTGCGTCACCCCAGAAAAGATGGCAGTCGGACAGCATTTTCGTCAGTACCGGGAC 720
HAdV-B7/NHRC1315 ...........................................A...........G..............A......... 720
HAdV-B3 ................................................................................ 720
Ad7/84-F6 CAGTTACAAACAGCACTGGCAGTGGACCTCTGGTCCTCCTTCCTTAAAGCGAACCCTCACGTGCACGAATGGGCCCTCGA 800
HAdV-B7/NHRC1315 .................C..........................C................................... 800
HAdV-B3 ................................................................................ 800
Ad7/84-F6 ACACTATGCTCTCACTGACCCTACAGATCTCACTTTTGAAGAACTCAAGAAGCTGCCTTATGTCAGGGGCACCCCTCGAT 880
HAdV-B7/NHRC1315 ................................................................................ 880
HAdV-B3 ..........................................................C..................... 880
Ad7/84-F6 TCTTAGAACTGTACATAGTGGGGCACAACATCAATGGCTTTGATGAGATCGTCTTGGCCGCTCAGGTTATCAATAACCGA 960
HAdV-B7/NHRC1315 ................................................................................ 960
HAdV-B3 ................................................................................ 960
Ad7/84-F6 GCAGAGGTCCCTCAGCCTTTCAGAATCACCCGAAATTTCATGCCCAGGGCCGGCAAGATCCTCTTCAATGATGTTACTTT 1040
HAdV-B7/NHRC1315 ................................................................................ 1040
HAdV-B3 ........T.............A......................................................... 1040
Ad7/84-F6 CGCTTTGCCCAACCCCGCCTACAAGAAGCGGGTGGACT 1078
HAdV-B7/NHRC1315 ...................................... 1078
HAdV-B3 ...................................... 1078
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3.3.3 Sequencing and phylogenetic analysis of HAdV-B3 and HAdV-B7 clinical 
isolates from later years and isolates from other HAdV-B types: 
A total of 23 isolates of HAdV3 and HAdV7 collected in different years following the 
outbreak (1986-1997) in addition to 11 isolates of HAdV-B types 11, 16, 21 and 35 were 
sequenced and analysed in different genome regions. 
The phylogenetic analysis of the hexon L2 region (Fig 3.50A) showed that HAdV-B3 and 
HAdV-B7 isolates from different years had the same clustering patterns as the outbreak 
isolates. Of the 12 HAdV-B3 isolates which were collected between 1986-1996, 11 
clustered with the reference strain NHRC 1276 and only one isolate from 1997 clustered 
with the HAdV-B3 prototype. All 10 HAdV-B7 isolates clustered with the reference strain 
NHRC 1315. Similar results were found by the phylogenetic analysis of these isolates in 
the fibre knob, penton (Fig 3.50B, C), E1A and DNA polymerase regions (Fig 3.51A, B) 
with no mismatches between the isolates.  
The isolates of other HAdV-B types clustered with their prototype in the hexon L2, fibre 
knob and penton regions. 
In the E1A region, all clinical isolates from different types of species B grouped close to 
their prototype except HAdV-B16 isolates (Fig 3.51A). One of these isolates (v1) was 
closer to HAdV-B50 with 0.4% nucleotide divergence comparing to 1.57% with HAdV-
B16 and the other two isolates (v2) were closer to HAdV-B21 with 0.27% nucleotide 
divergence comparing to 0.4% divergence with HAdV-B16 (Fig 3.52 & Fig 3.53). 
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Figure 3.50: Phylogenetic trees of nucleotide sequences of the species B clinical isolates. A: hexon 
L2. B: Fibre knob. C: penton. Only one example of each variant has been used in the tree and the 
numbers of isolates are in square brackets. The isolates from 1983-1985 outbreak are in boxes. 
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Figure 3.51: Phylogenetic trees of the nucleotide sequences of the species B clinical isolates. A: E1A. B: 
DNA polymerase. Only one example of each variant has been used in the tree tree and the numbers of isolates 
are in square brackets. The isolates from 1983-1985 outbreak are in boxes and the isolates that changed their 
clustering patterns are underlined.  
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Figure 3.52: Nucleotide sequence alignment of the E1A region of HAdV-B16 and HAdV-50 
prototypes with variant 84-22 which  represents variants 1. 
 
Ad16/84-22 CTTATGGGGGAGGAGTTATGTTGCAAGTTATCGCGGTAAAGGTGACGTAAAACGAGGTGTGGTTTGGACACGGAAGTAGA 80
HAdV-B16 ......T......................................................................... 80
HAdV-B50 ................................................................................ 80
Ad16/84-22 CAGTTTTCCCACGCTTACTGACAGGATATGAGGTGGTTTTGGGCGGATGCAAGTGAAAATTCTCCATTTTCGCGCGAAAA 160
HAdV-B16 .............T....................A............................................. 160
HAdV-B50 ..................................A............................................. 160
Ad16/84-22 CTGAATGAGGAAGTGAATTTCTGAGTCATTTCGCGGTTATGACAGGGTGGAGTATTTGCCGAGGGCCGAGTAGACTTTGA 240
HAdV-B16 ................................................................................ 240
HAdV-B50 ................................................................................ 240
Ad16/84-22 CCGTTTACGTGGAGGTTTCGATTACCGTGTTTTTCACCTAAATTTCCGCGTACGGTGTCAAAGTCCTGTGTTTTTACGTA 320
HAdV-B16 ................................................................................ 320
HAdV-B50 ................................................................................ 320
Ad16/84-22 GGTGTCAGCTGATCGCTAGGGTATTTAAACCTGTCGAGTTCCGTAAAGAGGCCACTCTTGAGTGCCAGCGAGAAGAGTTT 400
HAdV-B16 ..............A.............................C................................... 400
HAdV-B50 ............................................C................................... 400
Ad16/84-22 TCTCCTCCGCGCCGCGAGTCAGTTTTGCGCTTTGAAAATGAGACACCTGCGATTCCTGCCACAGGAGATTATCTCCAGCG 480
HAdV-B16 ............T................................................................... 480
HAdV-B50 ................................................................................ 480
Ad16/84-22 AGACCGGGATTGAAATACTGGAGTTTGTGGTAAATACCCTGATGGGAGATGACCCGGAACCGCCAGCGCAGCCTTTCGAT 560
HAdV-B16 ..........C.......................................................T............. 560
HAdV-B50 ..........A..................................................................... 560
Ad16/84-22 CCACCTACGCTGCACGATCTGTATGATTTAGAGGTAGACGGGCCGGACGATCCCAATGAGGAAGCTGTAAATGGGTTTTT 640
HAdV-B16 ............................................T..T................................ 640
HAdV-B50 ................................................................................ 640
Ad16/84-22 TACTGATTCTATGCTACTAGCTGCCGATGAAGGATTGGACATAAACCCTCCTCCTGAGACCCTTGATACCCCAGGGGTGG 720
HAdV-B16 ...............G................................................................ 720
HAdV-B50 ................................................................................ 720
Ad16/84-22 TTGTGGAAAGCGGCAGAGGTGGGATAAAATTGCCTGATCTGGGAGCAG 768
HAdV-B16 ........................A....................... 768
HAdV-B50 ................................................ 768
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Figure 3.53: Nucleotide sequence alignment of the E1A region of HAdV-B16 and HAdV-B21 
prototypes with isolate 84-44. 
 
In the DNA polymerase region, HAdV-B21 and HAdV-B35 isolates clustered close to their 
prototypes as in the previously analysed regions (Fig 3.51B). One isolate which clustered 
close to the HAdV-B11 prototype in the previously analysed regions aligned close to 
HAdV-B34 in the DNA polymerase region with 0.93% divergence comparing to 1.3% with 
HAdV-B11 (Fig 3.54).  
 
Ad16/84-44 CTTATGTAGGAGGAGTTATGTTGCAAGTTATCGCGGTAAAGGTGACGTAAAACGAGGTGTGGTTTGGACA 70
HAdV-B16 .......G.............................................................. 70
HAdV-B21 ...................................................................... 70
Ad16/84-44 CGGAAGTAGACAGTTTTCCCACGCTTACTGACAGGATATGAGGTAGTTTTGGGCGGATGCAAGTGAAAAT 140
HAdV-B16 .......................T.............................................. 140
HAdV-B21 ...................................................................... 140
Ad16/84-44 TCTCCATTTTCGCGCGAAAACTGAATGAGGAAGTGAATTTCTGAGTCATTTCGCGGTTATGACAGGGTGG 210
HAdV-B16 ...................................................................... 210
HAdV-B21 ...................................................................... 210
Ad16/84-44 AGTATTTGCCGAGGGCCGAGTAGACTTTGACCGTTTACGTGGAGGTTTCGATTACCGTGTTTTTCACCTA 280
HAdV-B16 ...................................................................... 280
HAdV-B21 ...................................................................... 280
Ad16/84-44 AATTTCCGCGTACGGTGTCAAAGTCCTGTGTTTTTACGTAGGTGTCAGCTGATCACTAGGGTATTTAAAC 350
HAdV-B16 ...................................................................... 350
HAdV-B21 ...................................................................... 350
Ad16/84-44 CTGTCGAGTTCCGTCAAGAGGCCACTCTTGAGTGCCAGCGAGAAGAGTTTTCTCCTCCGCGCTGCGAGTC 420
HAdV-B16 ...................................................................... 420
HAdV-B21 ...................................................................... 420
Ad16/84-44 AGTTTTGCGCTTTGAAAATGAGACACCTGCGATTCCTGCCACAGGAGATTATCTCCAGCGAGACCGGGAT 490
HAdV-B16 ...................................................................... 490
HAdV-B21 ...................................................................... 490
Ad16/84-44 CGAAATACTGGAGTTTGTGGTAAATACCCTGATGGGAGATGACCCGGAACCGCCAGTGCAGCCTTTCGAT 560
HAdV-B16 ...................................................................... 560
HAdV-B21 ...................................................................... 560
Ad16/84-44 CCACCTACGCTGCACGATCTGTATGATTTAGAGGTAGATGGGCCTGATGATCCCAATGAGGAAGCTGTAA 630
HAdV-B16 ......................................C............................... 630
HAdV-B21 ......................................C............................... 630
Ad16/84-44 ATGGGTTTTTTACTGATTCTATGCTGCTAGCTGCCGATGAAGGATTGGACATAAACCCTCCTCCTGAGAC 700
HAdV-B16 ...................................................................... 700
HAdV-B21 ..................................................................G... 700
Ad16/84-44 CCTTGATACCCCAGGGGTGGTTGTGGAAAGCGGCAGAGGTGGGAAAAAATTGCCTGATCTGGGAGCAG 768
HAdV-B16 .................................................................... 768
HAdV-B21 .................................................................... 768
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Figure 3.54: Nucleotide sequence alignment of the DNA polymerase region of HAdV-B11 and 
HAdV-B34 prototype with isolate 87-15. 
 
In addition, HAdV-B16 isolates also clustered differently in the DNA polymerase region 
and had the same clustering patterns as HAdV-B16 isolates in the E1A region. The closest 
type to one of the isolates (v1) was HAdV-B50 with 0.65% nucleotide and 0.84% amino 
acid divergence comparing to 0.93% nucleotide and 1.4% amino acid divergence with 
HAdV-B16. The other two isolates (v2) clustered with HAdV-B21 which was the closest 
Ad11/87-15 ATCAAGTACCATCTGAACCTCCCGCACGCCCTGGAAAAGATCATGCAAGTTAATCTTCTGTCCCTACCTACTAACCTGAG 80
HAdV-B11 ................................................................................ 80
HAdV-B34 ................................................................................ 80
Ad11/87-15 TCCGCAGCGTCTCAGGACTCTGGACAGCTCCAGCCTGCGCGCTCTCGTCCTTCAGCTCCGCCCCTCCCGCGCCGAGGTTT 160
HAdV-B11 ..............................................................................C. 160
HAdV-B34 .............................................G................................C. 160
Ad11/87-15 GGACTTGCCTCCCGCGGGGGCTCGTCAGCATGACCACCATCGAAACAGAAGATGAACAGGCCGATACAGCGAATATAGAA 240
HAdV-B11 ................................................................................ 240
HAdV-B34 .......................................C........................................ 240
Ad11/87-15 GAGCACGAGATACAATCGCCAGGCCTCAGCTTCCCACTGAAATTTCTCGTCAAGGGAAGCCAGGTACAGCTCATTCACGA 320
HAdV-B11 ...........................G........................................A........... 320
HAdV-B34 ...........................G.................................................... 320
Ad11/87-15 GATACAACCCGTGCAACGCTGCGACTACTGCGGCCGTCTGTACAAGCACAAACACGAATGCTCGGCGCGCCGCAGAAACT 400
HAdV-B11 ................................................................................ 400
HAdV-B34 ................................................................................ 400
Ad11/87-15 TCTACTTCCATCACATCAACAGCCAATCCTCCAACTGGTGGCAGGAAATCCAGTTCTTCCCGATCGGCTCTCATCCTCGC 480
HAdV-B11 ................................................................................ 480
HAdV-B34 ................................................................................ 480
Ad11/87-15 ACAGAAAGACTCTTCCTGACCTACGATGTGGAAACTTACACCTGGATGGGGTCCTTTGGCAAACAACTAGTTCCTTTCAT 560
HAdV-B11 ..................................................A............................. 560
HAdV-B34 ................................................................................ 560
Ad11/87-15 GCTGGTCATGAAACTCTCAGGAGAAGAGCGTCTCGTCAACATGGCCCACGATCTAGCCATTAAACTCAAGTGGGATCGAT 640
HAdV-B11 ................................................................................ 640
HAdV-B34 ..................................................................A............. 640
Ad11/87-15 GGCAACAAGACCCCAGAACCTTCTACTGTGTCACTCCAGAAAAAATGGCAATTGGCCAACATTTTCGTCAGTATCGGGAC 720
HAdV-B11 .........................................................GG..................... 720
HAdV-B34 ..........................................................G..................... 720
Ad11/87-15 CAGTTACAAACAGCACTGGCGGTGGATCTTTGGTCAACATTCCTCCATGCAAATCCTCACCTGCACGAATGGGCTCTCGA 800
HAdV-B11 .......................A............T.......A................................... 800
HAdV-B34 ....................................T.......A................................... 800
Ad11/87-15 ACACTACGCCTTATCTGACCCTACAGACCTAACCTTTGATGAGCTCAATAAGCTACCTCACGTCAGAGGCACGCCGCGTT 880
HAdV-B11 .....................C.........................G................................ 880
HAdV-B34 .................................................................A.............. 880
Ad11/87-15 TCATAGAATTATACATCGTAGGACACAACATCAACGGTTTCGACGAGATCGTCCTAGCTGCCCAGGTGATCAACAATCGA 960
HAdV-B11 ................................................................................ 960
HAdV-B34 ................................................................................ 960
Ad11/87-15 GCGGAAGTACCACAGCCTTTCCGCATCACTCGCAATTTTATGCCCAGAGCCGGCAAGATTCTCTTCAACGATGTTACTTT 1040
HAdV-B11 ....................T................................T..............T........... 1040
HAdV-B34 .....................................................T.......................... 1040
Ad11/87-15 CGCTTTGCCCAACCCCGCCTACAAGAAACGGGTAGACT 1078
HAdV-B11 ...................................... 1078
HAdV-B34 ...................................... 1078
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type to it with 0.1% nucleotide and 0.28% amino acid divergences comparing to 1.21% 
nucleotide and 1.95% amino acid divergence with HAdV-B16 (Fig 3.55 & Fig 3.56). 
 
Figure 3.55: Nucleotide sequence alignment of the DNA polymerase region of HAdV-B16 and 
HAdV-B50 prototype with isolate 84-22. 
 
Ad16/84-22 ATCAAGTACCATCTGAACCTCCCTCACGCCCTCGAAAAGATCATGCAAGTCAATCTCCTGACACTGCCTACTAACCTGAC 80
HAdV-B16 ................................................................................ 80
HAdV-B50 ................................................................................ 80
Ad16/84-22 TCCGCAGCGTCTCAGGACCCTGGACAGCTCCGGCCTGCGCGCTCTCGTCCTCGAGCTCCGCCCCTGCCCCGCCGAGGTCT 160
HAdV-B16 ................................A...................................G........... 160
HAdV-B50 ....................................................................G........... 160
Ad16/84-22 GGACTTGCCTCCCGCGAGGGCTCGTCAGCATGACCACCATCGAGACAGAAGATGGTCATGCCGATGCAGACAACATAGTA 240
HAdV-B16 ................................................................................ 240
HAdV-B50 ................................................................................ 240
Ad16/84-22 GAGCGCGAGGTACAAGCGCCAGGCCTCAATTTTCCACTGAAATTTCTCGTCAAAGGAAGTCAGGTACAACTCATTCATGA 320
HAdV-B16 ................................................................................ 320
HAdV-B50 ...............T................................................................ 320
Ad16/84-22 GGTGCATCCCGTGAATCGATGCGAGTACTGCGGCCGTCTGTACAAGCACAAGCATGAATGCTCGGCGCGTCGCAGGGAGT 400
HAdV-B16 ................................................................................ 400
HAdV-B50 ................................................................................ 400
Ad16/84-22 TCTACTTCCATCACATCAACAGCCATTCCTCCAACTGGTGGCAGGAGATCCAGTTCTTCCCGATTGGCTCTCATCCTCGC 480
HAdV-B16 ................................................................................ 480
HAdV-B50 ................................................................................ 480
Ad16/84-22 ACAGAAAGGCTCTTCCTCACCTACGATGTGGAAACCTACACCTGGATGGGGTCCTTTGGCAAGCAGCTAATCCCATTCAT 560
HAdV-B16 ..........................................................................C..... 560
HAdV-B50 ..........................................................................C..... 560
Ad16/84-22 GCTGGTCATGAAACTCTCTGGAGACCAGCGGCTCGTCAACATCGCCTACGACCTCGCCATGAAACTCAAGTGGGATCGCT 640
HAdV-B16 ................................................T.....G..T..A................... 640
HAdV-B50 ................................................T.....G.....A................... 640
Ad16/84-22 GGCGGCAGGACCCCCAAACCTTCTATTGCGTCACCCCAGAAAAGATGGCAGTCGGGCAGCATTTTCGTCAGTACCGGGAC 720
HAdV-B16 ...A............................................................................ 720
HAdV-B50 ................................................................................ 720
Ad16/84-22 CAGTTACAAACAGCACTGGCAGTGGACCTCTGGTCCTCCTTCCTCAAAGCGAACCCTCACGTGCACGAATGGGCCCTCGA 800
HAdV-B16 ............................................................C................... 800
HAdV-B50 ................................................................................ 800
Ad16/84-22 ACACTATGCTCTCACTGACCCTACAGACCTCACTTTTGAAGAACTCAAGAAGCTGCCTCATGTCAGGGGCACACCTCGAT 880
HAdV-B16 ................................................................................ 880
HAdV-B50 ........................................................................C....... 880
Ad16/84-22 TCTTAGAACTGTACATAGTGGGGCACAACATCAATGGCTTTGATGAGATCGTCTTGGCCGCTCAGGTTATCAATAACCGA 960
HAdV-B16 ................................................................................ 960
HAdV-B50 ................................................................................ 960
Ad16/84-22 GCAGAGGTCCCTCAGCCTTTCAGAATCACCCGAAATTTCATGCCCAGGGCCGGCAAGATCCTCTTCAATGATGTTACTTT 1040
HAdV-B16 ......................................T......................................... 1040
HAdV-B50 ................................................................................ 1040
Ad16/84-22 CGCTTTGCCCAACCCCGCCTACAAGAAGCGGGTGGACT 1078
HAdV-B16 ...................................... 1078
HAdV-B50 ...................................... 1078
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Figure 3.56: Nucleotide sequence alignment of the DNA polymerase region of HAdV-B16 and 
HAdV-B21 prototypes with isolate 84-44. 
 
 
 
 
 
Ad16/84-44 ATCAAGTACCATCTGAACCTCCCTCACGCCCTCGAAAAGATCATGCAAGTCAATCTCCTGACACTGCCTACTAACCTGAC 80
HAdV-B16 ................................................................................ 80
HAdV-B21 ................................................................................ 80
Ad16/84-44 TCCGCAGCATCTCAGGACCCTGGACAGCTCCGGCCTGCGCGCTCTCGTCCTCGAGCTCCGCCCCTGCCGCGCCGAGGTCT 160
HAdV-B16 ........G.......................A............................................... 160
HAdV-B21 ........G....................................................................... 160
Ad16/84-44 GGACTTGCCTCCCGCGAGGGCTCGTCAGCATGACCACCATCGAGACAGAAGATGGTCATGCCGATGCAGACAACATAGTA 240
HAdV-B16 ................................................................................ 240
HAdV-B21 ................................................................................ 240
Ad16/84-44 GAGCGCGAGGTACAAACGCCAGGCCTCAATTTTCCACTGAAATTTCTCGTCAAAGGAAGTCAGGTACAACTCATTCATGA 320
HAdV-B16 ...............G................................................................ 320
HAdV-B21 ................................................................................ 320
Ad16/84-44 GGTGCATCCCGTGAATCGCTGCGAGTACTGCGGCCGTCTGTACAAGCACAAGCATGAATGCTCGGCGCGTCGCAGGGAGT 400
HAdV-B16 ..................A............................................................. 400
HAdV-B21 ................................................................................ 400
Ad16/84-44 TCTACTTCCATCACATCAACAGCCATTCCTCCAACTGGTGGCAGGAGATCCAGTTCTTCCCGATTGGCTCTCATCCTCGC 480
HAdV-B16 ................................................................................ 480
HAdV-B21 ................................................................................ 480
Ad16/84-44 ACAGAAAGGCTCTTCCTCACCTACGATGTGGAAACCTACACCTGGATGGGGTCCTTTGGCAAGCAGCTAATCCCCTTCAT 560
HAdV-B16 ................................................................................ 560
HAdV-B21 ................................................................................ 560
Ad16/84-44 GCTGGTCATGAAACTCTCTGGAGACCAGCGGCTCGTCAACATCGCCTATGACCTCGCCATGAAACTCAAGTGGGATCGCT 640
HAdV-B16 ......................................................G..T..A................... 640
HAdV-B21 ................................................................................ 640
Ad16/84-44 GGCGGCAGGACCCCCAAACCTTCTATTGCGTCACCCCAGAAAAGATGGCAGTCGGGCAGCATTTTCGTCAGTACCGGGAC 720
HAdV-B16 ...A............................................................................ 720
HAdV-B21 ................................................................................ 720
Ad16/84-44 CAGTTACAAACAGCACTGGCAGTGGACCTCTGGTCCTCCTTCCTCAAAGCGAACCCTCACGTGCACGAATGGGCCCTCGA 800
HAdV-B16 ............................................................C................... 800
HAdV-B21 ................................................................................ 800
Ad16/84-44 ACACTATGCTCTCACTGACCCTACAGATCTCACTTTTGAAGAACTCAAGAAGCTGCCTCATGTCAGGGGCACCCCTCGAT 880
HAdV-B16 ...........................C............................................A....... 880
HAdV-B21 ................................................................................ 880
Ad16/84-44 TCTTAGAACTGTACATAGTGGGGCACAACATCAATGGCTTTGATGAGATCGTCTTGGCCGCTCAGGTTATCAATAACCGA 960
HAdV-B16 ................................................................................ 960
HAdV-B21 ................................................................................ 960
Ad16/84-44 GCAGAGGTCCCTCAGCCTTTCAAAATCACCCGAAATTTCATGCCCAGGGCCGGCAAGATCCTCTTCAATGATGTTACTTT 1040
HAdV-B16 ......................G...............T......................................... 1040
HAdV-B21 ................................................................................ 1040
Ad16/84-44 CGCTTTGCCCAACCCCGCCTACAAGAAGCGGGTGGACT 1078
HAdV-B16 ...................................... 1078
HAdV-B21 ...................................... 1078
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3.3.4 Gene stability of HAdV-B clinical isolates: 
The phylogenetic analysis of the clinical isolates from the outbreak in different genome 
regions showed no mismatches between HAdV-B3, HAdV-B7 and other HAdV-B types in 
the hexon L2, fibre and penton regions which indicates that the genome is stable in these 
regions. The same results were found with HAdV-B3 and HAdV-B7 from different years 
following the outbreak which indicates that genome of these two types has been stable for 
over 13 years. 
No mismatches were detected in HAdV-B3 and HAdV-B7 isolates in the E1A region 
unlike 3 HAdV-B16 isolates that clustered with different HAdV-B types. In the DNA 
polymerase region, one HAdV-B7 isolate from the outbreak was clustered with HAdV-B3. 
In addition, HAdV-16 and HAdV-B11 isolates were clustered with different HAdV-B types 
in this region (Table 3.11).  
Isolate SN 
serotype 
Hexon L2 Fibre knob Penton E1A DNA 
polymerase 
Type Var Type Var Type Var Type Var Type Var 
84-F6 7 7 V1 7 V1 7 V2 7 V1 3 (I) V5  
87-15 11 11 V1 11 V1 11 V1 11 V1 34 V1 
84-22 16 16 V1 16 V1 16 V1 50 V1 50 V1 
84-44 16 16 V2 16 V2 16 V2 21 V2  21 V2  
85-95 16 16 V2 16 V2 16 V2 21 V2  21 V2  
 
Table 3.11: Typing results of isolates which changed their clustering patterns in different genome 
regions. The table summarises the isolates, serum neutralization (SN) typing, types and variants 
(Var) in different genome regions. The changes in the clustering patterns are indicated in bold.  
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3.4 Adenovirus persistence and latency in tonsils and adenoids: 
 
3.4.1 Quantitation of recombinant plasmid DNA:  
Spectrophotometer measurements (GeneQuant II Machine, Pharmacia Biotech) were used 
to determine the concentration of the purified plasmid which contains the 140 bp adenovirus 
2 PCR product of AdRJC1/AdRJC2 primers. The concentration was 189µg/ml (average of 
three readings) with A260/A280 average ratio of 1.87 which indicates that plasmid 
preparation was relatively pure.  
The copy numbers of the recombinant plasmid can be calculated as following: 
- The size of the recombinant plasmid was 4071bp (the size of the plasmid 3931 bp in 
addition to 140 bp of the target region of adenovirus). 
- The molecular weight of 1 kbp of DNA is 6.6 × 10
5
 so the molecular weight of this 
recombinant plasmid:  4.071 × 6.6 × 10
5
 g = 4.071 × 6.6 × 10
5
 × 10
6
 µg 
-Avogadro’s number (the number of molecules in 1 molar mass)  is = 6.022 × 1023. 
Therefore, the number of molecules in 189 µg of this DNA is: 
(189 × 6.022 × 10
23
) /4.071 × 6.6 × 10
5
 × 10
6
 = 42.37 × 10
12
 molecules /1ml. 
                                                                           =  42.37 × 10
9
 molecules /1µl 
                                                                           =     21 × 10
10
 molecules /5µl 
3.4.2 Real-Time PCR: 
Ten-fold serial dilutions ranging from 8.4 × 10
5 
to 8.4 copies of purified plasmid DNA 
containing the AdRJC1/AdRJC2 primers target region of the adenovirus genome were used 
to determine the sensitivity of the assay. AdRJC1 and AdRJC2 primers together with 
TaqMan probe were used for the amplification. Dilutions were run in three replicates and 
some of the higher dilutions were run in four replicates. Negative controls were included in 
each run. 
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The assay was able to detect consistently 84 copies and sometimes 8.4 copies (Fig 3.57 & 
Table 3.12). 
 
Figure 3.57: A real‐time PCR plot resulting from the amplification of ten-fold serial dilutions of 
plasmid DNA containing the target region of the adenovirus genome. The change in normalized 
fluorescence signal of the reporter dye (ΔRn) was plotted against the cycle number. 
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Dilution Copy 
number 
Ct Dilution Copy 
number 
Ct 
10
-5
 8.4 × 10
5
 20.93 10
-8
 8.4 × 10
2
 32.24 
10
-5
 8.4 × 10
5
 20.99 10
-8
 8.4 × 10
2
 32.17 
10
-5
 8.4 × 10
5
 20.87 10
-9
 84 35.58 
10
-6
 8.4 × 10
4
 24.60 10
-9
 84 36.18 
10
-6
 8.4 × 10
4
 24.76 10
-9
 84 36.27 
10
-6
 8.4 × 10
4
 24.78 10
-9
 84 36.27 
10
-7
 8.4 × 10
3
 28.66 10
-10
 8.4 38.50 
10
-7
 8.4 × 10
3
 28.68 10
-10
 8.4 39.00 
10
-7
 8.4 × 10
3
 28.76 10
-10
 8.4 Negative 
10
-8
 8.4 × 10
2
 32.25 10
-10
 8.4 Negative 
 
Table 3.12: Ct values and copy numbers of 10-fold serial dilutions of plasmid DNA. 
 
A standard curve which was constructed by plotting the Ct values of the plasmid DNA 
dilutions against the starting quantities of the plasmid in these dilutions showed a linear 
correlation between input DNA and cycle threshold (Fig 3.58), with a correlation 
coefficient (R
2
) of 0.989 and a slope of -3.547. The efficiency of the real-time PCR was 
91.4%. 
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Figure 3.58: A standard curve using data from table 1.1 was constructed by plotting the Ct values of 
the plasmid DNA dilutions against the starting quantities of the plasmid in these dilutions.  
 
3.4.3 Isolation of the lymphocytes from tonsils and adenoids: 
The enzymatic method was not suitable for lymphocyte isolation. After 30 minutes and one 
hour of incubation at 37°C the trypsin had not significantly affected the tissues. After 
incubation overnight there were still remaining non-disrupted tissues and microscopy 
showed very few cells released from the tissues.  
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The cotton muslin method for mechanical disruption also produced a very low number of 
cells. The mechanical disruption using a tissue sieve method was more successful. The total 
cell count ranged from 0.52 ×10
8
 to 3.2 ×10
8
.  
3.4.4 Real-Time PCR of isolated lymphocytes from tonsils and adenoids: 
The extracted DNA of isolated lymphocytes from 116 tonsils and adenoids samples was 
tested by real-time PCR.  Two replicates of each sample and plasmid dilution (ranging from 
8.4 x 10
5
 to 8.4 copies) in addition to a negative control were tested in each run. Eighty four 
(72.41%) tonsils and adenoids samples were positive for HAdV by real-time PCR. Tonsils 
and adenoids were available from the same patient in 6 cases. Both tissues were positive for 
adenovirus DNA in two cases, adenoids only were positive in three cases and both tissues 
were negative in the remaining case. Adenoids samples only were available from a further 
four patients and all of them were positive which make 90% of the adenoids positive for 
adenovirus. A second run for DNA from different extracts was carried out for samples of 
patients 1-34 and the results were close to the first run. 
3.4.5 Viral load: 
The viral load in the positive samples ranged from 280 to more than 2.6 × 10
6
 copies/10
7
 
cells. The viral load was not the same in the right and left tonsils in most of the cases. In 
some cases one of the tonsils was negative while the other one was positive. The viral load 
was higher in the adenoids than in the tonsils in the two cases where both tonsils and 
adenoids were positive (Table 3.13).   
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Patient Sample Mean Ct 
(1st  run) 
Viral load  
(Copies/107cells) 
Mean Ct 
(2nd  run) 
Viral load  
(Copies/107cells)  
Age Sex 
1 R 36.86 9289 37.83 9699 4 
 
M 
 L 37.5 6198 38.45 6595 
2 R 39.28 2028 40.16 2275 14 
 
F 
 L Neg 0 Neg 0 
3 R Neg 0 Neg 0 10 
 
M 
 L Neg 0 Neg 0 
4 R 34.6 38802 35.48 41850 4 
 
F 
 L 34.63 40921 35.57 42792 
5 R 41.19 627 42.05 729 13 
 
F 
 L 39.39 1875 40.22 2184 
6 R 38.18 4045 39.12 4351 7 
 
M 
 L 36.97 8697 37.86 9525 
7 R 37.46 6382 38.34 7066 7 
 
F 
 L 38.09 4261 38.89 4708 
8 R 41.02 673 41.96 741 13 
 
M 
 L 39.42 1854 40.3 2088 
9 R 34.53 40666 35.45 42664 4 
 
 
F 
 
 
L 34.19 50311 35.14 51712 
AD 33.93 59466 34.85 62100 
10 R 38.39 3592 39.31 3910 5 
 
F 
 L 38.49 3576 38.64 3570 
11 AD 41.62 466 41.79 460 3 M 
12 R Neg 0 Neg 0 7 
 
F 
 L Neg 0 Neg 0 
13 R 36.55 12526 36.69 12568 6 
 
M 
 L 36.73 11121 36.87 11158 
14 R 37.46 6963 37.59 7036 5 
 
F 
 L 37.4 7195 37.55 7335 
15 R Neg 0 Neg 0 16 
 
M 
 L Neg 0 Neg 0 
16 R Neg 0 Neg 0 9 
 
M 
 L 40.15 948 40.59 915 
17 R 34.82 27850 35.33 26266 6 
 
M 
 L 33.9 50014 34.35 49281 
18 R 41.65 450 42.17 430 4 
 
F 
 L 38.77 2242 39.20 2215 
19 R 30.87 348529 31.34 338316 5 
 
F 
 L 27.72 2608680 28.15 2604075 
20 R 40.11 945 40.59 904 9 
 
F 
 L 40.33 822 40.75 816 
21 R 28.9 1820616 29.02 1848750 4 
 
M 
 L 28.72 2040311 28.87 2041200 
22 R Neg 0 Neg 0 4 
 
M 
 L Neg 0 Neg 0 
23 R Neg 0 Neg 0 15 
 
F 
 L Neg 0 Neg 0 
 
Table 3.13: Ct values and viral load in the tonsils and adenoids samples. R: Right tonsil, L: Left 
tonsil, AD: Adenoids, F: Female, M: male, Neg: Negative. ND: Not done. 
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Patient Sample Mean Ct Viral load 
(Copies/107cells) 
Mean Ct  
(2nd  run) 
Viral load (2nd  run, 
Copies/107cells)  
Age Sex 
24 R Neg 0 Neg 0 3 
 
F 
 L 37.24 6279 37.66 6375 
25 R 41.53 406 40.83 420 2 
 
F 
 L 42.1 280 41.32 304 
26 R 38.46 3066 37.82 3031 5 
 
M 
 L 38.26 3483 37.53 3631 
27 R 38.96 2185 38.19 2356 4 
 
M 
 L 39.21 1861 38.54 1891 
28 R Neg 0 Neg 0 12 
 
F 
 L Neg 0 Neg 0 
29 AD 33.07 108541 32.38 109893 4 M 
30 R Neg 0 Neg 0 5 
 
M 
L Neg 0 Neg 0 
AD 34.17 52119 34.80 51045 
31 AD 37.15 7237 37.79 7017 5 F 
32 R 35.84 17245 36.44 17185 12 F 
 L 35.17 26965 35.79 26334 
33 R 38.65 2710 39.23 2694 9 
 
M 
 L 39.46 1570 40.06 1564 
34 R 33.91 62071 34.52 6136 7 
 
F 
 L 34.08 55381 34.71 53889 
35 R 37.19 7054 ND ND 12 
 
F 
 L 37.69 5323 ND ND 
36 R Neg 0 ND ND 13 
 
M 
 L Neg 0 ND ND 
37 R Neg 0 ND ND 4 
 
 
F 
 
 
L Neg 0 ND ND 
AD 33.74 35158 ND ND 
38 R Neg 0 ND ND 11 
 
 
F 
 
 
L Neg 0 ND ND 
AD Neg 0 ND ND 
39 R 31.21 190071 ND ND 6 
 
M 
 L 30.53 295138 ND ND 
40 R 38.18 1837 ND ND 5 
 
F 
 L 38.91 1128 ND ND 
41 R 38.4 1603 ND ND 11 
 
F 
 L 39.15 964 ND ND 
42 R 40.13 501 ND ND 8 
 
F 
 L 40.25 462 ND ND 
43 R 37 4005 ND ND 12 
 
F 
 L 36.35 6177 ND ND 
44 R 37.15 3810 ND ND 9 
 
F 
 L 35.75 9213 ND ND 
45 R 38.14 5148 ND ND 6 
 
M 
 L 37.34 8766 ND ND 
46 R 38.83 3292 ND ND 7 
 
F 
 L Neg 0 ND ND 
 
 
 
 
 
Table 3.13 (continued) 
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Patient Sample Mean Ct Viral load 
(Copies/107cells) 
Mean Ct 
(2nd  run) 
Viral load (2nd  run, 
Copies/107cells)  
Age Sex 
47 R 38.57 3993 ND ND 3 
 
 
M 
 
 
L 37.84 6244 ND ND 
AD 36.68 13266 ND ND 
48 R 36.91 11379 ND ND 5 
 
F 
 L 37.6 7305 ND ND 
49 R 38.78 3397 ND ND 15 
 
M 
 L 40.55 1108 ND ND 
50 R Neg 0 ND ND 3 
 
 
M 
 
 
L Neg 0 ND ND 
AD 37.82 5508 ND ND 
51 R 42.34 339 ND ND 14 
 
F 
 L 42.10 433 ND ND 
52 R Neg 0 ND ND 13 
 
M 
 L Neg 0 ND ND 
53 R 42.05 451 ND ND 4 
 
M 
 L 39.65 1942 ND ND 
54 R 38.68 3126 ND ND 5 
 
M 
 L 38.27 4090 ND ND 
55 R Neg 0 ND ND 13 
 
F 
 L 40.21 1300 ND ND 
56 AD 37.47 6954 ND ND 4 F 
57 R Neg 0 ND ND 2 
 
M 
 L Neg 0 ND ND 
 
 
 
 
No relation was found between the viral load and the sex of the patient. The younger 
patients’ samples have a higher viral load than the samples of older ones. This negative 
relation between the age of the patient and the viral load was found to be statistically 
significant (Spearman's rank correlation coefficient, r = -0.258, P = 0.0177) (Fig 3.59).  
Table 3.13 (continued) 
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Figure 3.59: Relationship between viral load per 10
7
 and patient age. Each point represents one 
sample. 
 
3.4.6 Sensitivity of gel-based PCR: 
A nested PCR assay was used for DNA amplification. Sequencing of the PCR products and 
phylogenetic analysis was used for adenovirus typing in these samples. The sensitivity of 
the nested PCR was determined by comparison to the sensitivity of AdRJC1/AdRJC2 
primers. 
3.4.6.1 Primers AdRJC1/AdRJC2: 
Serial 10-fold dilutions of purified plasmid DNA containing the target region of the 
adenovirus genome with initial concentration of 21×10
10 
copies/5µl were tested. Clear 
bands of 140 bp product were visible up to 10
-9
 (lane 9) equivalent to 210 copies/5µl and a 
faint band can be seen at 10
-10
 (lane 10) equivalent to 21 copies/5µl (Fig 3.60). This was 
repeated twice more with the same results.  
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Figure 3.60: Agarose gel electrophoretogram of serial dilutions of plasmid DNA with 
AdRJC1/AdRJC2 primers. Lane 1:  Quantitative DNA ladder, lane 2: Negative control, lanes 3-12: 
10
-3
-10
-12
 dilutions of plasmid DNA.  
 
The same assay was also applied to 10-fold serial dilutions of HAdV-C2 whole genome. It 
was able to detect up to 10
-10
 dilution (lane 7, Fig 3.61) suggesting this dilution contained 
21-210 copies/5µl of adenovirus DNA. The actual copy number of this DNA is unknown. 
This was repeated on 2 further occasions with the same result. 
 
  
 
 
 Figure 3.61: Agarose gel electrophoretogram of serial dilutions of HAdV-C2 DNA using 
AdRJC1/AdRJC2 primers. Lane1: Quantitative DNA ladder, lane 2:  Negative control, lanes 3-9: 
10
-6
- 10
-12
  dilutions of HAdV-C2 DNA.  
 
 
 
2000 bp> 
1000 bp> 
500 bp> 
250 bp> 
100 bp> 
 
<140 bp 
 <140 bp 
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3.4.6.2 Primers AdhexF1, AdhexR1 and AdhexF2, AdhexR2 (Nested PCR): 
Serial 10-fold dilutions of HAdV-C2 whole genome DNA were amplified over 40 cycles 
using the external primers. The internal amplification was then performed using 0.5 μL of 
the amplicons obtained from the first reaction using internal primers. Bands of 820 bp 
product were visible on the gel as expected. The contamination control (lane 2) was 
negative (Fig 3.62).  
Clear bands of the product were visible up to a dilution of 10
-9
 (lane 7) and a faint bands 
can be seen at 10
-10
 (lane 8) and 10
-11
 (lane 9) which in comparison with Figure 1.5 
suggests a detection limit of 2.1-21 copies/5µl. This was repeated on 3 further occasions 
with the same result.  
 
Figure 3.62: Agarose gel electrophoretogram of serial dilutions of HAdV-C2 DNA using the nested 
PCR. Lane1: Blank. Lane2:  Quantitative ladder, lane 3: Negative control, lanes 4-9: 10
-6
-10
-11
 
dilutions of HAdV-C2 DNA.  
 
 In an attempt to improve the sensitivity of this assay, different volumes of the PCR 
products of the external amplification ranging from 1µl to 5 µl were used in the internal 
amplification instead of 0.5 µl. Clearer bands were observed with 5 µl volume (Fig 3.63) 
and this volume was used in the subsequent experiments. 
 
< 820 bp 
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Figure 3.63: Agarose gel electrophoretogram of serial dilutions of HAdV-C2 DNA using the nested 
PCR with different volumes of amplicon used in the second reaction. Lane 1: Quantitative DNA 
ladder, lane 11: Negative control, lanes 2-4: 10
-9
 - 10
-11
 dilutions (3 µl amplicon used), lanes 5-7: 
10
-9
 - 10
-11
 dilutions (4 µl amplicon used) and lanes 8-10: 10
-9
 - 10
-11
 dilutions (5 µl amplicon used).   
 
3.4.7 Typing of HAdVs in isolated lymphocytes from tonsils and adenoids using nested 
PCR: 
DNA from 78 of the 84 positive samples could be amplified and most of the samples 
showed clear bands. Six samples were positive for adenovirus by real-time PCR but no 
PCR products were detected on the gel when these samples were amplified by the nested 
PCR. These samples are: 2R, 10R, 10L, 51R, 51L and 55L.  
3.4.7.1 Sequencing and phylogenetic analysis:  
The nested PCR primers target is the hexon L1 region including HVR1-6. Sequencing of 
the cleaned PCR products and phylogenetic analysis of this region of the hexon was carried 
out (Fig 3.64). 
 
 
 
 
< 820 pb 
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Figure 3.64: Phylogenetic analysis of the hexon L1 region of tonsils and adenoids samples and 
prototypes of species B, C, E, F and G . Only one example of each variant was included in the tree 
and indicated in boxes.   
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Most of the detected HAdVs types 64/78 (82%) belonged to species C. HAdV-E4 was 
detected in 6/78 samples (7.70%) and the same number of samples 6/78 (7.70%) contained 
HAdV-B3 and HAdV-B7 of species B. Only 2/78 samples (2.56%) contained HAdV-F41 
of species F. HAdV-C1 was the most commonly detected type in these samples followed 
by HAdV-C2 then HAdV-C5 (Fig 3.65). 
 
 
All the variants of these types were reported previously in the GenBank except HAdV-
C1v1, HAdV-C1v2 and HAdV-C5v3. The same type was detected in the right and left 
tonsils from the same patient except in case 27 which contained HAdV-C5 in the right 
tonsil and HAdV-C2 in the left tonsil. Positive tonsils and adenoids tissues were available 
from two cases and the same type was detected in tonsils and adenoids from the same 
patient.  All HAdV-B types were detected in patients  9 years of age and over while HAdV-
C types were detected in most of the cases in younger children.  
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Ad2 (20 samples),  
25.64%
Ad5 (18 samples),  
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1.  
2.  
Figure 3.65: Detected species and types of HAdVs in tonsils and adenoids.  
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3.4.8 DNA Methylation: 
DNA methylation reduce gene expression and this could be one of the mechanisms of 
adenovirus persistence or latency in tonsils and adenoids. Six tonsils and one adenoid 
samples of HAdV-C types 1, 2 and 5 in addition to two clinical isolates of HAdV-C types 2 
and 5 have been chosen to study the DNA methylation. 
3.4.8.1 Bisulfite specific PCR: 
Semi- nested PCR was used to amplify the target regions of E1A promoter and major late 
promoter (MLP) after bisulfite treatment. Bands with size of 269 bp and 352 bp appeared 
on the gel as expected for E1A promoter and the MLP regions respectively (Fig 3.66 and 
Fig. 3.67).     
 
Figure 3.66: Agarose gel electrophoretogram of bisulfite specific PCR products of E1A promoter 
region. Lane1: Blank. Lane 2:  Quantitative DNA ladder, lane 3: Negative control, lane 4: Sample 
45R, lane 5: Sample 45L, lane 6: Sample 47R, lane 7: Sample 47L, lane 8: Sample 47AD, lane 9: 
Isolate Ad2Iso, lane 10: Sample 40R, lane 11: Sample 40L, lane 12: Isolate Ad5Iso.  
 
 
Figure 3.67: Agarose gel electrophoretogram of bisulfite specific PCR products of MLP region of 
HAdV-C2 samples and isolates. Lane1: Blank. Lane 2:  Quantitative DNA ladder, lane 3: Negative 
control, lane 4: Sample 47R, lane 5: Sample 47L, lane 6: Sample 47AD, lane 7: Isolate Ad2Iso. 
<269 bp 
<352 bp 
2000 bp > 
1000 bp > 
500  bp > 
250  bp > 
100  bp > 
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3.4.8.2 Sequencing of the E1A promoter and MLP regions: 
3.4.8.2.1 E1A promoter region: 
The semi-nested PCR products were cleaned and sequenced. No cytosine was detected in 
the sense strand and no guanine was detected in the anti-sense strand of the sequence of this 
region after bisulfite treatment which indicates that no DNA methylation occurred in this 
region in all the tonsils and adenoids and clinical isolates tested as shown in the following 
figures. 
 
Figure 3.68: Multiple sequence alignment of the E1A region sense strand of HAdV-C1 reference 
strain and bisulfite treated tonsils samples 45R and 45L. The alignment shows no cytosine in the 
tonsils samples which indicates that no methylation occurred in these samples. TATA sequence 
(binding site for transcription factors in the promoter) is indicated in black box.   
 
 
 
Figure 3.69: Multiple sequence alignment of the E1A region anti-sense strand of HAdV-C1 
reference strain and bisulfite treated tonsils samples 45R and 45L. The alignment shows no 
guanine in the tonsils samples which indicates that no methylation occurred in these samples.  
 
HAdV-C1 GTTGGCGTTTTATTATTATAGTCAGCTGACGTGTAGTGTATTTATACCCGGTGAGTTCCTCAAGAGGCCA
45R .....T................T..T...T................TTT........TT.T......TT.
45L .....T................T..T...T................TTT........TT.T......TT.
HAdV-C1 CTCTTGAGTGCCAGCGAGTAGAGTTTTCTCCTCCGAGCCGCTCCGACACCGGGACTGAAAATGAGACATA
45R T.T.......TT..T............T.TT.TT...TT.T.TT..T.TT....T...........T...
45L T.T.......TT..T............T.TT.TT...TT.T.TT..T.TT....T...........T...
HAdV-C1 TTATTTGCCACGGAGGTGTTATTACCGAAGAAATGGCCGCCAGTCTTTTGGACCAGCTAA
45R .......TT.T.............TT..........TT.TT...T.......TT.TT...
45L .......TT.T.............TT..........TT.TT...T.......TT.TT...
HAdV-C1 TTAGCTGGTCCAAAAGACTGGCGGCCATTTCTTCGGTAATAACACCTCCGTGGCAAATAATATGTCTCAT
45R ...A..AA.......A...AA.AA..........AA.............A.AA..........A......
45L ...A..AA.......A...AA.AA..........AA.............A.AA..........A......
HAdV-C1 TTTCAGTCCCGGTGTCGGAGCGGCTCGGAGGAGAAAACTCTACTCGCTGGCACTCAAGAGTGGCCTCTTG
45R .....A....AA.A..AA.A.AA...AA.AA.A............A..AA.......A.A.AA......A
45L .....A....AA.A..AA.A.AA...AA.AA.A............A..AA.......A.A.AA......A
HAdV-C1 AGGAACTCACCGGGTATAAATACACTACACGTCAGCTGACTATAATAATAAAACGCCAAC
45R .AA........AAA................A...A..A................A.....
45L .AA........AAA................A...A..A................A.....
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Figure 3.70: Multiple sequence alignment of the E1A region sense strand of HAdV-C2 reference 
strain and bisulfite treated tonsils samples 47R, 47L, 47AD and isolate Ad2Iso. The alignment 
shows no cytosine in the tonsils samples which indicates that no methylation occurred in these 
samples. TATA sequence is indicated in black box. 
 
 
 
Figure 3.71: Multiple sequence alignment of the E1A region anti-sense strand of HAdV-C2 
reference strain and bisulfite treated tonsils samples 47R, 47L, 47AD and isolate Ad2Iso. The 
alignment shows no guanine in the tonsils samples which indicates that no methylation occurred in 
these samples.  
 
HAdV-C2 GTTGGCGTTTTATTATTATAGTCAGCTGACGCGCAGTGTATTTATACCCGGTGAGTTCCTCAAGAGGCCA
47R .....T................T..T...T.T.T............TTT........TT.T......TT.
47L .....T................T..T...T.T.T............TTT........TT.T......TT.
47AD .....T................T..T...T.T.T............TTT........TT.T......TT.
Ad2Iso .....T................T..T...T.T.T............TTT........TT.T......TT.
HAdV-C2 CTCTTGAGTGCCAGCGAGTAGAGTTTTCTCCTCCGAGCCGCTCCGACACCGGGACTGAAAATGAGACATA
47R T.T.......TT..T............T.TT.TT...TT.T.TT..T.TT....T...........T...
47L T.T.......TT..T............T.TT.TT...TT.T.TT..T.TT....T...........T...
47AD T.T.......TT..T............T.TT.TT...TT.T.TT..T.TT....T...........T...
Ad2Iso T.T.......TT..T............T.TT.TT...TT.T.TT..T.TT....T...........T...
HAdV-C2 TTATCTGCCACGGAGGTGTTATTACCGAAGAAATGGCCGCCAGTCTTTTGGACCAGCTGA
47R ....T..TT.T.............TT...A......TT.TT...T.......TT..T...
47L ....T..TT.T.............TT...A......TT.TT...T.......TT..T...
47AD ....T..TT.T.............TT...A......TT.TT...T.......TT..T...
Ad2Iso ....T..TT.T.............TT...A......TT.TT...T.......TT.TT...
HAdV-C2 TCAGCTGGTCCAAAAGACTGGCGGCCATTTCTTCGGTAATAACACCTCCGTGGCAGATAATATGTCTCAT
47R ...A..AA.......A...AA.AA......T...AA.............A.AA..A.......A......
47L ...A..AA.......A...AA.AA......T...AA.............A.AA..A.......A......
47AD ...A..AA.......A...AA.AA......T...AA.............A.AA..A.......A......
Ad2Iso ...AA.AA.......A...AA.AA......T...AA.............A.AA..A.......A......
HAdV-C2 TTTCAGTCCCGGTGTCGGAGCGGCTCGGAGGAGAAAACTCTACTCGCTGGCACTCAAGAGTGGCCTCTTG
47R .....A....AA.A..AA.A.AA...AA.AA.A............A..AA.......A.A.AA......A
47L .....A....AA.A..AA.A.AA...AA.AA.A............A..AA.......A.A.AA......A
47AD .....A....AA.A..AA.A.AA...AA.AA.A............A..AA.......A.A.AA......A
Ad2Iso .....A....AA.A..AA.A.AA...AA.AA.A............A..AA.......A.A.AA......A
HAdV-C2 AGGAACTCACCGGGTATAAATACACTGCGCGTCAGCTGACTATAATAATAAAACGCCAAC
47R .AA........AAA............A.A.A...A..A................A.....
47L .AA........AAA............A.A.A...A..A................A.....
47AD .AA........AAA............A.A.A...A..A................A.....
Ad2Iso .AA........AAA............A.A.A...A..A................A.....
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Figure 3.72: Multiple sequence alignment of the E1A region sense strand of HAdV-C5 reference 
strain and bisulfite treated tonsils samples 40R, 40L and isolate Ad5Iso. The alignment shows no 
cytosine in the tonsils samples which indicates that no methylation occurred in these samples. 
TATA sequence is indicated in black box. 
 
 
 
Figure 3.73: Multiple sequence alignment of the E1A region anti-sense strand of HAdV-C5 
reference strain and bisulfite treated tonsils samples 40R, 40L and isolate Ad5Iso. The alignment 
shows no guanine in the tonsils samples which indicates that no methylation occurred in these 
samples.  
 
 
 
 
 
HAdV-C5 GTTGGCGTTTTATTATTATAGTCAGCTGACGTGTAGTGTATTTATACCCGGTGAGTTCCTCAAGAGGCCA
40R .....T................T..T...T................TTT........TT.T......TT.
40L .....T................T..T...T................TTT........TT.T......TT.
Ad5Iso .....T................T..T...T................TTT........TT.T......TT.
HAdV-C5 CTCTTGAGTGCCAGCGAGTAGAGTTTTCTCCTCCGAGCCGCTCCGACACCGGGACTGAAAATGAGACATA
40R T.T.......TT..T............T.TT.TT..TTT.T.TT..T.TT....T.........A.T...
40L T.T.......TT..T............T.TT.TT..TTT.T.TT..T.TT....T.........A.T...
Ad5Iso T.T.......TT..T............T.TT.TT..TTT.T.TT..T.TT....T...........T...
HAdV-C5 TTATCTGCCACGGAGGTGTTATTACCGAAGAAATGGCCGCCAGTCTTTTGGACCAGCTGA
40R ....T..TT.T.............TT...A......TT.TT.T.T.......TT.TT...
40L ....T..TT.T.............TT...A......TT.TT.T.T.......TT.TT...
Ad5Iso ....T..TT.T.............TT..........TT.TT.T.T.......TT.TT...
HAdV-C5 TCAGCTGGTCCAAAAGACTGGCGGCCATTTCTTCGGTAATAACACCTCCGTGGCAGATAATATGTCTCAT
40R ...A..AA.......A...AA.AA......T...AA.............A.AA..A.......A.T....
40L ...A..AA.......A...AA.AA......T...AA.............A.AA..A.......A.T....
Ad5Iso ...A..AA.......A...AA.AA..........AA.............A.AA..A.......A......
HAdV-C5 TTTCAGTCCCGGTGTCGGAGCGGCTCGGAGGAGAAAACTCTACTCGCTGGCACTCAAGAGTGGCCTCTTG
40R .....A....AA.A..AA.A.AA...AA.AA.A............A..AA.......A.A.AA......A
40L .....A....AA.A..AA.A.AA...AA.AA.A............A..AA.......A.A.AA......A
Ad5Iso .....A....AA.A..AA.A.AA...AA.AA.A............A..AA.......A.A.AA......A
HAdV-C5 AGGAACTCACCGGGTATAAATACACTACACGTCAGCTGACTATAATAATAAAACGCCAAC
40R .AA........AAA................A...A..A................A.....
40L .AA........AAA................A...A..A................A.....
Ad5Iso .AA........AAA................A...A..A................A.....
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3.4.8.2.2 MLP region: 
Similar results to those of the E1A region were found in the MLP region. After bisulfite 
treatment, no cytosine was detected in the sense strand and no guanine was detected in the 
anti-sense strand which means that no methylation occurred in this region for all tested 
samples and isolates. It was reported methylation of adenovirus MLP in vitro resulted in 
inhibition of specific transcription factors which inhibits the transcription from adenovirus 
MLP (The in vitro methylated position is indicated in blue box in the alignments below, 
nucleotide position 5981 of HAdV-C2 J01917). No methylation was found in this position 
or elsewhere in all tested samples and isolates.   
The following figures show the methylation status of the sense and anti-senses strands of 
the tested samples and isolates:  
 
 
Figure 3.74: Multiple sequence alignment of the MLP region sense strand of HAdV-C1 reference 
strain and bisulfite treated tonsils samples 45R and 45L. The alignment shows no cytosine in the 
tonsils samples which indicates that no methylation occurred in these samples. TATA sequence is 
indicated in black box and the in vitro methylated position is indicated in blue box. 
 
HAdV-C1 GGGTGTGAAGACACATGTCCCCCTCTTCGGCATCAAGGAAGGTGATTGGTTTATAGGTGTATGCCACGTGACCGGGTGTT
45R T..........T.T....TGTTT.T..T..T..T..................G........G.TT.T....TT.......
45L T..........T.T....TGTTT.T..T..T..T..................G........G.TT.T....TT.......
HAdV-C1 CCTGAAGGGGGGGTATAAAAGGGGGTGGGGGCGCGTTCGTCCTCACTCTCTTCCGCATCGCTGTCTGCGAGGGCCAGCTG
45R TT..........T..................T.T...T..TT.T.T.T.T..TT.T..T.T...T..T.....TT..T..
45L TT..........T..................T.T...T..TT.T.T.T.T..TT.T..T.T...T..T.....TT..T..
HAdV-C1 TTGGGGTGAGTACTCCCTCTGGAAAGCGGGCATGACTTCTGCGCTAAGGTTGTCAGTTTCCAAAAACGAGGAGGATTTGA
45R ............T.TTT.T..A....T...T....T..T..T.T....A....T.....TT.....T.............
45L ............T.TTT.T..A....T...T....T..T..T.T....A....T.....TT.....T.............
HAdV-C1 TATTCACCTGGCCCGCGGTGATGCCTTTGAGGGTGGCCGCGTCCATCTGGTCAGA
45R ....T.TT...TTT.T.......TT...........TT.T..TT..T....T...
45L ....T.TT...TTT.T.......TT...........TT.T..TT..T....T...
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Figure 3.75: Multiple sequence alignment of the MLP region anti-sense strand of HAdV-C1 
reference strain and bisulfite treated tonsils samples 45R and 45L. The alignment shows no 
guanine in the tonsils samples which indicates that no methylation occurred in these samples.  
 
 
 
 
Figure 3.76: Multiple sequence alignment of the MLP region sense strand of HAdV-C2 reference 
strain and bisulfite treated tonsils samples 47R, 47L, 47AD and isolate Ad2Iso. The alignment 
shows no cytosine in the tonsils samples which indicates that no methylation occurred in these 
samples. TATA sequence is indicated in black box and the in vitro methylated position is indicated 
in blue box. 
  
 
HAdV-C1 TCTGACCAGATGGACGCGGCCACCCTCAAAGGCATCACCGCGGGCCAGGTGAATATCAAATCCTCCTCGTTTTTGGAAAC
45R ...A....A..AA..A.AA...........AA.......A.AAA...AA.A.................A.....AA....
45L ...A....A..AA..A.AA...........AA.......A.AAA...AA.A.................A.....AA....
HAdV-C1 TGACAACCTTAGCGCAGAAGTCATGCCCGCTTTCCAGAGGGAGTACTCACCCCAACAGCTGGCCCTCGCAGACAGCGATG
45R .A....T....A.A..A..A....A...A....T..A.AAA.A..............A..AA.....A..A...A.A..A
45L .A....T....A.A..A..A....A...A....T..A.AAA.A..............A..AA.....A..A...A.A..A
HAdV-C1 CGGAAGAGAGTGAGGACGAACGCGCCCCCACCCCCTTTTATACCCCCCCTTCAGGAACACCCGGTCACGTGGCATACACC
45R .AA..A.A.A.A.AA..A...A.A..................A..........AA.......AA....A.AA.C......
45L .AA..A.A.A.A.AA..A...A.A..................A..........AA.......AA....A.AA.C......
HAdV-C1 TATAAACCAATCACCTTCCTTGATGCCGAAGAGGGGGACATGTGTCTTCACACCC
45R ..C..................A..A..A..A.AAACA....A.A..........A
45L ..C..................A..A..A..A.AAACA....A.A..........A
HAdV-C2 GGGTGTGAAGACACATGTCGCCCTCTTCGGCATCAAGGAAGGTGATTGGTTTATAGGTGTAGGCCACGTGACCGGGTGTT
47R T..........T.T....T.TTT.T..T..T..T..................G..........TT.T....TT.......
47L T..........T.T....T.TTT.T..T..T..T..................G..........TT.T....TT.......
47AD T..........T.T....T.TTT.T..T..T..T..................G..........TT.T....TT.......
Ad2Iso T..........T.T....T.TTT.T..T..T..T..................G..........TT.T....TT.......
HAdV-C2 CCTGAAGGGGGGCTATAAAAGGGGGTGGGGGCGCGTTCGTCCTCACTCTCTTCCGCATCGCTGTCTGCGAGGGCCAGCTG
47R TT..........T..................T.T...T..TT.T.T.T.T..TT.T..T.T...T..T.....TT..T..
47L TT..........T..................T.T...T..TT.T.T.T.T..TT.T..T.T...T..T.....TT..T..
47AD TT..........T..................T.T...T..TT.T.T.T.T..TT.T..T.T...T..T.....TT..T..
Ad2Iso TT..........T..................T.T...T..TT.T.T.T.T..TT.T..T.T...T..T.....TT..T..
HAdV-C2 TTGGGGTGAGTACTCCCTCTCAAAAGCGGGCATGACTTCTGCGCTAAGATTGTCAGTTTCCAAAAACGAGGAGGATTTGA
47R ............T.TTT.T.G.....T...T....T..T..T.T.........T.....TT.....T.............
47L ............T.TTT.T.G.....T...T....T..T..T.T.........T.....TT.....T.............
47AD ............T.TTT.T.G.....T...T....T..T..T.T.........T.....TT.....T.............
Ad2Iso ............T.TTT.T.G.....T...T....T..T..T.T....G....T.....TT.....T.............
HAdV-C2 TATTCACCTGGCCCGCGGTGATGCCTTTGAGGGTGGCCGCGTCCATCTGGTCAGA
47R ....T.TT...TTT.T.......TT...........TT.T..TT..T....T...
47L ....T.TT...TTT.T.......TT...........TT.T..TT..T....T...
47AD ....T.TT...TTT.T.......TT...........TT.T..TT..T....T...
Ad2Iso ....T.TT...TTT.T.......TT...A.......TT.T..TT..T....T...
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Figure 3.77: Multiple sequence alignment of the MLP region anti-sense strand of HAdV-C2 
reference strain and bisulfite treated tonsils samples 47R, 47L, 47AD and isolate Ad2Iso. The 
alignment shows no guanine in the tonsils samples which indicates that no methylation occurred in 
these samples.  
 
 
 
Figure 3.78: Multiple sequence alignment of the MLP region sense strand of HAdV-C5 reference 
strain and bisulfite treated tonsils samples 40R, 40L and isolate Ad5Iso. The alignment shows no 
cytosine in the tonsils samples which indicates that no methylation occurred in these samples. 
TATA sequence is indicated in black box and and the in vitro methylated position is indicated in 
blue box. 
HAdV-C2 TCTGACCAGATGGACGCGGCCACCCTCAAAGGCATCACCGCGGGCCAGGTGAATATCAAATCCTCCTCGTTTTTGGAAAC
47R ...A....A..AA..A.AA...........AA.......A.AAA...AA.A.................A.....AA....
47L ...A....A..AA..A.AA...........AA.......A.AAA...AA.A.................A.....AA....
47AD ...A....A..AA..A.AA...........AA.......A.AAA...AA.A.................A.....AA....
Ad2Iso ...A....A..AA..A.AA.......T...AA.......A.AAA...AA.A.................A.....AA....
HAdV-C2 TGACAATCTTAGCGCAGAAGTCATGCCCGCTTTTGAGAGGGAGTACTCACCCCAACAGCTGGCCCTCGCAGACAGCGATG
47R .A.........A.A..A..A....A...A.....C.A.AAA.A..............A..AA.....A..A...A.A..A
47L .A.........A.A..A..A....A...A.....C.A.AAA.A..............A..AA.....A..A...A.A..A
47AD .A.........A.A..A..A....A...A.....C.A.AAA.A..............A..AA.....A..A...A.A..A
Ad2Iso .A....C....A.A..A..A....A...A.....C.A.AAA.A..............A..AA.....A..A...A.A..A
HAdV-C2 CGGAAGAGAGTGAGGACGAACGCGCCCCCACCCCCTTTTATAGCCCCCCTTCAGGAACACCCGGTCACGTGGCCTACACC
47R .AA..A.A.A.A.AA..A...A.A..................A..........AA.......AA....A.AA........
47L .AA..A.A.A.A.AA..A...A.A..................A..........AA.......AA....A.AA........
47AD .AA..A.A.A.A.AA..A...A.A..................A..........AA.......AA....A.AA........
Ad2Iso .AA..A.A.A.A.AA..A...A.A..................A..........AA.......AA....A.AA........
HAdV-C2 TATAAACCAATCACCTTCCTTGATGCCGAAGAGGGCGACATGTGTCTTCACACCC
47R ..C..................A..A..A..A.AAA.A....A.A..........A
47L ..C..................A..A..A..A.AAA.A....A.A..........A
47AD ..C..................A..A..A..A.AAA.A....A.A..........A
Ad2Iso ..C..................A..A..A..A.AAA.A....A.A..........A
HAdV-C5 GGGTGTGAAGACACATGTCGCCCTCTTCGGCATCAAGGAAGGTGATTGGTTTGTAGGTGTAGGCCACGTGACCGGGTGTT
40R ...........T.T....T.TTT.T..T..T..T.............................TT.T....TT.......
40L ...........T.T....T.TTT.T..T..T..T.............................TT.T....TT.......
Ad5Iso ...........T.T....T.TTT.T..T..T..T.............................TT.T....TT...G...
HAdV-C5 CCTGAAGGGGGGCTATAAAAGGGGGTGGGGGCGCGTTCGTCCTCACTCTCTTCCGCATCGCTGTCTGCGAGGGCCAGCTG
40R TT..........T..................T.T...T..TT.T.T.T.T..TT.T..T.T...T..T.....TT..T..
40L TT..........T..................T.T...T..TT.T.T.T.T..TT.T..T.T...T..T.....TT..T..
Ad5Iso TT..........T..................T.T...T..TT.T.T.T.T..TT.T..T.T...T..T.....TT..T..
HAdV-C5 TTGGGGTGAGTACTCCCTCTGAAAAGCGGGCATGACTTCTGCGCTAAGATTGTCAGTTTCCAAAAACGAGGAGGATTTGA
40R ............T.TTT.T.......T...T....T..T..T.T.........T.....TT.....T.............
40L ............T.TTT.T.......T...T....T..T..T.T.........T.....TT.....T.............
Ad5Iso ............T.TTT.T.......T...T....T..T..T.T.........T.....TT.....T.............
HAdV-C5 TATTCACCTGGCCCGCGGTGATGCCTTTGAGGGTGGCCGCATCCATCTGGTCAGA
40R ....T.TT...TTT.T.......TT...........TT.T..TT..T....T...
40L ....T.TT...TTT.T.......TT...........TT.T..TT..T....T...
Ad5Iso ....T.TT...TTT.T.......TT...........TT.T..TT..T....T...
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Figure 3.79: Multiple sequence alignment of the MLP region anti-sense strand of HAdV-C5 
reference strain and bisulfite treated tonsils samples 40R, 40L and isolate Ad5Iso. The alignment 
shows no guanine in the tonsils samples which indicates that no methylation occurred in these 
samples.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HAdV-C5 TCTGACCAGATGGATGCGGCCACCCTCAAAGGCATCACCGCGGGCCAGGTGAATATCAAATCCTCCTCGTTTTTGGAAAC
40R ...A....A..AA..A.AA...........AA.......A.AAA...AA.A.................A.....AA....
40L ...A....A..AA..A.AA...........AA.......A.AAA...AA.A.................A.....AA....
Ad5Iso ...A....A..AA..A.AA...........AA.......A.AAA...AA.A.................A.....AA....
HAdV-C5 TGACAATCTTAGCGCAGAAGTCATGCCCGCTTTTCAGAGGGAGTACTCACCCCAACAGCTGGCCCTCGCAGACAGCGATG
40R .A.........A.A..A..A....A...A.......A.AAA.A..............A..AA.....A..A...A.A..A
40L .A.........A.A..A..A....A...A.......A.AAA.A..............A..AA.....A..A...A.A..A
Ad5Iso .A.........A.A..A..A....A...A.......A.AAA.A..............A..AA.....A..A...A.A..A
HAdV-C5 CGGAAGAGAGTGAGGACGAACGCGCCCCCACCCCCTTTTATAGCCCCCCTTCAGGAACACCCGGTCACGTGGCCTACACC
40R .AA..A.A.A.A.AA..A...A.A..................A..........AA.......AA....A.AA........
40L .AA..A.A.A.A.AA..A...A.A..................A..........AA.......AA....A.AA........
Ad5Iso .AA..A.A.A.A.AA..A...A.A..................A..........AA...C...AA....A.AA........
HAdV-C5 TACAAACCAATCACCTTCCTTGATGCCGAAGAGGGCGACATGTGTCTTCACACCC
40R .....................A..A..A..A.AAA.A....A.A...........
40L .....................A..A..A..A.AAA.A....A.A...........
Ad5Iso .....................A..A..A..A.AAA.A....A.A...........
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4. Discussion:   
4.1 Molecular analysis of HAdV-D isolates from AIDS patients: 
Phylogenetic analysis of the hexon, fibre and penton of the adenovirus prototypes was 
carried out previously. These proteins are the main structural proteins of the adenovirus and 
the immunogenic determinates are present on them (Horwitz 2001a). Some HAdV-D 
prototypes e.g. HAdV-D15 and HAdV-D29 may have originated via recombination 
between those determinants (Madisch  et al. 2005; Madisch  et al. 2007). 
In patients with AIDS, the most commonly isolated HAdVs are from HAdV-D and HAdV-
B species In addition, intermediate strains have been frequently isolated from these patients 
(Hierholzer et al.1988; Hierholzer 1992). However, most of the work on adenovirus 
isolates from AIDS patients has been carried out using serology and restriction enzyme 
analysis and little work has be done on the molecular level, probably because adenoviruses 
are not frequently isolated from AIDS patients nowadays because of the success of modern 
antiretroviral drug treatment of these patients.   
A total of 31 HAdV-D clinical isolates from AIDS patients were typed previously by Al 
Qurashi (2009) using sequencing and phylogenetic analysis of the hexon L2 region 
(including HVR7) and fibre knob region. Most of these isolates (28) had contradictory 
typing results in these two regions so they are clearly intermediate strains. In addition, two 
isolates (Aids23 &Aids25) appear to be completely new. One isolate (Aids32) was typed as 
a HAdV-D23 variant in both hexon L2 and fibre knob regions and included in this study 
because it was mistyped in the fibre knob region and so thought to be an intermediate 
strain.  
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The previously typed clinical isolates were sequenced and analysed in the hexon L1 
(including HVR1-6), the fibre shaft and penton regions for evidence of any multiple 
recombination events or any indication of new types of HAdV.  
4.1.1 Sequencing and phylogenetic analysis of the hexon L1 region: 
This region was analysed to confirm the previous typing of the isolates in the hexon L2 
region and also because the L1 region is larger and both L1 and L2 contain the neutralizing 
(type- specific) epitope of the hexon (Gall et al. 1998). The phylogenetic analysis was done 
by the widely used neighbour joining method which is a simple and effective distance 
based method for phylogenetic tree construction (Mihaescu et al. 2009).  
Only one isolate (Aids7) had a prototype sequence (HAdV-D20) in the L1 region but the 
rest of the isolates had varying degrees of divergence from the prototype sequences, some 
resulting in amino acid changes. Some of these variants were reported previously such as 
19v3 which is identical to the clinical isolate HAdV-D19C (Robinson et al, 2009b) but 
other variants e.g. 17v2, 23v1 and 26v3 have not been reported before. This phylogenetic 
analysis of the hexon L1 region showed that all identified isolates had the same typing 
results as the hexon L2 region. Two isolates (Aids23 and Aids25) could not be typed in 
either hexon region.  
These results indicate that no recombination events occurred between the hexon L1 and the 
hexon L2 regions. However, variation between the L1 and L2 regions was observed. In 3 
isolates from patient 10 (Aids2, Aids13, Aids50) HAdV-D17v1 in HVR7 is paired with 
17v2 of HVR1-6 in which a section of 18 nucleotides have been deleted from the 17v1 
version of HVR1-6 (Aids18, Aids24, Aids39, Aids51). Intra-hexon recombination events 
have been reported in HAdV-A (Walsh et al. 2010b), HAdV-B (Walsh et al. 2010) and 
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HAdV-D (Lu and Erdman 2006; Walsh et al. 2009). However, these recombination events 
occurred between the hexon variable regions (HVR1-7) and the conserved sequence on the 
carboxy terminal end of the hexon. This kind of recombination was not detected here 
because the sequencing was carried out for the hexon L1 and L2 regions (HVR1-7) only 
and did not include other regions of the hexon.  
4.1.2 Sequencing and phylogenetic analysis of the partial fibre shaft region: 
Analysis of the fibre shaft region was carried out to investigate any recombination events 
between the fibre knob and the fibre shaft regions which have been reported previously in 
HAdV-D prototypes by Darr et al. (2009). In addition, they detected a similar fibre 
shaft/knob recombination in one intermediate strain HAdV-D19H30 which suggests a 
multiple recombination event.  
Some of the isolates in this study had the same sequence as the prototype but others had 
varying degrees of divergence from the prototype sequence, some resulting in significant 
amino acid changes. Among the variants only H29v1 has been reported previously (Darr et 
al. 2009).  
All intermediate strains in addition to isolate Aids32 had the same typing results in the fibre 
knob and fibre shaft regions.  However, some isolates had the same fibre shaft as the 
prototype but had varying degrees of divergence from the prototype sequence in the fibre 
knob. Three isolates which had untyped fibre knob sequences HU1, HU2 and HU3, could 
not be typed in the fibre shafts regions either. The fibre shaft sequences of HU1 and HU3 
were very close to each other and might represent variants of the same new type of fibre 
gene.  
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4.1.3 Sequencing and phylogenetic analysis of the partial penton region: 
The full penton sequences are not available for all HAdV-D types. However, sequences 
corresponding to the amplified fragments of the penton including the two variable regions 
(HVR and RGD) are available for all HAdV-D types. A multi sequence alignment of the 
available full penton sequences of HAdV-D types in GenBank showed that the regions 
outside the amplified fragment are highly conserved which means that the amplified 
fragment can represent the whole penton. 
Eleven penton types could not be identified by phylogenetic analysis of nucleotide and 
amino acid sequences of this fragment of the clinical isolates penton. This large number of 
unidentified penton types indicated that recombination within the penton needed to be 
investigated, especially as this kind of recombination was reported in HAdV-D previously 
(Robinson et al, 2009a).    
The penton HVR1 and RGD loop phylogenetic trees and nucleotide alignments revealed 
unidentified types of these two regions. The trees showed also inconsistent clustering of 
HAdV-D types in these two regions in many cases of both HAdV-D prototypes and the 
clinical isolates. For example, HAdV-D49 clustered with HAdV-D types 19, 48 and 23 in 
in the HVR phylogenetic tree and the nucleotide alignment but in the RGD loop tree and 
alignment the same type HAdV-D49 located in with different types, HAdV-D13, 32, 44. 
These results suggest possible intra-penton recombination events in the origin of HAdV-D 
and in these clinical isolates resulting in the HVR region derived from one type and the 
RGD loop from a different type.  
Three of the new types of penton (PU1, PU2, PU9) were found to be genuine new types 
because they contained unknown HVR and RGD regions.  Other new penton types were 
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found to be a result of recombination between two previously known types or between one 
known type and one previously unknown type. 
The conserved sequence bordering the HVR and the RGD loop might help the isolates to 
undergo homologous recombination. Madisch et al (2007) analysed the central region of 
the penton for 52 adenovirus prototypes but did not describe intra-penton recombination. 
However, they suggested swapping of two variable penton regions between adenovirus 
types as a method for vector development. This type of recombination in the penton was 
described previously in HAdV-D by Robinson et al. (2009a). However, they detected these 
events in few types because only 9 HAdV-D types which have fully sequenced pentons 
were included in the analysis. Robinson et al. (2010) described the recombination of the 
HVR and RGD regions of HAdV-D9 and HAdV-D26 in the penton of the new HAdV-D56. 
However, HAdV-D9, HAdV-D10, HAdV-D26 and HAdV-D56 have similar HVR and 
RGD regions which suggests that no recombination occurred in the penton of HAdV-D56 
but these types are sharing the sequence of these regions of the penton.  
4.1.4 Multiple recombination events: 
The previously reported typing results of hexon L2 (HVR7) and fibre knob regions of the 
clinical isolates (Al Qurashi, 2009) showed recombination events between these two 
regions of these isolates. The typing results of the hexon L1 and fibre shaft regions 
confirmed these results. Moreover, typing of the penton region showed further 
recombination events within the penton. 
Different types and variants were isolated from the same patient over time. One example of 
these changes is the case of patient 10 where 6 changes occurred between 1992 and 1994. 
Other changes occurred in patients 17 and 24. It is not clear if, in these patients, new 
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variants rapidly outgrow and replace their predecessors or if the latter remain at lower 
levels. 
Intermediate isolates which had untyped fibre regions Ad26v3HU1 and Ad20v1HU2 had 
also untyped pentons PU1 and PU4 respectively. Isolates Aids23 and Aids25 which had 
untyped hexon and fibre genes (AdU1HU3) had also untyped penton PU2.  These isolates 
might represent new types of adenovirus. 
The reason for multi-recombination events in these isolates could be the prolonged 
shedding of several types of HAdV-D from gastrointestinal tract of AIDS patients which 
provides the opportunity for mutations and recombination to occur resulting in new variants 
and intermediate strains (Crawford-Miksza and Schnurr 1996a; De Jong et al. 1999; 
Echavarria 2008). 
Two of the latest identified types HAdV-D53 and HAdV-D56 are recombinants (Robinson 
et al.  2010; Walsh et al. 2009). The HAdV-D53 genome has at least five recombination 
events resulting in emergent type which causes epidemic keratoconjunctivitis (Walsh et al. 
2009). Many HAdV-D types and intermediate strains were isolated from AIDS patients 
which indicates that recombination might occur in AIDS patients more frequently.  
Other multiple recombination events have been detected in two intermediate strains of  
HAdV-D which have unknown pentons in addition to their contradictory hexons and fibres 
(Madisch  et al. 2007). 
The mechanisms of recombination are not clear but it was suggested that immune selective 
pressure might be the driver for recombination in adenovirus (Robinson et al. 2009a).  
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Coinfection with more than one type of adenovirus was reported previously (Echavarria et 
al. 2006; Vora et al. 2006) which may suggest the results reported in this work are a 
consequence of this. However, clear sequences with no ambiguity were obtained in this 
study which indicate that each isolate contain one type only.  In addition, the consistent 
typing results of the hexon L1 and L2 regions also indicates that each isolate contain one 
type only. This does not exclude the possibility that other types could be present in low 
levels that could not be detected. 
The results from this part of the study indicate that HAdV-D is not stable in AIDS patients 
and support the suggestion that recombination events are a common feature of HAdVs and 
play a role in their evolution (Crawford-Miksza and Schnurr 1996a; Lukashev et al. 2008). 
On the other hand, these results are in contrast to the results from HAdV-B species in this 
study (see later) and to some previous reports which indicated that adenovirus genome is 
stable in general (Mahadevan et al. 2010; Purkayastha et al. 2005; Seto et al. 2010a). 
The stability of the adenovirus genome should be considered when these viruses are 
developed as vectors or vaccines. 
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4.2 Molecular analysis of the full genomes of isolates Aids25, Aids59 and Aids32: 
4.2.1 Candidate novel types of HAdV-D: 
Sequencing and phylogenetic analysis of the hexon L1, hexon L2, fibre knob, fibre shaft 
and penton regions resulted in detection of six isolates which might represent new types of 
adenovirus. These isolates are:  
- Isolates Aids4 and Aids28 which had a variant of type 26 hexon, untyped fibre HU1 and 
untyped penton PU1. 
- Isolates Aids58 and Aids59 which had a variant of type 20 hexon, untyped fibre HU2 and 
untyped penton PU4. 
- Isolates Aids23 and Aids25 which had untyped hexon U1, untyped fibre HU3 and 
untyped penton PU2.  
All these isolates were cultured successfully except isolates Aids4 and Aids28 and this 
could be because the storage conditions were not optimal for these two isolates which were 
isolated in 1993 and 1994.  
Isolates Aids25 and Aids59 were chosen for full genome sequencing. In addition, isolate 
Aids32 was included in the analysis because its fibre was typed wrongly as unidentified 
fibre (HU1) in previous work (Al Qurashi 2009). This isolate was cultured and also sent for 
full genome sequencing based on the previous typing of the fibre in addition to the analysis 
of the hexon which was a variant of type 23 and the penton which was unidentified type 
PU5. The analysis of the fibre shafts of the clinical isolate was carried out later and 
revealed that Aids32 had a variant of type 23 in this region which was confirmed by 
reanalyzing of the fibre knob. Two samples of Aids59 and Aids25 DNA extracts were 
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subjected to sequencing while one sample of Aids32 extract was sequenced using the next- 
generation sequencing system: 454 GS FLX Titanium.  
The serum neutralization (SN) test was used historically to identify new types of 
adenovirus after virus isolation. However, this test needs successful cultivation of the virus 
and the availability of reliable reagents for all known adenoviruses which make it time 
consuming and not applicable in some cases when the virus is difficult to grow.   
Sequencing and phylogenetic analysis of one genome region such as the hexon has been 
used for adenovirus typing. However, this analysis alone could be misleading. For example, 
HAdV-D53, which has a genome with multi-recombination events, was typed as HAdV-
D22 by sequencing of the hexon L1 or L2 regions because it has a recombination with 
HAdV-D22 in this region only while the rest of genome is not related to HAdV-D22 
(Walsh et al. 2009). Analysis of other regions such as fibre and penton is helpful to identify 
new types. However, full genome sequencing and bioinformatics are the best way to 
identify and analyse new types of adenovirus.  The latest identified types of adenovirus 
(HAdV-D53, HAdV-D54, HAdV-B55 and HAdV-D56) have all been defined by 
bioinformatics and molecular analysis and called types rather than serotypes to distinguish 
them from other types identified earlier by serology. 
4.2.2 General features of the genome: 
The genome features and organization of the three isolates Aids25, Aids59 and Aids32 
were similar to other species D adenoviruses with four early, two intermediate and five late 
transcription regions. Aids25, Aids59 and Aids32 genomes have G+C contents of 57.39%, 
56.97% and 56.80% respectively, consistent with the G+C content of other HAdV-D 
members (Shenk 2001). 
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The 5’ and 3’ ends of the genomes possess inverted terminal repeat (ITR) sequence at each 
end. These sequences contain the core origin motif which is essential for DNA replication 
(Chen et al. 1990). Other binding sites for factors which are important for efficient DNA 
replication can be detected such as nuclear  III (NFIII) and cellular factors Sp1 and ATF 
(Mul et al. 1990). The NFI motif which is absent from HAdV-D (Walsh et al. 2009) could 
not be detected in the ITRs. Two virus associated RNA (VA RNA) sequences have been 
identified in the three genomes. They play a role in cellular protein synthesis stimulation 
and host antiviral defence inhibition (O'Malley et al. 1986). 
4.2.3 Full genome phylogenetic analysis and global pairwise alignments: 
The full genome phylogenetic tree of the three genomes with those HAdVs where full 
genome sequences are available in the GenBank showed that these isolates belong to 
HAdV-D species. Aids25 was branching with HAdV-D48 and Aids32 with HAdV-D29. 
However, the full genome nucleotide divergence between Aids25 and HAdV-D48 was 
5.9% and between Aids32 and HAdV-D29 was 7.1%. These divergences are higher than 
the divergence between some existing HAdV-D types such as HAdV-D56 and HAdV-D9 
which have a divergence of 1.7% and HAdV-D22 and HAdV-D37 which is 5.7%. Aids59 
did not branch off any other type which supports that Aids59 is a new type of HAdVs. 
Aids25, Aids59 and Aids32 full genome alignments with selected types of adenovirus 
species using mVISTA showed a closer relationship between the genomes of the three 
isolates and HAdV-D9, the representative type of species D than any representative of other 
species. A global pairwise alignment of the full genomes of the isolates with all other 
completely sequenced HAdV-D types was performed.  A high level of conservation 
between the isolates genome and all other HAdV-D types in all genome regions except 
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penton, hexon, E3 and fibre regions can be observed which is similar to other HAdV-D 
types (Robinson et al. 2008). However, the genomes of these isolates were not identical to 
any other genome included in the analysis. 
4.2.4 Detailed analysis of selected genes: 
4.2.4.1 E3: 
E3 region proteins which are not required for DNA replication play an important role in 
modifying the host immune response (Horwitz 2001b). This region had unique sequences 
in the three isolates Aids25, Aids59 and Aids32. However, E3 region sequences are not 
available for all HAdV-D types and parts of this region could be similar to those yet to be 
sequenced. For example, Aids32 hexon and fibre are similar to HAdV-D23 so E3 of 
Aids32 could be related to HAdV-D23 E3 which is not available in the GenBank. 
4.2.4.2 Penton: 
4.2.4.2.1 Aids25 and Aids32 penton: 
Aids25 penton represents a new penton type with unknown HVR and RGD regions. The 
closest penton type to Aids25 was HAdV-D48 with 3.4% nucleotide and 3% amino acid 
divergence which is more than the divergence between existing types of HAdVs such as 
HAdV-D36 and HAdV-D29 with 1.7% divergence. BLASTP results showed also that 
Aids25 penton had 98% nucleotide and 97.7 % amino acid homology with adenovirus 
prime strain 17’H30 (AJ296013) which was described first by Adrian et al. (1987). 
Aids32 penton also represents a new type of penton which resulted from recombination 
between HVR of HAdV-D32 and unknown RGD region. The closest type to Aids32 RGD 
region was HAdV-D23.  
201 
 
4.2.4.2.2 Aids59 penton: 
HAdV-D types 37 and 53 pentons which are identical were the closest to Aids59 penton in 
both amino acid and nucleotide sequences with 6% nucleotide and amino acid divergence. 
There was a deletion of 78 nucleotides from the Aids59 penton resulting in a 26 amino acid 
deletion in RGD loop region including the RGD motif (Arg-Gly-Asp). All HAdVs contain 
the RGD motif in the penton except HAdV-F40 and HAdV-F41 (Albinsson and Kidd 1999) 
and no HAdV-D variant with naturally deleted RGD motif deletion has been reported 
previously.  
After the fibre knob interaction with the primary receptor, the penton RGD motif interacts 
with cellular integrins which mediates virus internalization (Wickham et al, 1993). HAdV-
A31 have an additional RGD motif in protein IX which might bind to the integrins 
(Hofmayer et al. 2009) but no RGD motif was detected in the Aids59 IX protein. The 
interaction between RGD motif and integrins has also an important role in the induction of 
innate immune responses (Liu and Muruve 2003). RGD interaction with β3 integrin 
triggers cytokine and chemokine production by activating the IL-1α_IL-1RI pathway (Di 
Paolo et al. 2009a).  Chintakuntlawar et al (2010) found that adenovirus empty capsid was 
able to induce keratitis in mouse cornea. They suggested that the cellular infiltrates and 
chemokine expression induced by the viral capsid is a result of interaction between RGD 
motif and integrins because it could be blocked by RGD peptide. The fibre-pseudotyped 
and penton RGD deleted vectors induce less chemokine and at the same time retain 
humoral immunity which makes them suitable for vaccines (Schoggins and Falck-Pedersen, 
2006). Moreover, Nemerow (2009) and Shayakhmetov et al (2005) suggested using 
modified capsid vectors (RGD motif deleted) to reduce the innate immunity response. 
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Di Paolo et al. (2009b) found that one of the mechanisms of adenovirus sequestration is the 
intraction between the penton RGD motif with hepatocytes and endothelial cells of the 
liver. They showed that when RGD motif deleted vector was injected into mice, the virus 
trapping in the liver was reduced significantly.   
HAdV-C5 have been used widely as a vector (Abbink et al. 2007) but recently HAdV-D 
vectors have been developed (Baden et al. 2009, Ruzsics et al. 2006) to avoid the pre 
existing immunity of HAdV-C5 and to take the advantage of the different tissue tropism 
and the use of different cellular receptors by HAdV-D (Ruzasics et al. 2006). Using a 
naturally deleted RGD motif HAdV-D such as Aids59 as a vector has extra advantages of 
reducing the innate immunity response, avoiding the instability caused by penton 
modification and reducing the liver sequestration when given intravenously.  
It is not clear if the immunodeficiency played a role in the survival of the RGD deleted 
Aids59 in the AIDS patient but no difference was observed in the time taken for the CPE to 
appear when Aids59 and Aids25 were cultivated in the cell culture.  
4.2.4.3 Hexon: 
4.2.4.3.1 Aids25 hexon: 
Aids25 hexon, like other HAdV hexons, consists of seven HVRs in L1 and L2 loops in 
addition to conserved regions. Aids25 hexon was not branching off any of HAdV-D types 
in the nucleotide sequence phylogenetic tree. The phylogenetic tree of the amino acid 
sequences of Aids25 with all HAdV-D types showed that Aids25 hexon was branching 
with HAdV-D28 but with a divergence of 6.1 % which is higher than the divergence 
between existing types of species D such as the divergence between HAdV-D30 and 
HAdV-D13 which is 3.5% and between HAdV-D15 and HAdV-D56 which is 1.4%. 
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The L1 and L2 of Aids25 including HVR1-7 regions which contains the hexon neutralizing 
epitope have been sequenced previously and found to be dissimilar to the L1 and L2 
regions of all other HAdVs. The closest L1 region to Aids25 was the L1 region of HAdV-
D17 in the nucleotide and amino acid sequences with 79.42% and 80.21% homology 
respectively. The closest HVR7 to Aids25 was the HVR7 of HAdV-D10 in the amino acid 
sequence with 75% homology but HAdV-D27 was the closest in the nucleotide sequence 
with 73.1% homology. All the above results indicate that Aids25 has a new hexon which is 
dissimilar to all other HAdVs hexons.  
Aids25 was neutralized by anti HAdV-17 antibodies but this result may not be accurate 
because of the high divergence between Aids25 and HAdV-D17 hexon variable regions 
especially as SN results are sometimes difficult to interpret and cross-reactions may occur. 
The exact location of the neutralizing epitope which is encoded by the L1 and L2 regions of 
the hexon has not been determined. However, the previous neutralization result of Aids25 
may suggest that hexon HVR4, which is the closest to HAdV-D17 (93.4% homology), may 
contribute to the neutralizing epitope more than other regions.  
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4.2.4.3.2 Aids59 hexon: 
The closest type to the Aids59 hexon was HAdV-D20 and they branched together in the 
nucleotide and amino acid phylogenetic trees of the full hexon. However, the nucleotide 
divergence for the full hexon between these two types was 3.8% which is higher than the 
divergence between existing species D types.  
The pairwise sequence alignment using mVISTA showed that the Aids59 hexon variable 
regions are closest to HAdV-D20 than any other type excepted at the beginning of L1 
(HVR1). The second part of the hexon has a similar level of homology to all HAdV-D 
types including HAdV-D20. The divergence between Aids59 and HAdV-D20 in the hexon 
L1 region, which contains the hypervariable regions HVR1-6, was higher than in L2 region 
which contain HVR7 (7.32% in L1 comparing to 3.24% in L2). Moreover, 21 of 39 
nucleotide substitutions in the L1 region were detected in HVR1. This suggests a possible 
recombination event in Aids59 hexon L1 region. Nucleotide sequence alignment of Aids59 
hexon with other HAdV-D types showed that two fragments of HAdV-D51 were present in 
L1 of Aids59. Most of the first fragment was in the HVR1 and the second fragment was 
between HVR2 and HVR3.  
Illegitimate recombination, including insertions and deletions, occurs in hexon HVRs 
(Crawford-Miksza and Schnurr 1996a). However, the recombination event at the beginning 
of the Aids59 L1 region indicates that homologous recombination can also take place in the 
hexon HVRs. The same patterns of recombination were detected previously by Lu and 
Erdman (2006) in two HAdV-D20 isolates. The first isolate had an identical L1 sequence to 
Aids59 and had exactly the same fragments of HAdV-D51 within L1 region. The second 
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isolate had a fragment of HAdV-D37 in the HVR1 of hexon L1 region. No further 
information is available about these two isolates.  
Further investigation of the recombination events in Aids59 hexon was carried out using 
SimPlot and BootScan plot analysis. The recombination event in L1 of Aids59 hexon was 
not detected by the analysis because of the small size of the fragments. Surprisingly, the 
analysis showed that only HVRs 2-6 of L1 and HVR7 of L2 regions of the hexon are 
similar to HAdV-D20 while the conserved C terminus of the hexon is not similar to any 
other HAdV-D type which indicates another recombination event in the Aids59 hexon. The 
HVRs 2-6 of L1 and L2 regions of HAdV-D20 were framed by a previously untyped 
sequence in Aids59. This was confirmed by the nucleotide sequences alignment and 
phylogenetic analysis of the conserved C terminus of the hexon of Aids59 and all HAdVs. 
This pattern of recombination has been detected more frequently in HAdVs than the 
recombination within the L1 region.  HAdV-D53 hexon has L1 and L2 regions of HAdV-
D22 framed by a previously unknown sequence and similar patterns were observed in 
HAdV-D types 13, 32 and 39 and HAdV-B16 (Walsh et al. 2009). HAdV-B55 has the L1 
and L2 of HAdV-B11 while the rest of the genome of HAdV-B14 and this recombination 
resulted in serotype changing of HAdV-B55 (Walsh et al. 2010a).  
The seven HVRs of the L1 and L2 regions contain the neutralizing epitope of the hexon 
(Gall et al. 1998). Aids59 was neutralized by anti HAdV-D20 antibodies despite the 
recombination with HAdV-D51. This may be related to the location of this recombination 
in HVR1 which is in the internal surface of the protein and may contribute less to the 
neutralizing epitope of the hexon (Crawford-Miksza and Schnurr 1996b).  
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4.2.4.3.3 Aids32 hexon: 
The nucleotide and amino acid phylogenetic analysis of Aids32 full hexon sequence 
showed that Aids32 hexon is very close to HAdV-D23 with 98% nucleotide and 99% 
amino acid homology. The nucleotide sequence alignment and mVISTA analysis showed 
that the conserved region in the carboxy-terminal of Aids32 hexon is less homologous to 
the same region of HAdV-D23 than the amino terminal end. BootScan and SimPlot of full 
hexon sequences of all HAdVs and Aids32 showed a high similarity level in the amino- 
terminal which contain the HVR1-7 while the rest of the hexon did not show similarity to 
any HAdVs which indicates a possibility of recombination events between HAdV-D23 and 
a previously unknown yet hexon sequence. Similar recombination events has been observed 
with the Aids59 hexon as discussed earlier.   
4.2.4.4 Fibre: 
The general features of Aids25, Aids59 and Aids32 fibres are similar to all HAdVs and can 
be divided into three parts: tail, shaft and knob (Green et al. 1983). Aids 25 and Aids59 
have unique fibre region sequences. The closest fibre type to Aids25 is HAdV-D28 fibre 
with 82.5% nucleotide and amino acid homology while the closest type to Aids59 fibre 
sequence is HAdV-D22 with 77% nucleotide and 75% amino acid homology.  
The closest fibre type to Aids32 was HAdV-D23 in the shafts and knob region. The full 
genome sequence of HAdV-D23 fibre is not available in the GenBank. However, the knob 
and the shaft regions form most of the fibre sequence and the rest of the fibre which is 
related to the tail is very conserved among HAdV-D types. This indicates that the Aids32 
fibre is most likely a variant of HAdV-D23. 
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The conserved sequence tail-shaft junction GVLSL and shafts-knob junction TLWT can be 
observed in Aids25, Aids59 and Aids32 fibres. The heparan sulphate-binding site which 
has been observed only in in HAdV-C fibre shafts (Darr et al. 2009; Nicol et al. 2004) 
cannot be seen in the fibre shafts of the three genomes. The fibre knob contains Tyr and 
Lys amino acids which play a role in the sialic acid binding (Burmeister et al. 2004). The 
FNPVYPYD motif which interacts with the penton can be observed as well. The three fibre 
shafts do not contain the two flexibility loops which appear in some of HAdV-D fibre 
shafts (Darr et al. 2009).  
4.2.5 Full genome general discussion: 
Aids25 and Aids59, which represent two new types of HAdV-D isolated from AIDS 
patients, have been fully sequenced and analysed. In addition, Aids32 which is more likely 
a variant of HAdV-D23 was also fully sequenced and analysed.  
HAdV-D contains 35 types making it the largest HAdV species. In patients with AIDS, the 
most commonly isolated HAdVs are from HAdV-D and HAdV-B species (Hierholzer 
1992; Kojaoghlanian et al. 2003). Nine of the last 14 described types of adenovirus 
(HAdV43- HAdV51) were isolated from AIDS patients and all of these types belong to 
species D (HAdV-D) except HAdV-B50 (De Jong et al. 1999; Ishiko and Aoki 2009; Jones 
et al. 2007; Walsh et al. 2009; Walsh et al. 2010a). These types could be circulating and 
causing asymptomatic infections in the immunocompetent population but not detected. The 
reason that many types of adenoviruses have been detected in AIDS patients could be 
related to the weak immune system of these patients which give the opportunity for these 
types of adenovirus to cause symptomatic infection in these patients who are screened more 
frequently.  
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It was reported recently that adenovirus shedding rate in AIDS patients is 75% and the 
shedding of more than one type rate is 53% (Curlin et al, 2010). The prolonged shedding of 
several types of HAdV and especially species D from the gastrointestinal tract of AIDS 
patients increases the possibility for these types to interact resulting in recombination 
events and new variants or types (Crawford-Miksza and Schnurr 1996a; De Jong et al. 
1999). There was no evidence of other types of adenoviruses (coinfection) in Aids59 and 
Aids25 isolates as discussed previously in this study. However, low levels of other types 
could be present in the same patients. 
Identification of new types of adenovirus could be a result of detection of a totally new type 
or a type which is a result of mutations or recombination events between other existing and 
known types. Homologous and illegitimate (insertion and deletion) recombination events 
are a common feature of HAdVs and they have been suggested to play a role in their 
evolution (Crawford-Miksza and Schnurr 1996a). HAdV-D53 which contains at least five 
recombination events is an example of these new types (Walsh et al. 2009). 
Some recombination events in the Aids59 hexon with existing types of HAdVs have been 
shown in this study. However, many coding regions of Aids59 and Aids25 including 
penton, hexon (of Aids25), E3 and fibre, which are the variable regions among all HAdVs, 
are dissimilar to any sequenced adenoviruses genome regions. The sequences of these 
regions could be related to previously unknown HAdVs or known types of species D that 
have yet to be sequenced.  
Aids32 is most likely a variant of HAdV-D23 because it is the closest type to it in all 
available regions of HAdV-D23 in GenBank which are hexon, fibre, penton and E1A in 
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addition to a 241 nucleotide fragment of DNA polymerase and 521 nucleotide fragment of 
VA RNA.    
The exact relation between these new types and other HAdVs is difficult to be concluded 
because many HAdV-D are not fully sequenced yet. One of the problems in analysing new 
types of adenovirus genomes is the lack of full annotation of some completely sequenced 
adenoviruses which make the database search BLASTP for protein similarity less accurate. 
However, manual annotation was carried out for the partially annotated genomes used in 
this study and multi sequence alignments were used to calculate the similarities.   
Recombination events may occur in non-coding regions and the best way to study these 
events is the full genome sequencing analysis which is also the best method to study new 
types of adenoviruses and give better understanding to their evolution especially with the 
increasing use of them as gene delivery vectors.   
4.3 Molecular analysis of HAdV-B clinical isolates: 
The previous part of the study focused on the genome stability of species D adenovirus and 
this part is another step for better understanding of the stability and evolution of species B 
adenovirus. 
Genome stability of HAdV-B3 has been investigated previously by comparing the full 
genome sequence of the prototype strain which was isolated in 1953 to two recently 
isolated field strains and one laboratory strain. This investigation provided evidence that the 
HAdV-B3 genome is stable over 50 years (Mahadevan et al. 2010). Other evidence of 
genome stability of HAdV-B7, HAdV-E4 (Purkayastha et al. 2005) and HAdV-C5 (Seto et 
al. 2010a) over a long period of time were reported.  
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The above mentioned reports are in contrast to the species D  results of this study and other 
studies which found that recombination events are common in adenoviruses, play an 
important role in its evolution and may result in emergent types (Walsh et al. 2010a). In 
addition, there are some reports of recombination between hexon and fibre of HAdV-B 
(Adrian & Wigand 1986; Kajon and Wadell 1996; Kajon et al. 2010).  
In this part of the study, the above mentioned two conflicting views about the stability of 
the adenovirus genome will be investigated. This is important for adenovirus vector and 
vaccine development and for better understanding of its evolution. In addition, this part of 
the study will also provide information about the epidemiology of HAdV-B types 3 and 7 
in the Manchester area.  
A total of 96 isolates collected from the Manchester area were typed previously by serum 
neutralization (SN). Most of these isolates were HAdV-B3 and HAdV-B7 collected during 
a 15 months outbreak from the same area which gave them the opportunity to interact. The 
rest of the isolates were types 3 and 7 collected in different years following the outbreak in 
addition to other adenovirus species B isolates from different years.  Different primers were 
used to amplify fragments of the adenovirus variable regions: hexon L2, fibre knob and 
penton which are the main structural proteins and contain the antigenic determinants. In 
addition, Analysis was performed for two non structural regions, DNA polymerase and 
E1A which were reported as unstable regions and undergo recombination in species C 
adenovirus (Lukashev et al. 2008).  
HAdV genome is conserved in all regions except hexon, penton, fibre and E3 regions and 
most of the molecular epidemiology studies which used sequencing and phylogenetic 
analysis were carried out for the hexon region only (Biere and Schweiger 2010; Fujimoto et 
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al. 2008). This is the first study to analysis adenovirus species B types in five different 
genome regions. 
HAdV-B3 and HAdV-B7 outbreak isolates were circulating at the same time and in the 
same area which gave them the opportunity to interact and undergo recombination in vivo. 
However, the phylogenetic grouping results of all the isolates in the regions, hexon L2, 
penton,  fibre knob and E1A were found to be consistent  and no mismatches were 
observed between types 3 and 7 isolates or between them and any other HAdV-B types 
which indicates that adenovirus genome is stable in these regions. Most of the HAdV-B3 
and HAdV-B7 isolates in the DNA polymerase region had the same clustering patterns as 
the other regions. An exception was one isolate that clustered with HAdV-B7 NHRC1315 
reference strain in all the regions analysed but appeared closer to HAdV-B3 prototype in 
the DNA polymerase region. However, this change of clustering was the results of three 
nucleotides substitutions only which suggests a natural variation rather than recombination. 
The types 3 and 7 isolates from different years had also the same clustering patterns which 
also indicates the stability of the genome over long periods of time (more than 13 years).  
The same result was found for isolates from HAdV-B types other than 3 and 7 in the hexon 
L2, fibre knob and penton regions. However, different clustering patterns were observed for 
HAdV-B16 isolates in the E1A and DNA polymerase regions (one isolate clustered with 
HAdV-B50 and two with HAdV-B21). In addition, HAdV-B11 isolate became closer to 
HAdV-B34 in the DNA polymerase region. These results indicate that E1A and DNA 
polymerase region might be less stable than the other three structural regions: hexon L2, 
penton and fibre knob. 
Only a few sequences of HAdV-B16 are available in the GenBank which is not enough to 
understand the natural variation of this type. The divergences between the prototype of 
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HAdV-B16 and the prototypes of HAdV-B21 and HAdV-B50 in DNA polymerase region 
are 1.2% (11 nucleotides) and 0.7% (7 nucleotides) respectively and these divergences in 
E1A region are 0.4% (3 nucleotides) and 1.4% (10 nucleotides) respectively. These 
divergences are very low in comparison with other regions of HAdV-B16 with HAdV-B21 
and HAdV-B50 which are as follows: hexon L1: 30.7 and 41%, hexon L2: 25.5 and 24.4%, 
fibre knob: 42.3% and 41.7%, penton: 19.3% and 19 % respectively. So, the difference in 
the clustering patterns of HAdV-B16 isolates in the structural and non structural region 
could be because of the natural variation of this type rather than recombination.  
Fifteen isolates of HAdV-B collected in Portugal during a pediatric outbreak were typed by 
phylogenetic analysis of the hexon and fibre regions (Rebelo-de-Andrade et al. 2010). Most 
of the isolates belonged to HAdV-B3 (10 isolates) and the rest to HAdV-B7. None of 
HAdV-B3 isolates clustered with the prototype but they clustered with to HAdV-B3 
NHRC1276 reference strain which is the same as cluster II in this study. The rest of the 
isolates which belonged to type 7 did not cluster with the prototype but with HAdV-B7 
NHRC1315 reference strain. The phylogenetic analysis for the fibre region revealed the 
same clustering patterns as in the hexon region for all isolates except one isolate. 
In a recent study from Germany, Biere and Schweiger (2010) analysed 38 HAdV-B3 
clinical isolates by phylogenetic analysis of the hexon L1 and L2. The isolates were 
grouped in 3 clusters α, β and γ. The first cluster α was identical to the HAdV-B3 prototype 
which is the same as cluster I in this study. The γ was identical to HAdV-B3 NHRC1276 
reference strain which is the same as cluster II in this study. The last cluster β was close to 
isolates from East Asia and none of the isolates in this study belonged to this cluster.  
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A total of 129 HAdV-B3 clinical isolates, collected from 1994 to 2006 in Japan,  were 
studied by phylogenetic analysis of the hexon L1 and L2 (Fujimoto et al. 2008). These 
isolates were grouped into 3 clusters: 3x, 3y and 3z. The third cluster (3z) was identical to 
HAdV-B3 NHRC1276 reference strain which is the same as cluster II in this study. None 
of the isolates in this study belonged to the other two clusters 3x and 3y. Most of the 
clinical isolates in of HAdV-B7 in previous reports did not cluster with the prototype 
consistent with the finding in this study (Erdman et al. 2002; Li and Wadell 1999). 
All the isolates of HAdV-B3 cluster I were from 1983 and 1984 (outbreak isolates) except 
isolate 97-03 which was isolated in 1997.  The remaining isolates collected in different 
years outside the outbreak (1986-1996) in addition to some outbreak isolates belonged to 
cluster II. This may indicate that both clusters dominated during 1983-1984, then cluster II 
became predominant untill 1997 when cluster I appeared again. However, the small number 
of the analysed isolates outside the outbreak could be the reason for this result. 
 It was reported previously that a specific genotype of species B could dominate in a 
specific time or a particular geographical area (Erdman et al. 2002; Kim et al. 2003). For 
example, phylogenetic analysis of the full hexon of HAdV-B3 isolates from Taiwan 
collected between 1983-2005 revealed two clusters, one of them contained most of the 
isolates collected between 1983-1999 and the second one contained most of the isolates 
collected between 2001 and 2005 (Lin et al. 2010).  
The stability of 16 HAdV-C isolates collected from different geographic regions was 
studied by Lukashev et al. (2008). These isolates were analysed in four genome regions: 
hexon, fibre, DNA polymerase and E1A. All of the isolates clustered with their prototypes 
in the hexon and fibre regions except one. However, in the other two regions the clustering 
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patterns were different and most of the isolates did not cluster with their prototypes and 
some of them had identical sequences to different types.  Although 96 isolates collected 
from the same area have been examined in our study, only four of them changed their 
clustering patterns in the DNA polymerase and E1A regions and none of them became 
identical to different type in these two regions. This indicates that HAdV-B types are more 
stable than HAdV-C types in these two regions.  
The results obtained from this part of the study indicate the HAdV-B types and especially 
HAdV-B3 and HAdV-B7 are stable in general which supports the earlier mentioned reports 
about adenovirus genome stability over long period of time. However, results from species 
D isolates analysed from AIDS patients indicated that adenovirus genome of these isolates 
was not stable. The above mentioned findings are just indications and it is difficult to 
determine if the genome is completely stable or not especially with the short time frame of 
comparison. This means that both views about adenovirus stability are valid and some 
factors may play a role in this stability such as adenovirus species, coinfections and tropism 
in addition to patients’ factors. In addition, another factor can affect the stability analysis is 
the sample selection and isolates of species D from immunocompetent individuals in 
addition to isolates from species B from immunocompromised patients should be included 
in further analysis.  
The results of this part of study about species B genome stability are important because 
adenovirus vectors of this species are under development (McVey et al. 2010) and vaccines 
against types of this species such as HAdV-B3 and HAdV-B7 might be developed in the 
future.  
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4.4 Adenovirus persistence and latency in tonsils and adenoids: 
Species C adenoviruses (types 1, 2, 5 and 6) in addition to types 3, 4 and 7 were cultured 
from tonsils and adenoids (Israel 1962; Rowe et al. 1953; Van Der Veen & Lambriex  
1973). More recently, adenovirus DNA has been detected in tonsils and adenoids even 
when cultivation failed (Garnett et al. 2002; Garnett et al. 2009). This suggests that 
adenoviruses are capable of establish persistent or latent infections in these tissues. 
One of the areas of adenovirology needing further investigation is adenovirus persistence 
and latency in human tissues especially, as the mechanisms of adenovirus latency are not 
clear (Horwitz 2001a) and a possible interaction between these latent viruses and 
adenovirus vector may occur. In addition, the latent infections of adenovirus in lung could 
also play a role in the pathogenesis of chronic obstructive pulmonary disease (COPD) and 
asthma (Hayashi 2002; Marin et al, 2000). Moreover, the reactivation of these infections 
may cause serious diseases in immunocompromised patients (Kojaoghlanian et al. 2003). 
The aim of this part of the study was to investigate the nature of adenovirus persistence and 
latency in human tonsils and adenoids. This was carried out by isolation of the lymphocytes 
from these tissues, examining these cells for evidence of adenovirus infections, determining 
the viral load and typing of adenoviruses in positive samples. In addition, one of the 
possible mechanisms of adenovirus persistence/latency which is DNA methylation was 
investigated. 
4.4.1 Real-Time PCR sensitivity: 
The sensitivity of the assay was determined by testing 10-fold dilutions of purified plasmid 
DNA containing the target region of the adenovirus genome. 
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The cycle threshold (Ct) value, which is the cycles number required for the fluorescence 
signal to exceed the background signal, was determined for each dilution. The Ct values are 
correlated to the copy number of the DNA in each dilution and can be used to determine the 
copy number in unknown samples. The standards and the samples were run in minimum of 
two replicates to avoid sampling variation. 
The assay was able initially to detect between 8.4 and 84 copies of plasmid DNA.  
Real-time PCR was used to detect adenovirus in this study because it has many advantages 
over the gel-based PCR such as the quantitative detection with high sensitivity especially 
when the low copy number of the target is predicted such as a latent adenovirus DNA in the 
tonsils and adenoids.  In addition, the closed system of real-time PCR reduces the risk of 
contamination and there is no need for post-PCR procedures such as gel electrophoresis.   
4.4.2 Isolation of lymphocytes from adenoids and tonsils: 
Right and left tonsils from the same patients were analysed separately to find out if 
adenovirus will be detected in one tonsil but not in the other and if the same type is present 
in both tonsils. When adenoids are available with tonsils from the same patient, they were 
also analysed separately. 
The mechanical disruption was done initially using cotton muslin. Some tissues remained 
in the muslin which affected the count of collected cells especially when the size of the 
tonsil was small. An enzymatic method using 0.25% trypsin in PBS was attempted but this 
method was not sufficient to disrupt the tissue even after incubation at 37°C for long 
periods. This suggests that trypsin is not suitable for disruption of this kind of tissue. 
Another mechanical method was used to isolate the cells from the tissues by pushing them 
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through a stainless steel tissue sieve. This was the most successful method for the isolation 
of lymphocytes.  
4.4.3 Real-Time PCR of isolated lymphocytes from tonsils and adenoids: 
 Eighty four of 116 (72.41%) tonsils and adenoids samples were positive for HAdV by real- 
time PCR. Two previous reports found detectable levels of adenovirus DNA in 79% and 
85% of tonsils and adenoids using real- time PCR (Garnett et al, 2002; Garnett et al, 2009). 
Both percentages in these reports are slightly higher than this study despite that the assay 
used in these previous studies was specific for HAdV-C types. This could be because right 
and left tonsils were analysed together in both reports. In addition, tonsils were analysed 
with adenoids in most of the cases (163/203) of the second report (Garnett et al, 2009). This 
will give false positive results in some cases when one of the tissues is positive and the 
other one from the same patient is negative. 
Both tonsils and adenoids were positive in 2 out of 6 cases where both tissues were 
available from the same patient. Adenoids only were positive in three cases and both tissues 
were negative in one case. All adenoids which were available from four patients who 
underwent adenoidectomy only were positive. Tonsils and adenoids of 40 patients were 
analysed separately by Garnett et al. (2009). Both tissues were positive in 27 patients and 
negative in 2 patients. Either tonsils or adenoids of 11 patients were positive.  
In some cases one of the tonsils was negative for adenovirus while the other one from the 
same case was positive. However, the positive samples in all of these cases were weakly 
positive and there is a possibility that the virus was in the other tonsil but in low level and 
could not be detected. The other possibility is that only one tonsil contained adenovirus 
DNA. Right and left tonsils are separated anatomically like adenoids so it is possible for 
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one of them only to be positive for adenovirus .None of the previous reports analysed right 
and left tonsils separately but there are several reports of tonsillar cancer in one side tonsil 
only (Chaiyachati et al, 2008; Tominaga et al, 1996) and the possible association between 
human papillomavirus (HPV) or Epstein-Barr (EBV) virus and tonsillar cancer was 
documented in the literature (Klussmann et al, 2003; Rotnáglová et al, 2011; 
Szkaradkiewicz et al, 2002). This indicates that one tonsil only could be infected with these 
viruses.  
The viral load was higher in the adenoids than in the tonsils in the two cases with both 
tonsils and adenoids were positive. Garnett et al. (2002) and Garnett et al. (2009) reported 
similar results and suggested that the different susceptibility of tonsils and adenoids to 
adenovirus infection could be the reason especially as the type of epithelia that coat tonsils 
are different from that coating adenoids.  
No relation was found between the viral load and the sex of the patient. The negative 
relation between the age of the patients and the viral load was found to be statistically 
significant (P value using Spearman's rank correlation coefficient = 0.0177 which is <0.05). 
Similar results were reported previously by Garnett et al. (2009) and they suggested that 
more recent infection in the younger patients could be the reason for the higher viral load. 
4.4.4 Typing of HAdVs in isolated lymphocytes from tonsils and adenoids: 
Nested PCR assays followed by sequencing were used for typing of adenovirus. Fragments 
of the hexon gene hypervariable regions (HVR1-6), which with HVR7 contain most of type 
specific variation in the hexon, were amplified.   
DNA from only 78 of the 84 samples positive by real- time PCR could be amplified using 
the nested PCR assay. Nested PCR which involves two amplification reactions was used to 
219 
 
reduce non-specific products. The amplification using the external primers may amplify 
non-specific DNA fragments but the second amplification using the internal primers will 
produce more specific products.  
All the positive samples by real-time PCR were positive using the nested PCR except six 
samples. The nested PCR detected DNA in samples with lower viral load than these six 
samples which indicates that the sensitivity of the nested PCR is not the reason for these 
samples to be negative. Garnett et al. (2009) found that three samples were negative by gel- 
based nested PCR while positive by quantitative real-time PCR. They suggested that 
sequence variations in the target region could be the reason for this result.  
Species C types which is the most common adenovirus species (La Rosa et al. 2011; 
Schmitz et al. 1983) were detected in 82% of the samples. Different types from other 
species were also detected such as HAdV-B3 and HAdV-B7 (7.70%), HAdV-E4 (7.70%) 
and HAdV-F41 (2.56%). HAdV-C1 was the most commonly detected type in these samples 
followed by HAdV-C2 then HAdV-C5. None of the samples contained HAdV-C6 which is 
the least isolated type of HAdV-C (Schmitz et al. 1983). 
 All these types have been detected or cultured from tonsils and adenoids previously except 
HAdV-F41 (Israel 1962; Garnett et al. 2002; Garnett et al. 2009; Van Der Veen & 
Lambriex  1973). HAdV-F species including types 40 and 41 are associated with 
gastrointestinal tract infections and this is the first report of HAdV-F detected in tonsils. 
There are only a few published reports about HAdV-F detected outside the gastrointestinal 
tract: in nasal swabs from two patients (Echavarria et al. 2006),  cerebrospinal fluid (CSF) 
and blood of  a child with Haemophilus influenzae invasive disease (Khetsuriani et al. 
2009) and in different tissues and the CSF of a patient with adenovirus disseminated 
disease following bone marrow transplantation (BMT) (Slatter et al. 2005). It is known that 
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HAdV-F types are enteric adenoviruses and this could be one of the reasons that little effort 
has been made to detect them outside the gastrointestinal tract. Moreover, these types are 
difficult to culture and produce cytopathic effect (CPE) in vitro. The exact reason that 
HAdV-F types are difficult to culture in vitro is not known and could be because they have 
adapted to replicate in the gastrointestinal epithelial cells (Tiemessen & Kidd 1995). Full or 
partial genome sequencing of these HAdV-F types and comparing them with HAdV-F 
types from the gastrointestinal tract could give a better understanding for this issue.  
Garnett et al, (2009) tested only the species C negative tonsils and adenoids samples for 
types from other species and found that only one sample of 62 contained HAdV-B3.  This 
could be because the assay that they used is less sensitive for species other than species C. 
In this study, the same adenovirus type was detected in tonsils and adenoids from the same 
patient as reported previously (Garnett et al. 2002; Garnett et al. 2009). Samples 27R 
contained HAdV-C5 while 27L contained HAdV-C2 and these were the only samples from 
the same patient that contain different types of adenovirus in the right and left tonsils. This 
could be because one type was predominant in one tonsils and the other type was there in 
low level and could not be detected. The other possibility is that HAdV-C5 infected the 
right tonsils only and HAdV-C2 infected the left tonsils only. 
HAdV-B3 and HAdV-B7 types were only detected in patients 9 years old and over but 
most of the HAdV-C types were observed in younger children. Generally, HAdV-C types 
are isolated from infants and young children more than other types while HAdV-B 3 and 7 
are isolated more from school age children (Schmitz et al. 1983).  
4.4.5 DNA methylation analysis: 
In this part of the study, the methylation status was analysed for DNA extracts from tonsils 
and adenoids in two genome regions in order to investigate if DNA methylation plays any 
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role in the persistence or latency of adenovirus in tonsils and adenoids. Two promoter 
regions were chosen for methylation analysis because the down regulation of the gene 
expression could be a result of methylation of these regions as mentioned above.  The first 
region is the E1A which regulates the transcription of adenovirus early genes (Kimelman et 
al, 1985). Hsu et al, (2010) reported that in vitro methylation of integrated adenovirus E1A 
promoter reduced the viral gene expression. The second region is the major late promoter 
(MLP) region which initiates the transcription of many structural proteins (Shenk 2001). 
One study showed that in vitro methylation of a specific binding site of transcription factors 
in the major late promoter (MLP) of adenovirus resulted in binding inhibition of these 
factors and this inhibition was greater when both the coding and non-coding strand were 
methylated (Watt & Molloy 1988). 
Early studies used restriction enzymes to study DNA methylation but this method is able to 
detect the methylation status in limited sites of the analysed sequence (Hoelzer et al. 2008). 
Nowadays, bisulfite treatment followed by PCR and sequencing is the gold standard for 
methylation analysis (Docherty et al. 2009).  
The treatment of the DNA with sodium bisulfite converts only unmethylated cytosine 
residues into uracil and leaves methylated cytosine of CpGs unchanged. Subsequently, the 
uracil will be replaced by thymine using PCR amplification. Finally, only methylated 
cytosine of CpGs will appear as cytosine in the sequencing.   
Different methods can be used following the bisulfite treatment for methylation analysis. In 
this study, non-methylation specific primers flanking GpCs were used to amplify the target 
fragment of DNA regardless of the methylation status. This method was chosen because 
primers will give the methylation profile of the whole targeted region in contrast to the 
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methylation specific primers which will anneal to CpGs sequence and either amplify the 
target or not depending on the methylation status of the primers regions only.  
The changes in the DNA after the bisulfite treatment will reduce the complexity of the 
sequence and make the designed primers for the PCR less specific (Darst et al. 2001). 
Semi-nested PCR was used to increase the specificity and to reduce the number of primers 
needed for nested PCR because of the limited number of suitable regions for primers i.e. 
the regions with no GpCs. Methyl Primer Express® software which is specific for 
methylation analysis primer design was used. Special PCR conditions were used with 
higher annealing temperature in the first few cycles to increase the specificity of the 
primers. 
4.4.6 DNA methyation in tonsils, adenoids and clinical isolates: 
Six different right and left tonsils samples in addition to one adenoid sample containing 
HAdV-C types were used for the methylation analysis. Two other clinical isolates of 
HAdV-C were included in the analysis for comparison. 
 Semi-nested PCR was used to amplify the target regions of E1A promoter and MLP after 
bisulfite treatment. No cytosine was detected in the sense strand and no guanine was 
detected in the anti-sense strand of the sequence of these two regions which indicates that 
the DNA is not methylated in these two regions in all tested samples and isolates. No 
methylation was found also in the MLP position which inhibits transcription from this 
region when methylated in vitro (Watt & Molloy 1988). These results indicate that DNA 
methylation dose not play a role in adenovirus persistence and latency in tonsils and 
adenoids.  
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The mechanisms by which adenovirus can evade the immune response and cell apoptosis 
are important to maintain the persistent or latent infection. However, other mechanisms 
may play a role in the persistence and latency of adenovirus. Viral microRNA (miRNA) 
could be one of these mechanisms. It was found that miRNAs play essential roles in 
herpesvirus latency by downregulating the expression of viral proteins or controlling host 
cell pathways to maintain the latent infection (Lei et al. 2010; Umbach et al. 2008). It was 
reported recently that 44 miRNAS are expressed at high levels and 36 at low level in 
adenovirus during its infection of Hep2 cells (Qi et al. 2010). However, the role of these 
miRNAs in adenovirus lifecycle is as yet unknown. 
4.5 Future work: 
Future work should include submitting of Aids25 and Aids59 sequences to the Human 
Adenovirus Working Group which coordinate and standardize the process of assigning 
names to novel human adenoviruses as suggested by Seto et al. (2011). The effects of the 
RGD deletion on Aids59 should be analysed in addition to the possibility of using it as a 
vector. 
Studying the genome stability in adenovirus isolates of species D from immunocompetent 
individuals in addition to isolates of species B from immunocompromised patients should 
be included in further analysis. 
Studying the stability of HAdVs in tonsils and adenoids by analyzing different genome 
regions of adenovirus samples from tonsils and adenoids to investigate any recombination 
events which is possible because infection with more one type of adenoviruses in tonsils 
was reported (Garnett et al. 2009). In addition, the possibility of recombination between 
latent adenovirus and adenovirus vector needs to be investigated. Analyzing tonsils and 
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adenoids samples from adults and comparing them with samples from children might 
provide useful information as well. 
The mechanisms of adenovirus latency need further investigation such as miRNAs. Other 
possible factors that could down regulate the viral gene expression, affect DNA replication 
or help the virus to evade immune response should be anlysed. Restriction endonuclease 
and Southern blotting could be used to find any evidence of integration of viral DNA into 
human chromosomes as a mechanism of latency. Lymphocytes could be cultured and 
stimulated with phytohaemagglutinin to produce metaphase chromosome spreads then the 
site of integration could be studied by fluorescent in situ hybridization technique (FISH).  
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